Use of indole compounds for fat reduction and skin and soft tissue tightening

ABSTRACT

The present invention relates to indole compounds and compositions and uses thereof, including uses of the indole compounds and compositions for the reduction or removal of localized fat deposits and/or tightening of skin and soft tissue laxity in subjects. The indole compounds can be employed, for example, in the cosmetic sector or for producing pharmaceutical products.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. patent application Ser. No.14/772,602, filed Sep. 3, 2015, which is the national stage ofInternational (PCT) Patent Application Serial No. PCT/US13/048368, filedJun. 27, 2013 which claims priority to U.S. Provisional PatentApplication No. 61/780,792, filed Mar. 13, 2013, the contents of eachapplication are hereby incorporated by reference in their entirety.

TECHNICAL FIELD

The present invention relates to indole compounds, compositions, anduses thereof, including uses of the indole compounds and compositionsfor the reduction or removal of localized fat deposits and/or tighteningof skin and soft tissue laxity in subjects. The indole compounds can beemployed, for example, in the cosmetic sector or for producingpharmaceutical products.

BACKGROUND

Liposuction is one of the most popular cosmetic surgery procedurescurrently available. It involves the surgical removal of fat depositsusing suction, optionally assisted by solutions to assist in fatremoval. Liposuction, also known as lipoplasty or suction lipectomy,reduces fat through an incision in the skin through which a cannula isinserted. Tumescent fluid is injected into the treatment region, thenthe cannula is inserted. The cannula is connected to a suction sourceand the unwanted fat is aspirated through the cannula and discarded.Liposuction is performed under general or local anesthesia, depending onthe amount and location of the fat to be reduced.

The use of liposuction and/or other surgical methods of fat removal areassociated with significant adverse events including temporary bruising,swelling, numbness or hypersensitivity, soreness and burning sensation,risk of infection, and pigmentation changes. Other more seriouscomplications include the formation of fat clots or blood clots, whichcan migrate to the lungs and cause death; excessive fluid loss, whichcan lead to shock; fluid accumulation that must be drained; fluidoverload leading to congestive heart failure; friction burns or otherdamage to the skin or nerves; and perforation injury to the vitalorgans. Additionally, liposuction requires a recovery time of up to 1-2weeks. Moreover, because surgical procedures such as liposuction requirelocal and occasionally general anesthesia, significantanesthesia-related risks are associated with surgical fat removal.

In 1959, phosphatidylcholine (hereinafter “PC”) was isolated and usedintravenously in Odessa, Russia, for the treatment of fat embolism. PChas also been used in treating xanthelasmas in Europe and in SouthAmerica. An injectable form of PC (LIPOSTABIL®, Sanofi-Aventis,Brigewater, N.J.) has been indicated for treatment of fat embolisms,coronary artery plaque, and fat tissue.

PC is often an ingredient in injectable fat reducing formulas. Whenisolated, it is produced as a powder. When reconstituted, it is quiteviscous and must be mixed with a detergent, such as sodium deoxycholate(hereinafter “DC”), to solubilize it sufficiently to create aninjectable form. DC is a bile salt that can function to make the PCsoluble in water or other biocompatible solvents; otherwise, the PC canprecipitate out of solution. DC has been described as having a“detergent” effect on fat dissolution in a porcine in vitro study andhas nonspecific effects on both adipose and muscle cells. Otherpharmaceuticals, such as FUNGIZONE® (Bristol Myers Squibb, New York,N.Y.) (an injectable form of amphotericin B), are commonly combined withbile salts to enhance their solubility and make them compatible withintravenous delivery.

While formulations of DC without PC (“DC formulations”) and formulationsof PC combined with DC (“PC/DC formulations”) have been shown to achievea level of fat reduction, substantial unresolved problems remain withthe use of such formulations and methods of use, as reported in Duncanet al. (Duncan D. Injection lipolysis for body contouring, p 59-70. BodyContouring, ed. Schiffman and DiGiuseppe, Springer 2010, Berlin.).

While meeting with some success, prior techniques and compositions havemet with certain limitations, such as skin loss, drainage of liquefiednecrotic fat, excessive fibrosis, injections into muscle causingweakness, nodules, or adhesions with limitation of range of motion,numbness, paresthesias, and marginal mandibular nerve palsy. Thereforeit would be desirable to have a method of reducing localized fatdeposits that does not require surgery or prolonged recovery time andhas fewer adverse side effects than currently available methods.

SUMMARY

The present invention relates to indole compounds, compositions, anduses thereof, including uses of the indole compounds and compositionsfor the reduction or removal of localized fat deposits and/or tighteningof skin and soft tissue laxity in subjects.

The present disclosure provides, in some embodiments, a method fornon-surgical reduction or removal of one or more localized fat depositsin a subject having localized fat accumulation comprising administeringto a target site in the fat deposit a composition comprising a compoundof Formula (I):

wherein

R¹ is hydrogen, C₁₋₆ alkyl, hydroxyl, or —(CH₂)_(x)—CONH₂;

R², R³, R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen,C₁₋₆alkyl, C₁₋₆alkoxy, amino, substituted amino, halogen, heteroaryl,substituted heteroaryl, —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl, —(CH₂)_(x)—OH,—(CH₂)_(x)—CN, —OCH₂C₆H₅, —OCOCH₃, —(CH₂)_(x)—CONH₂, —CHO,—(CH₂)_(x)—COOH, —(CH₂)_(x)—COOC₁₋₆ alkyl, —(CH₂)_(y)—CO—COOH, and—(CH₂)_(y)—C(H)(OH)—COOH; or

any two adjacent R⁴, R⁵, R⁶, and R⁷, together with the atoms they attachto, form a five to seven-membered carbocyclic ring; or

R² and R³, together with the atoms they attach to, form an unsubstitutedor substituted five to seven-membered heterocyclyl ring;

x is a number from zero to six; and

y is a number from zero to six;

or a pharmaceutically acceptable salt thereof.

The present disclosure provides, in some embodiments, a method forreducing a subcutaneous fat deposit in a subject having subcutaneous fatdeposit comprising administering to a target site in the subcutaneousfat deposit a composition comprising a compound of Formula (I):

wherein

R¹ is hydrogen, C₁₋₆ alkyl, hydroxyl, or —(CH₂)_(x)—CONH₂;

R², R³, R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen,C₁₋₆alkyl, C₁₋₆alkoxy, amino, substituted amino, halogen, heteroaryl,substituted heteroaryl, —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl, —(CH₂)_(x)—OH,—(CH₂)_(x)—CN, —OCH₂C₆H₅, —OCOCH₃, —(CH₂)_(x)—CONH₂, —CHO,—(CH₂)_(x)—COOH, —(CH₂)_(x)—COOC₁₋₆ alkyl, —(CH₂)_(y)—CO—COOH, and—(CH₂)_(y)—C(H)(OH)—COOH; or

any two adjacent R⁴, R⁵, R⁶, and R⁷, together with the atoms they attachto, form a five to seven-membered carbocyclic ring; or

R² and R³, together with the atoms they attach to, form an unsubstitutedor substituted five to seven-membered heterocyclyl ring;

x is a number from zero to six; and

y is a number from zero to six;

or a pharmaceutically acceptable salt thereof.

The present disclosure provides, in some embodiments, a method fortreating an adipose tissue disorder or an adipose tissue tumor in asubject comprising locally administering to the subject a compositioncomprising a compound of Formula (I):

wherein

R¹ is hydrogen, C₁₋₆ alkyl, hydroxyl, or —(CH₂)_(x)—CONH₂;

R², R³, R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen,C₁₋₆alkyl, C₁₋₆alkoxy, amino, substituted amino, halogen, heteroaryl,substituted heteroaryl, —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl, —(CH₂)_(x)—OH,—(CH₂)_(x)—CN, —OCH₂C₆H₅, —OCOCH₃, —(CH₂)_(x)—CONH₂, —CHO,—(CH₂)_(x)—COOH, —(CH₂)_(x)—COOC₁₋₆ alkyl, —(CH₂)_(y)—CO—COOH, and—(CH₂)_(y)—C(H)(OH)—COOH; or

any two adjacent R⁴, R⁵, R⁶, and R⁷, together with the atoms they attachto, form a five to seven-membered carbocyclic ring; or

R² and R³, together with the atoms they attach to, form an unsubstitutedor substituted five to seven-membered heterocyclyl ring;

x is a number from zero to six; and

y is a number from zero to six;

or a pharmaceutically acceptable salt thereof.

The present disclosure provides, in some embodiments, a method fordecreasing submental fat deposit under a skin area in a subjectcomprising administering to a target site in the fat deposit acomposition comprising a compound of Formula (I):

wherein

R¹ is hydrogen, C₁₋₆ alkyl, hydroxyl, or —(CH₂)_(x)—CONH₂;

R², R³, R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen,C₁₋₆alkyl, C₁₋₆alkoxy, amino, substituted amino, halogen, heteroaryl,substituted heteroaryl, —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl, —(CH₂)_(x)—OH,—(CH₂)_(x)—CN, —OCH₂C₆H₅, —OCOCH₃, —(CH₂)_(x)—CONH₂, —CHO,—(CH₂)_(x)—COOH, —(CH₂)_(x)—COOC₁₋₆ alkyl, —(CH₂)_(y)—CO—COOH, and—(CH₂)_(y)—C(H)(OH)—COOH; or

any two adjacent R⁴, R⁵, R⁶, and R⁷, together with the atoms they attachto, form a five to seven-membered carbocyclic ring; or

R² and R³, together with the atoms they attach to, form an unsubstitutedor substituted five to seven-membered heterocyclyl ring;

x is a number from zero to six; and

y is a number from zero to six;

or a pharmaceutically acceptable salt thereof.

The present disclosure provides, in some embodiments, a method forpreventing or reducing a skin condition (including method of tighteningskin and/or lax subcutaneous tissue) associated with aging in a subjectcomprising locally administering to the subject a composition comprisinga compound of Formula (I):

wherein

R¹ is hydrogen, C₁₋₆ alkyl, hydroxyl, or —(CH₂)_(x)—CONH₂;

R², R³, R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen,C₁₋₆alkyl, C₁₋₆alkoxy, amino, substituted amino, halogen, heteroaryl,substituted heteroaryl, —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl, —(CH₂)_(x)—OH,—(CH₂)_(x)—CN, —OCH₂C₆H₅, —OCOCH₃, —(CH₂)_(x)—CONH₂, —CHO,—(CH₂)_(x)—COOH, —(CH₂)_(x)—COOC₁₋₆ alkyl, —(CH₂)_(y)—CO—COOH, and—(CH₂)_(y)—C(H)(OH)—COOH; or

any two adjacent R⁴, R⁵, R⁶, and R⁷, together with the atoms they attachto, form a five to seven-membered carbocyclic ring; or

R² and R³, together with the atoms they attach to, form an unsubstitutedor substituted five to seven-membered heterocyclyl ring;

x is a number from zero to six; and

y is a number from zero to six;

or a pharmaceutically acceptable salt thereof.

The present disclosure provides, in some embodiments, a method fortreating sleep apnea in a subject comprising locally administering acomposition comprising a compound of Formula (I), wherein the sleepapnea is caused by a fat deposit around a trachea in the subject and theadministration of the composition is to the fat deposit around thetrachea, and wherein Formula (I) is:

wherein

R¹ is hydrogen, C₁₋₆ alkyl, hydroxyl, or —(CH₂)_(x)—CONH₂;

R², R³, R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen,C₁₋₆alkyl, C₁₋₆alkoxy, amino, substituted amino, halogen, heteroaryl,substituted heteroaryl, —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl, —(CH₂)_(x)—OH,—(CH₂)_(x)—CN, —OCH₂C₆H₅, —OCOCH₃, —(CH₂)_(x)—CONH₂, —CHO,—(CH₂)_(x)—COOH, —(CH₂)_(x)—COOC₁₋₆ alkyl, —(CH₂)_(y)—CO—COOH, and—(CH₂)_(y)—C(H)(OH)—COOH; or

any two adjacent R⁴, R⁵, R⁶, and R⁷, together with the atoms they attachto, form a five to seven-membered carbocyclic ring; or

R² and R³, together with the atoms they attach to, form an unsubstitutedor substituted five to seven-membered heterocyclyl ring;

x is a number from zero to six; and

y is a number from zero to six;

or a pharmaceutically acceptable salt thereof.

In some embodiments of any of the above methods, the compound is ofFormula (II):

wherein

R¹ is hydrogen, C₁₋₆ alkyl, or hydroxy;

R², R³, R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen,C₁₋₆alkyl, C₁₋₆alkoxy, amino, substituted amino, halogen,—(CH₂)_(x)—C(O)—OC₁₋₆ alkyl, —(CH₂)_(x)—OH, —(CH₂)_(x)—CN, —OCH₂C₆H₅,—CHO, —(CH₂)_(x)—COOH, —(CH₂)_(x)—COOC₁₋₆ alkyl, —(CH₂)_(y)—CO—COOH, and—(CH₂)_(y)—C(H)(OH)—COOH; or

any two adjacent R⁴, R⁵, R⁶, and R⁷, together with the atoms they attachto, form a five to seven-membered carbocyclic ring;

x is a number from zero to six; and

y is a number from zero to six;

or a pharmaceutically acceptable salt thereof.

In some embodiments of any of the above methods, the compound is ofFormula (III):

wherein

R¹ is hydrogen, C₁₋₆ alkyl, or hydroxy;

R², R³, R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen,C₁₋₆alkyl, C₁₋₆alkoxy, amino, substituted amino, halogen,—(CH₂)_(x)—C(O)—OC₁₋₆ alkyl, —(CH₂)_(x)—OH, —(CH₂)_(x)—CN, —OCH₂C₆H₅,—CHO, —(CH₂)_(x)—COOH, —(CH₂)_(x)—COOC₁₋₆ alkyl, —(CH₂)_(y)—CO—COOH, and—(CH₂)_(y)—C(H)(OH)—COOH; or

any two adjacent R⁴, R⁵, R⁶, and R⁷, together with the atoms they attachto, form a five to seven-membered carbocyclic ring;

x is a number from zero to six; and

y is a number from zero to six;

or a pharmaceutically acceptable salt thereof;

provided that at least one of R², R³, R⁴, R⁵, R⁶, and R⁷ is bromo.

In some embodiments of any of the above methods, the compound is ofFormula (IV):

wherein

R¹ is hydrogen, C₁₋₆ alkyl, or hydroxy;

R², R³, R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen,C₁₋₆alkyl, C₁₋₆alkoxy, amino, substituted amino, halogen,—(CH₂)_(x)—C(O)—OC₁₋₆ alkyl, —(CH₂)_(x)—OH, —(CH₂)_(x)—CN, —OCH₂C₆H₅,—CHO, —(CH₂)_(x)—COOH, —(CH₂)_(x)—COOC₁₋₆ alkyl, —(CH₂)_(y)—CO—COOH, and—(CH₂)_(y)—C(H)(OH)—COOH; or

any two adjacent R⁴, R⁵, R⁶, and R⁷, together with the atoms they attachto, form a five to seven-membered carbocyclic ring;

x is a number from zero to six; and

y is a number from zero to six;

or a pharmaceutically acceptable salt thereof;

provided that at least one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —CHO or—(CH₂)_(x)—COOH.

In some embodiments of any of the above methods, the compound is ofFormula (V):

wherein

R¹ is hydrogen or C₁₋₆ alkyl;

R², R³, R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen,C₁₋₆alkyl, C₁₋₆alkoxy, —OCH₂C₆H₅, halogen, —CHO, —(CH₂)_(x)—COOH; and

x is a number from zero to six;

or a pharmaceutically acceptable salt thereof.

In some embodiments of any of the above methods, the compound is ofFormula (VI):

wherein

R¹ is hydrogen or C₁₋₆ alkyl;

R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen, C₁₋₆alkyl,C₁₋₆alkoxy, amino, substituted amino, halogen, heteroaryl, substitutedheteroaryl, —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl, —(CH₂)_(x)—OH, —(CH₂)_(x)—CN,—OCH₂C₆H₅, —OCOCH₃, —(CH₂)_(x)—CONH₂, —CHO, —(CH₂)_(x)—COOH,—(CH₂)_(x)—COOC₁₋₆ alkyl, —(CH₂)_(y)—CO—COOH, and—(CH₂)_(y)—C(H)(OH)—COOH;

R⁸, R¹⁰, and R¹¹ are independently selected from hydrogen, halogen,—(CH₂)_(x)—C(O)—OC₁₋₆ alkyl, —(CH₂)_(x)—OH, —(CH₂)_(x)—CN, —OCH₂C₆H₅,—OCOCH₃, —(CH₂)_(x)—CONH₂, —CHO, —(CH₂)_(x)—COOH, —(CH₂)_(x)—COOC₁₋₆alkyl, —(CH₂)_(y)—CO—COOH, —(CH₂)_(y)—C(H)(OH)—COOH, phenyl, andsubstituted phenyl; wherein the substituted phenyl is substituted with1-4 substituents selected from hydroxyl, C₁₋₆alkoxy, and C₁₋₆alkyl;

R⁹ is hydrogen or C₁₋₆ alkyl;

x is a number from zero to six; and

y is a number from zero to six;

or a pharmaceutically acceptable salt thereof.

In some embodiments, the compound is selected from Compounds 2, 10, 29,38, 40, 41, 43, and 44. In some embodiments, the compound is Compound 2.In some embodiments, the compound is Compound 43. In some embodiments,the administering step is by injection, transdermal pump, transdermalpatch, or a subdermal depot. In some embodiments, the administering stepis by subcutaneous injection. In some embodiments, the subject is amammal. In some embodiments, the subject is a human. In someembodiments, the method further comprises administering to the subject asecond therapeutic agent.

In some embodiments, the compound of Formula (I) is a compound selectedfrom those species described or exemplified in the detailed descriptionbelow.

In a further aspect, the present disclosure provides a compositioncomprising a compound of Formula (I) or a pharmaceutically acceptablesalt, solvate, or hydrate thereof. The compositions may further comprisea pharmaceutically acceptable excipient (such as pharmaceuticallyacceptable excipients suitable for injection). The present disclosurealso provides a composition comprising a compound of Formula (I) or apharmaceutically acceptable salt thereof for use as a medicament.

The present disclosure also provides a composition comprising a compoundof Formula (I) or a pharmaceutically acceptable salt thereof and apharmaceutically acceptable excipient, wherein the composition issuitable for local administration, such as injection (such assubcutaneous injection, intradermal injection, or intramuscularinjection), transdermal pump, transdermal patch, or subdermal depot.

In another aspect, the present disclosure provides a compositioncomprising a compound of Formula (I) or a pharmaceutically acceptablesalt thereof for use in therapy.

The present disclosure provides, in some embodiments, a compositioncomprising a compound of Formula (I) for non-surgical reduction orremoval of one or more localized fat deposits in a subject. The presentdisclosure provides, in some embodiments, a composition comprising acompound of Formula (I) for reducing a subcutaneous fat deposit in asubject. The present disclosure provides, in some embodiments, acomposition comprising a compound of Formula (I) for treating an adiposetissue disorder or an adipose tissue tumor in a subject. The presentdisclosure provides, in some embodiments, a composition comprising acompound of Formula (I) for decreasing submental fat deposit under askin area in a subject. The present disclosure provides in someembodiments, a composition comprising a compound of Formula (I) forpreventing or reducing a skin condition (including method of tighteningskin and lax subcutaneous tissue) associated with aging in a subject.The present disclosure provides, in some embodiments, a compositioncomprising a compound of Formula (I) for the treatment or improvement ofskin and soft tissue laxity due to aging, weight loss, geneticdeterminants or other disorder. The present disclosure provides, in someembodiments, a composition comprising a compound of Formula (I) fortreating sleep apnea in a subject.

The present disclosure provides, in some embodiments, a compositioncomprising a compound of Formula (I) for the manufacture of a medicamentfor non-surgical reduction or removal of one or more localized fatdeposits in a subject. The present disclosure provides, in someembodiments, a composition comprising a compound of Formula (I) for themanufacture of a medicament for reducing a subcutaneous fat deposit in asubject. The present disclosure provides, in some embodiments, acomposition comprising a compound of Formula (I) for the manufacture ofa medicament for treating an adipose tissue disorder or an adiposetissue tumor in a subject. The present disclosure provides, in someembodiments, a composition comprising a compound of Formula (I) for themanufacture of a medicament for decreasing submental fat deposit under askin area in a subject. The present disclosure provides in someembodiments, a composition comprising a compound of Formula (I) for themanufacture of a medicament for preventing or reducing a skin condition(including method of tightening skin and lax subcutaneous tissue)associated with aging in a subject. The present disclosure provides, insome embodiments, a composition comprising a compound of Formula (I) forthe manufacture of a medicament for the treatment or improvement of skinand soft tissue laxity due to aging, weight loss, genetic determinantsor other disorder. The present disclosure provides, in some embodiments,a composition comprising a compound of Formula (I) for the manufactureof a medicament for treating sleep apnea in a subject.

The present disclosure provides a kit for the reduction or removal oflocalized fat deposits and/or skin and soft tissue tightening in asubject. The present disclosure provides a kit comprising a container,wherein the container comprises a composition comprising a compound ofFormula (I). The present disclosure provides a syringe comprising acomposition comprising a compound of Formula (I). The present disclosureprovides a unit dose comprising an amount of a composition comprising acompound of Formula (I).

Additional embodiments, features, and advantages of the invention willbe apparent from the following detailed description and through practiceof the invention.

For the sake of brevity, the disclosures of the publications cited inthis specification, including patents, are herein incorporated byreference.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1. (A) Change in Ethidium Bromide Fluorescence (EB) Intensity as afunction of incubation time. Approximately 1.5-2 million adipocytecells/ml were incubated for varying amounts of time in the presence oftest compounds. (B) Magnified portion of FIG. 1A highlighting thediverse range of activity.

FIG. 2. Histogram profiles of Ethidium Bromide Fluorescence Intensityand signal ratio at (A-B) 1 hour (C-D) 4 hours (E-F) 18 hours and (G-H)24 hours after incubation of adipocytes with test compounds. The signalratio is a normalized measure of cell death that incorporates live cellquantity.

FIG. 3. Concentration dependent effects of test compounds on adipocytecell cytotoxicity (EB signal) after incubation for (A) 1 hour (B) 12hours and (C) 24 hours.

FIG. 4. Histogram profiles of Ethidium Bromide Fluorescence Intensityand signal ratio after incubation of adipocytes with 10 mg/ml drugsubstance for (A-B) 1 hour (C-D) 12 hours and (E-F) 24 hours.

FIG. 5. LIVE/DEAD® assay results for test compounds for adipocytes,dermis, muscle, and endothelial cells for Compound A (Aqualyx®) andCompounds 2, 29, 40, 41, and 43.

FIG. 6. LIVE/DEAD® assay results for test compounds for adipocytes,dermis, and muscle cells for Compound B (saline control) and Compounds1, 2, 3, 4, 5, and 10. All the bars in FIG. 9 indicate kill rate(ethidium). In the compound number, “a” refers to compound tissuepreference at 2 hours. In the compound number, “b” refers to compoundtissue preference at 5 hours.

FIG. 7. LIVE/DEAD® assay results for test compounds for adipocytes,dermis, and muscle cells for Compound C (saline control), Compounds Dand E (deoxycholate), and Compounds 29, 7, 33, 38, and 40. All the barsin FIG. 7 indicate kill rate (ethidium). In the compound number, “a”refers to compound tissue preference at 2 hours. In the compound number,“b” refers to compound tissue preference at 5 hours.

FIG. 8. LIVE/DEAD® assay results for test compounds for adipocytes,dermis, and muscle cells for Compound F (saline control), Compounds G(Aqualyx®), and Compounds 41, 43, and 44. All the bars in FIG. 8indicate kill rate (ethidium). In the compound number, “a” refers tocompound tissue preference at 2 hours. In the compound number, “b”refers to compound tissue preference at 5 hours.

FIG. 9A shows a saline control with adipocytes intact. FIG. 9B shows ahistology test sample with 1% deoxycholate at 4 hours. FIG. 9C shows ahistology test sample with PC50/DC 24 at 12 hours. FIG. 9D shows ahistology test sample with Compound 88 at 4 hours. FIG. 9E shows ahistology test sample with Compound 41 at twelve hours. FIG. 9F shows ahistology test sample with Compound 38 at four hours. FIG. 9G shows ahistology test sample with Compound 2 at 1 hour. FIG. 9H shows ahistology test sample with Compound 29 at 12 hours. FIG. 9I shows ahistology test sample with Compound 33 at 4 hours.

FIG. 10 shows a diagram of an injection pattern for basic level users ofan injectable lipolytic composition.

FIG. 11 shows the kill rate of adipocytes, dermal cells, nerve cells,muscle cells, and endothelial cells treated with saline, excipient,phosphatidylcholine plus deoxycholate, or Aqualyx.

FIG. 12 shows the kill rate of adipocytes, dermal cells, nerve cells,muscle cells, and endothelial cells treated with test compounds A-Ecompared to Aqualyx, phosphatidylcholine plus deoxycholate, and salinecontrols.

FIG. 13 shows the kill rate of adipocytes, dermal cells, nerve cells,muscle cells, and endothelial cells treated with test compounds F-Jcompared to Aqualyx, phosphatidylcholine plus deoxycholate, and salinecontrols.

FIG. 14 shows the effect of a sample compound on a mouse fat pad graftone day after injection.

FIG. 15 shows the effect of Compound B on a mouse fat pad graft one weekafter injection.

FIG. 16 shows the effect of deoxycholate on a mouse fat pad graft oneday after injection.

FIG. 17 shows the effect of Compound D (above) compared to excipientcontrol (below) on a mouse fat pad graft one week after injection.

FIG. 18 shows the effect of Compound H on a mouse fat pad graft one weekafter injection.

FIG. 19 shows the effect of Compound I on a mouse fat pad graft twoweeks after injection.

FIG. 20 shows the effect of Compound I on a fat pad graft four weeksafter injection.

FIG. 21 shows the effect of phosphatidylcholine plus deoxycholate on amouse fat pad graft four weeks after injection.

FIG. 22 shows a scanning electron micrograph of the effect of salinecontrol on fat cells.

FIG. 23 shows a scanning electron micrograph of the effect ofdeoxycholate on fat cells.

FIG. 24 shows a scanning electron micrograph of an untreated, culturedadipocyte.

FIG. 25 shows a scanning electron micrograph of an intact adipocyte invivo.

FIG. 26 shows a scanning electron micrograph of cultured adipocytestreated with phosphatidylcholine plus deoxycholate four hours aftertreatment.

FIG. 27 shows a scanning electron micrograph of adipocytes treated invivo with phosphatidylcholine plus deoxycholate four weeks aftertreatment.

FIG. 28 shows a scanning electron micrograph of a single culturedadipocyte treated with deoxycholate after four hours of treatment.

FIG. 29 shows a scanning electron micrograph of tissue treated withdeoxycholate four weeks after treatment.

FIG. 30 shows a mechanism of action for adipocyte cell death.

FIG. 31 shows a mechanism of action for adipocyte cell death.

FIG. 32 shows a scanning electron micrograph of adipocytes treated withCompound A in vivo four weeks after treatment.

FIG. 33 shows a scanning electron micrograph of the effect of Compound Bon a cultured adipocyte.

FIG. 34 shows a scanning electron micrograph of adipocytes treated withCompound B in vivo four weeks after treatment.

FIG. 35 shows a scanning electron micrograph of adipocytes treated withCompound C in vivo after four hours of treatment.

FIG. 36 shows a scanning electron micrograph of adipocytes treated withDMSO excipient in vivo four weeks after treatment.

FIG. 37 shows a scanning electron micrograph of an adipocyte undergoingporation.

FIG. 38 shows a scanning electron micrograph of an adipocyte with lipiddroplets underneath its cell membrane.

FIG. 39 shows a scanning electron micrograph of an adipocyte undergoingeffusion.

FIG. 40 shows a scanning electron micrograph of an adipocyte treatedwith Compound J four weeks after treatment.

FIG. 41 shows a scanning electron micrograph of an adipocyte undergoingcell death.

FIG. 42 shows a scanning electron micrograph of adipocytes treated withsaline in vivo four weeks after treatment.

FIG. 43 shows a scanning electron micrograph of adipocytes treated withphosphatidyl choline and deoxycholate in vivo four weeks aftertreatment.

FIG. 44 shows a scanning electron micrograph of adipocytes treated withdeoxycholate in vivo four weeks after treatment.

FIG. 45 shows a scanning electron micrograph of adipocytes treated withCompound J four weeks after treatment.

FIG. 46 shows a scanning electron micrograph of human fat treated withCompound D four weeks after treatment.

FIG. 47 shows a scanning electron micrograph of adipocytes treated withCompound E in vivo, four weeks after treatment.

FIG. 48 shows a scanning electron micrograph of adipocytes treated withCompound I in vivo, four weeks after treatment.

FIG. 49 shows a scanning electron micrograph of adipocytes treated withCompound H four weeks after treatment.

FIG. 50 shows a scanning electron micrograph of adipocytes treated withCompound I four hours after treatment.

DEFINITIONS

The following terms have the following meanings unless otherwiseindicated. Any undefined terms have their art recognized meanings.

“Alkyl” refers to monovalent saturated aliphatic hydrocarbyl groupshaving from 1 to 10 carbon atoms and preferably 1 to 6 carbon atoms.This term includes, by way of example, linear and branched hydrocarbylgroups such as methyl (CH₃—), ethyl (CH₃CH₂—), n-propyl (CH₃CH₂CH₂—),isopropyl ((CH₃)₂CH—), n-butyl (CH₃CH₂CH₂CH₂—), isobutyl ((CH₃)₂CHCH₂—),sec-butyl ((CH₃)(CH₃CH₂)CH—), t-butyl ((CH₃)₃C—), n-pentyl(CH₃CH₂CH₂CH₂CH₂—), neopentyl ((CH₃)₃CCH₂—), and n-hexyl (CH₃(CH₂)₅—).

“Alkoxy” refers to the group —O-alkyl, wherein alkyl is as definedherein. Alkoxy includes, by way of example, methoxy, ethoxy, n-propoxy,isopropoxy, n-butoxy, t-butoxy, sec-butoxy, n-pentoxy, and the like. Theterm “alkoxy” also refers to the groups alkenyl-O—, cycloalkyl-O—,cycloalkenyl-O—, and alkynyl-O—, where alkenyl, cycloalkyl,cycloalkenyl, and alkynyl are as defined herein.

“Amino” refers to the group —NH₂.

“Substituted amino” refers to the group —NRR where each R isindependently selected from the group consisting of hydrogen, alkyl,substituted alkyl, cycloalkyl, substituted cycloalkyl, alkenyl,substituted alkenyl, cycloalkenyl, substituted cycloalkenyl, alkynyl,substituted alkynyl, aryl, heteroaryl, and heterocyclyl provided that atleast one R is not hydrogen.

“Carbaldehyde” and “carboxaldehyde” refer to the group —CHO.

“Halogen” refers to fluoro, chloro, bromo, and iodo.

The terms “carbocyclic ring”, “carbocycle” or “carbocyclic ring system”denote a ring or ring system wherein the atoms forming the ring backboneare selected only from carbon. Unless otherwise indicated, a carbocyclicring can be a saturated, partially unsaturated, or fully unsaturatedring. When a fully unsaturated carbocyclic ring satisfies Huckel's rule,then the ring is also called an “aromatic ring”. “Saturated carbocyclic”refers to a ring having a backbone consisting of carbon atoms linked toone another by single bonds; unless otherwise specified, the remainingcarbon valences are occupied by hydrogen atoms.

“Heteroaryl” refers to an aromatic group of from 1 to 15 carbon atoms,such as from 1 to 10 carbon atoms and 1 to 10 heteroatoms selected fromthe group consisting of oxygen, nitrogen, and sulfur within the ring.Such heteroaryl groups can have a single ring (such as, pyridinyl,imidazolyl or furyl) or multiple condensed rings in a ring system (forexample as in groups such as, indolizinyl, quinolinyl, benzofuran,benzimidazolyl or benzothienyl), wherein at least one ring within thering system is aromatic and at least one ring within the ring system isaromatic, provided that the point of attachment is through an atom of anaromatic ring. In certain embodiments, the nitrogen and/or sulfur ringatom(s) of the heteroaryl group are optionally oxidized to provide forthe N-oxide (N→O), sulfinyl, or sulfonyl moieties. This term includes,by way of example, benzimidazolyl, pyridinyl, pyrrolyl, indolyl,thiophenyl, and furanyl. Unless otherwise constrained by the definitionfor the heteroaryl substituent, such heteroaryl groups can be optionallysubstituted with 1 to 5 substituents, or from 1 to 3 substituents,selected from acyloxy, hydroxy, thiol, acyl, alkyl, alkoxy, alkenyl,alkynyl, cycloalkyl, cycloalkenyl, substituted alkyl, substitutedalkoxy, substituted alkenyl, substituted alkynyl, substitutedcycloalkyl, substituted cycloalkenyl, amino, substituted amino,aminoacyl, acylamino, alkaryl, aryl, aryloxy, azido, carboxyl, carboxylester, cyano, halogen, nitro, heteroaryl, heteroaryloxy, heterocyclyl,heterocyclooxy, aminoacyloxy, oxyacylamino, thioalkoxy, substitutedthioalkoxy, thioaryloxy, thioheteroaryloxy, sulfonylamino, —SO-alkyl,—SO-substituted alkyl, —SO-aryl, —SO-heteroaryl, —SO₂-alkyl,—SO₂-substituted alkyl, —SO₂-aryl and —SO₂-heteroaryl, andtrihalomethyl.

Examples of heteroaryls include, but are not limited to, benzimidazole,pyrrole, imidazole, pyrazole, pyridine, pyrazine, pyrimidine,pyridazine, indolizine, isoindole, indole, purine, isoquinoline,quinoline, phthalazine, naphthylpyridine, quinoxaline, quinazoline,cinnoline, pteridine, carbazole, carboline, phenanthridine, acridine,phenanthroline, isothiazole, phenazine, isoxazole, phenoxazine,phenothiazine, piperidine, piperazine, phthalimide,4,5,6,7-tetrahydrobenzo[b]thiophene, thiazole, thiophene,benzo[b]thiophene, and the like.

“Heterocycle,” “heterocyclic,” “heterocycloalkyl” or “heterocyclyl”refers to a saturated or partially unsaturated group having a singlering or multiple condensed rings, including fused, bridged, or spiroring systems, and having from 3 to 20 ring atoms, including 1 to 10hetero atoms. These ring atoms are selected from the group consisting ofcarbon, nitrogen, sulfur, or oxygen, wherein, in fused ring systems, oneor more of the rings can be cycloalkyl, aryl, or heteroaryl, providedthat the point of attachment is through the non-aromatic ring. Incertain embodiments, the nitrogen and/or sulfur atom(s) of theheterocyclic group are optionally oxidized to provide for N-oxide,—S(O)—, or —SO₂— moieties.

Examples of heterocycles include, but are not limited to, azetidine,dihydroindole, indazole, quinolizine, imidazolidine, imidazoline,piperidine, piperazine, indoline, 1,2,3,4-tetrahydroisoquinoline,thiazolidine, morpholinyl, thiomorpholinyl (also referred to asthiamorpholinyl), 1,1-dioxothiomorpholinyl, piperidinyl, pyrrolidine,tetrahydrofuranyl, and the like.

Where a heteroaryl or heterocyclyl group is “substituted,” unlessotherwise constrained by the definition for the heteroaryl orheterocyclic substituent, such heteroaryl or heterocyclic groups can besubstituted with 1 to 5, or from 1 to 3 substituents, selected fromalkyl, substituted alkyl, alkoxy, substituted alkoxy, cycloalkyl,substituted cycloalkyl, cycloalkenyl, substituted cycloalkenyl, acyl,acylamino, acyloxy, amino, substituted amino, aminoacyl, aminoacyloxy,azido, cyano, halogen, hydroxyl, oxo, thioketo, carboxyl, carboxylester, thioaryloxy, thioheteroaryloxy, thioheterocyclooxy, thiol,thioalkoxy, substituted thioalkoxy, aryl, aryloxy, heteroaryl,heteroaryloxy, heterocyclyl, heterocyclooxy, hydroxyamino, alkoxyamino,nitro, sulfonylamino, —SO-alkyl, —SO-substituted alkyl, —SO-aryl,—SO-heteroaryl, —SO-heterocyclyl, —SO₂-alkyl, —SO₂-substituted alkyl,—SO₂-aryl, —SO₂-heteroaryl, and —SO₂-heterocyclyl.

The term “substituted,” when used to modify a specified group orradical, can mean that one or more hydrogen atoms of the specified groupor radical are each, independently of one another, replaced with thesame or different substituent groups.

In a certain embodiment, a group that is substituted has 1, 2, 3, or 4substituents, 1, 2, or 3 substituents, 1 or 2 substituents, or 1substituent.

It is understood that in all substituted groups defined above, compoundsarrived at by defining substituents with further substituents tothemselves (e.g., substituted aryl having a substituted aryl group as asubstituent which is itself substituted with a substituted aryl group,which is further substituted by a substituted aryl group, etc.) are notintended for inclusion herein. In such cases, the maximum number of suchsubstitutions is three. For example, serial substitutions of substitutedaryl groups specifically contemplated herein are limited to substitutedaryl-(substituted aryl)-substituted aryl.

Unless indicated otherwise, the nomenclature of substituents that arenot explicitly defined herein are arrived at by naming the terminalportion of the functionality followed by the adjacent functionalitytoward the point of attachment. For example, the substituent“arylalkyloxycarbonyl” refers to the group (aryl)-(alkyl)-O—C(O)—.

As to any of the groups disclosed herein which contain one or moresubstituents, it is understood, of course, that such groups do notcontain any substitution or substitution patterns which are stericallyimpractical and/or synthetically non-feasible. In addition, the subjectcompounds include all stereochemical isomers arising from thesubstitution of these compounds.

The term “pharmaceutically acceptable salt” means a salt which isacceptable for administration to a subject, such as a mammal (salts withcounterions having acceptable mammalian safety for a given dosageregime). Such salts can be derived from pharmaceutically acceptableinorganic or organic bases and from pharmaceutically acceptableinorganic or organic acids. “Pharmaceutically acceptable salt” refers topharmaceutically acceptable salts of a compound, which salts are derivedfrom a variety of organic and inorganic counter ions well known in theart and include, by way of example only, sodium, potassium, calcium,magnesium, ammonium, tetraalkylammonium, and the like; and when themolecule contains a basic functionality, salts of organic or inorganicacids, such as hydrochloride, hydrobromide, formate, tartrate, besylate,mesylate, acetate, maleate, oxalate, and the like.

The term “salt thereof” means a compound formed when a proton of an acidis replaced by a cation, such as a metal cation or an organic cation andthe like. Where applicable, the salt is a pharmaceutically acceptablesalt, although this is not required for salts of intermediate compoundsthat are not intended for administration to the subject. By way ofexample, salts of the present compounds include those wherein thecompound is protonated by an inorganic or organic acid to form a cation,with the conjugate base of the inorganic or organic acid as the anioniccomponent of the salt.

“Solvate” refers to a complex formed by combination of solvent moleculeswith molecules or ions of the solute. The solvent can be an organiccompound, an inorganic compound, or a mixture of both. Some examples ofsolvents include, but are not limited to, methanol,N,N-dimethylformamide, tetrahydrofuran, dimethylsulfoxide, and water.When the solvent is water, the solvate formed is a hydrate.

“Tautomer” refers to alternate forms of a molecule that differ only inelectronic bonding of atoms and/or in the position of a proton, such asenol-keto and imine-enamine tautomers, or the tautomeric forms ofheteroaryl groups containing a —N═C(H)—NH— ring atom arrangement, suchas pyrazoles, imidazoles, benzimidazoles, triazoles, and tetrazoles. Aperson of ordinary skill in the art would recognize that othertautomeric ring atom arrangements are possible.

It will be appreciated that the term “or a salt or solvate orstereoisomer thereof” is intended to include all permutations of salts,solvates and stereoisomers, such as a solvate of a pharmaceuticallyacceptable salt of a stereoisomer of subject compound.

As used herein, an “effective dosage” or “effective amount” of drug,compound, or pharmaceutical composition is an amount sufficient toeffect beneficial or desired results. An effective dosage can beadministered in one or more administrations. As is understood in theclinical context, an effective dosage of a drug, compound, orpharmaceutical composition may or may not be achieved in conjunctionwith another drug, compound, or pharmaceutical composition. Thus, an“effective dosage” may be considered in the context of administering oneor more therapeutic agents, and a single agent may be considered to begiven in an effective amount if, in conjunction with one or more otheragents, a desirable result may be or is achieved.

As used herein, “in conjunction with” refers to administration of onetreatment modality in addition to another treatment modality. As such,“in conjunction with” refers to administration of one treatment modalitybefore, during or after administration of the other treatment modalityto the individual.

An “individual” or a “subject” is a mammal, more preferably a human.Mammals also include, but are not limited to, farm animals, sportanimals, pets (such as cats, dogs, horses), primates, mice and rats.

As used herein and in the appended claims, the singular forms “a,” “an,”and “the” include plural reference unless the context clearly indicatesotherwise.

Reference to “about” a value or parameter herein includes (anddescribes) embodiments that are directed to that value or parameter perse. For example, description referring to “about X” includes descriptionof “X.”

It is understood that aspect and variations of the invention describedherein include “consisting” and/or “consisting essentially of” aspectsand variations.

Unless defined otherwise, all technical and scientific terms used hereinhave the same meaning as commonly understood by one of ordinary skill inthe art to which this invention belongs. Although any methods andmaterials similar or equivalent to those described herein can also beused in the practice or testing of the present invention, the preferredmethods and materials are now described. All publications mentionedherein are incorporated herein by reference to disclose and describe themethods and/or materials in connection with which the publications arecited.

Except as otherwise noted, the methods and techniques of the presentembodiments are generally performed according to conventional methodswell known in the art and as described in various general and morespecific references that are cited and discussed throughout the presentspecification. See, e.g., Loudon, Organic Chemistry, 4^(th) edition, NewYork: Oxford University Press, 2002, pp. 360-361, 1084-1085; Smith andMarch, March's Advanced Organic Chemistry: Reactions, Mechanisms, andStructure, 5^(th) edition, Wiley-Interscience, 2001.

The nomenclature used herein to name the subject compounds isillustrated in the Examples herein. This nomenclature has generally beenderived using the commercially-available AutoNom software (MDL, SanLeandro, Calif.).

It is appreciated that certain features of the invention, which are, forclarity, described in the context of separate embodiments, may also beprovided in combination in a single embodiment. Conversely, variousfeatures of the invention, which are, for brevity, described in thecontext of a single embodiment, may also be provided separately or inany suitable subcombination. All combinations of the embodimentspertaining to the chemical groups represented by the variables arespecifically embraced by the present invention and are disclosed hereinjust as if each and every combination was individually and explicitlydisclosed, to the extent that such combinations embrace compounds thatare stable compounds (i.e., compounds that can be isolated,characterized, and tested for biological activity). In addition, allsubcombinations of the chemical groups listed in the embodimentsdescribing such variables are also specifically embraced by the presentinvention and are disclosed herein just as if each and every suchsub-combination of chemical groups was individually and explicitlydisclosed herein.

DETAILED DESCRIPTION

The present invention provides methods and lypolytic indole compoundsfor reducing fat and/or tightening skin and lax soft tissue. Tissuespecificity is an important consideration for developing lipolyticagents. Compounds that are not tissue-specific may have significanteffect on neighboring tissues, for example necrosis of blood vessels,eccrine, glands, the reticular layer of the dermis, and demyelination ofperipheral nerves, leading to side effects such as skin loss, itching,numbness, paresthesia, or even mandibular nerve palsy. It wassurprisingly found that indole-based compounds are effective in killingadipocytes selectively and while in the meantime less toxic to musclecells, nerve cells, and dermal cells. These compounds are thereforeparticularly suitable for fat reduction in vivo.

It was further surprisingly found that these indole compounds may havespecific functional profiles in terms of potency, cell specificity, andcell killing characteristics (for example apoptotic, cytolytic, and/orpyroptotic), and that such functional profiles make them particularlysuitable for fat reduction, skin and soft tissue tightening, and/orother applications discussed herein. A tailored treatment can thereforebe developed depending on the amount of fat to be removed, the amount ofanticipated post-treatment tissue laxity or firmness, as well as theeffect on the skin surface area.

For example, in some embodiments, the indole compounds are apoptotic andnon-inflammatory. It was previously shown that injection of currentlyavailable lipolysis drugs, such as deoxycholate or phosphatidylcholinecombined with deoxycholate, produce significant side effects such asprominent and immediate swelling, bruising, pain, and inflammation.Fat-reducing injections that cause little or no swelling, bruising, orpain would therefore be particularly advantageous in many instances andwould allow patients undergo more than one treatments in the desiredregion without severe sequelae. Examples of such desirable treatmentregions include, for example, abdomen, thighs, flanks, and any otherregions with significant adiposity.

In some embodiments, the indole compounds are cytolytic andinflammatory. The cytolytic effect, i.e., cell membrane rupture in softtissue is most likely to cause significant inflammation. While thismechanism may lead to swelling and possibly bruising, the inflammationmay lead to soft tissue tightening, skin surface area reduction, and theproduction of tissue firmness in the case of previous laxity. This isparticularly useful when removing fat in areas involving skin laxity.For example, the degree of pendulous overhang of a region (such as ajowl or a “bat wing” of the arm) can be improved. An area whichpreviously drooped below a normal axis can be lifted, with restorationof a normal contour.

In some embodiments, the indole compounds are pyroptotic, i.e., having acombined effect of apoptosis and cytolysis. Such compounds areparticularly useful when both fat reduction and improvement and skinlaxity are desirable.

Thus, the present invention in one aspect provides compositions suitablefor reducing or removing localized fat deposits and/or tightening skin.In another aspect, there are provided methods for reducing or removinglocalized fat deposit and/or tightening skin. Also provided are kits,unit doses, and articles of manufacture useful for methods describedherein.

METHODS OF THE PRESENT INVENTION

The present disclosure provides methods for using an indole compound.The methods include, but are not limited to, a method for non-surgicalreduction of one or more localized fat deposits; a method for reducing asubcutaneous fat deposit; a method for treating an adipose tissuedisorder or an adipose tissue tumor; a method for decreasing submentalfat deposit under a skin area; a method of preventing or reducing a skincondition associated with aging; and a method for treating obstructivesleep apnea. The methods are described in more detail below.

The present disclosure provides methods for non-surgical reduction orremoval of one or more localized fat deposits in a subject havinglocalized fat accumulation comprising administering to a target site inthe fat deposit a composition comprising an indole compound (such as acompound of Formula (I)). In some embodiments, the method comprisesadministering a compound of any one of Formula (II), (III), (IV), (V)and (VI) or any one of Compounds 2, 10, 29, 38, 40, 41, 43, and 44. Insome embodiments, there is provided a method for non-surgical reductionor removal of one or more localized fat deposits in a subject havinglocalized fat accumulation comprising administering to a target site inthe fat deposit a composition comprising a compound of Formula (II). Insome embodiments, there is provided a method for non-surgical reductionor removal of one or more localized fat deposits in a subject havinglocalized fat accumulation comprising administering to a target site inthe fat deposit a composition comprising a compound of Formula (III). Insome embodiments, there is provided a method for non-surgical reductionor removal of one or more localized fat deposits in a subject havinglocalized fat accumulation comprising administering to a target site inthe fat deposit a composition comprising a compound of Formula (IV). Insome embodiments, there is provided a method for non-surgical reductionor removal of one or more localized fat deposits in a subject havinglocalized fat accumulation comprising administering to a target site inthe fat deposit a composition comprising a compound of Formula (V). Insome embodiments, there is provided a method for non-surgical reductionor removal of one or more localized fat deposits in a subject havinglocalized fat accumulation comprising administering to a target site inthe fat deposit a composition comprising a compound of Formula (VI). Insome embodiments, there is provided a method for non-surgical reductionor removal of one or more localized fat deposits in a subject havinglocalized fat accumulation comprising administering to a target site inthe fat deposit a composition comprising compound 2. In someembodiments, there is provided a method for non-surgical reduction orremoval of one or more localized fat deposits in a subject havinglocalized fat accumulation comprising administering to a target site inthe fat deposit a composition comprising compound 10. In someembodiments, there is provided a method for non-surgical reduction orremoval of one or more localized fat deposits in a subject havinglocalized fat accumulation comprising administering to a target site inthe fat deposit a composition comprising compound 29. In someembodiments, there is provided a method for non-surgical reduction orremoval of one or more localized fat deposits in a subject havinglocalized fat accumulation comprising administering to a target site inthe fat deposit a composition comprising compound 38. In someembodiments, there is provided a method for non-surgical reduction orremoval of one or more localized fat deposits in a subject havinglocalized fat accumulation comprising administering to a target site inthe fat deposit a composition comprising compound 40. In someembodiments, there is provided a method for non-surgical reduction orremoval of one or more localized fat deposits in a subject havinglocalized fat accumulation comprising administering to a target site inthe fat deposit a composition comprising compound 41. In someembodiments, there is provided a method for non-surgical reduction orremoval of one or more localized fat deposits in a subject havinglocalized fat accumulation comprising administering to a target site inthe fat deposit a composition comprising compound 43. In someembodiments, there is provided a method for non-surgical reduction orremoval of one or more localized fat deposits in a subject havinglocalized fat accumulation comprising administering to a target site inthe fat deposit a composition comprising compound 44. In someembodiments, the method is not used in conjunction with liposuction,lipoplasty, suction lipectomy, or ultrasonification. In someembodiments, the method herein is used in conjunction with liposuction,lipoplasty, or suction lipectonmy, or ultrasonification.

The present disclosure also provides a method for reducing asubcutaneous fat deposit in a subject having subcutaneous fat depositcomprising administering to a target site in the subcutaneous fatdeposit a composition comprising an indole compound (such as a compoundof Formula (I)). In some embodiments, the method comprises administeringa compound of any one of Formula (II), (III), (IV), (V) and (VI) or anyone of Compounds 2, 10, 29, 38, 40, 41, 43, and 44. In some embodiments,there is provided a method for reducing a subcutaneous fat deposit in asubject having subcutaneous fat deposit comprising administering to atarget site in the subcutaneous fat deposit a composition comprising acompound of Formula (II). In some embodiments, there is provided amethod for reducing a subcutaneous fat deposit in a subject havingsubcutaneous fat deposit comprising administering to a target site inthe subcutaneous fat deposit a composition comprising a compound ofFormula (III). In some embodiments, there is provided a method forreducing a subcutaneous fat deposit in a subject having subcutaneous fatdeposit comprising administering to a target site in the subcutaneousfat deposit a composition comprising a compound of Formula (IV). In someembodiments, there is provided a method for reducing a subcutaneous fatdeposit in a subject having subcutaneous fat deposit comprisingadministering to a target site in the subcutaneous fat deposit acomposition comprising a compound of Formula (V). In some embodiments,there is provided a method for reducing a subcutaneous fat deposit in asubject having subcutaneous fat deposit comprising administering to atarget site in the subcutaneous fat deposit a composition comprising acompound of Formula (VI). In some embodiments, there is provided amethod for reducing a subcutaneous fat deposit in a subject havingsubcutaneous fat deposit comprising administering to a target site inthe subcutaneous fat deposit a composition comprising compound 2. Insome embodiments, there is provided a method for reducing a subcutaneousfat deposit in a subject having subcutaneous fat deposit comprisingadministering to a target site in the subcutaneous fat deposit acomposition comprising compound 10. In some embodiments, there isprovided a method for reducing a subcutaneous fat deposit in a subjecthaving subcutaneous fat deposit comprising administering to a targetsite in the subcutaneous fat deposit a composition comprising compound29. In some embodiments, there is provided a method for reducing asubcutaneous fat deposit in a subject having subcutaneous fat depositcomprising administering to a target site in the subcutaneous fatdeposit a composition comprising compound 38. In some embodiments, thereis provided a method for reducing a subcutaneous fat deposit in asubject having subcutaneous fat deposit comprising administering to atarget site in the subcutaneous fat deposit a composition comprisingcompound 40. In some embodiments, there is provided a method forreducing a subcutaneous fat deposit in a subject having subcutaneous fatdeposit comprising administering to a target site in the subcutaneousfat deposit a composition comprising compound 41. In some embodiments,there is provided a method for reducing a subcutaneous fat deposit in asubject having subcutaneous fat deposit comprising administering to atarget site in the subcutaneous fat deposit a composition comprisingcompound 43. In some embodiments, there is provided a method forreducing a subcutaneous fat deposit in a subject having subcutaneous fatdeposit comprising administering to a target site in the subcutaneousfat deposit a composition comprising compound 44. The methods describedherein, in some embodiments, are useful for one or more of thefollowing: 1) killing fat cells in a localized region; 2) dissolving fatin the localized region; and/or 3) for cosmetic purposes.

Adipose tissue (or body fat, or fat deposit, or fat) is loose connectivetissue containing adipocytes. Adipose tissue can be found, for example,at the skin (subcutaneous fat), around internal organs (visceral fat),in bone marrow (yellow bone marrow) and in breast tissue. The presentmethods can be used for reducing fat deposit in any of these adiposetissues. The fat to be reduced or removed can be of varying hardness,depending on its contents. In certain embodiments, the fat deposit issoft fat. In certain embodiments, the fat deposit is fibrotic fat. Whileadipocytes are one component of the fatty layer, there are manydifferent cell types in the hypodermis. About 18% of these cells areadipocytes. There is also a fibroseptal network—the collagenousframework in which the adipocytes reside. This layer is also known asthe stromal vascular fraction. The present methods can be used forreducing the fibroseptal network.

The compositions and methods can be used to treat any adipose conditionin a subject. Adipose conditions include, for example, disorders such asmetabolic syndrome, obesity, fat redistribution syndrome, eyelid fatherniation, lipoma, herniation, cellulite, lipodystrophy (includingbuffalo hump lipodystrophy), dorsocervical fat, visceral adiposity,breast enlargement, hyperadiposity, diffused body fat around trunk andarms, fat deposits associated with cellulite, Dercum's disease,Madelung's neck, lipedema, piezogenic nodules, Launois Cleret syndrome,and xanthelasma.

The present disclosure also provides for a method for treating anadipose tissue disorder or an adipose tissue tumor in a subjectcomprising locally administering to the subject a composition comprisingan indole compound (such as a compound of Formula (I)). In someembodiments, the method comprises administering a compound of any one ofFormula (II), (III), (IV), (V) and (VI) or any one of Compounds 2, 10,29, 38, 40, 41, 43, and 44. In some embodiments, there is provided amethod for treating an adipose tissue disorder or an adipose tissuetumor in a subject comprising locally administering to the subject acomposition comprising a compound of Formula (II). In some embodiments,there is provided a method for treating an adipose tissue disorder or anadipose tissue tumor in a subject comprising locally administering tothe subject a composition comprising a compound of Formula (III). Insome embodiments, there is provided a method for treating an adiposetissue disorder or an adipose tissue tumor in a subject comprisinglocally administering to the subject a composition comprising a compoundof Formula (IV). In some embodiments, there is provided a method fortreating an adipose tissue disorder or an adipose tissue tumor in asubject comprising locally administering to the subject a compositioncomprising a compound of Formula (V). In some embodiments, there isprovided a method for treating an adipose tissue disorder or an adiposetissue tumor in a subject comprising locally administering to thesubject a composition comprising a compound of Formula (VI). In someembodiments, there is provided a method for treating an adipose tissuedisorder or an adipose tissue tumor in a subject comprising locallyadministering to the subject a composition comprising compound 2. Insome embodiments, there is provided a method for treating an adiposetissue disorder or an adipose tissue tumor in a subject comprisinglocally administering to the subject a composition comprising compound10. In some embodiments, there is provided a method for treating anadipose tissue disorder or an adipose tissue tumor in a subjectcomprising locally administering to the subject a composition comprisingcompound 29. In some embodiments, there is provided a method fortreating an adipose tissue disorder or an adipose tissue tumor in asubject comprising locally administering to the subject a compositioncomprising compound 38. In some embodiments, there is provided a methodfor treating an adipose tissue disorder or an adipose tissue tumor in asubject comprising locally administering to the subject a compositioncomprising compound 40. In some embodiments, there is provided a methodfor treating an adipose tissue disorder or an adipose tissue tumor in asubject comprising locally administering to the subject a compositioncomprising compound 41. In some embodiments, there is provided a methodfor treating an adipose tissue disorder or an adipose tissue tumor in asubject comprising locally administering to the subject a compositioncomprising compound 43. In some embodiments, there is provided a methodfor treating an adipose tissue disorder or an adipose tissue tumor in asubject comprising locally administering to the subject a compositioncomprising compound 44. In some embodiments, the method is for cosmeticpurposes.

Adipose tissue disorders include, for example, disorders such asmetabolic syndrome, familial lipomatosis, lipoma, Dercum's disease,Madelung's neck, lipedema, piezogenic nodule, xanthelasma,lipodystrophy, and cellulite. Adipose tissue disorders show, in contrastto the food-related obesity-correlated lipohypertrophy, tissueconditions or identities which can be pathologically differentiatedunambiguously and which can be described by histological parameters ofscarring and inflammation, but also by connective tissue encapsulationsand by changes in the histological adipose tissue morphology itself.

A lipoma is an adipose tissue tumor, which is benign, slow-growing,usually spherical, possibly pedunculated (=I. pendulum) or even villous(=I. arborescens, for example of the synovial villi) mesenchymal tumorscomposed of enlarged-adipose tissue cells, such as in a subcutaneouscell tissue, possibly with central ossification (=I. ossificans),becoming mucoid (=I. myxomatodes) or calcifying (=I. petrificans), alsowith increased connective tissue and capsule formation (=I. fibrosum),neoangiogenesis (=I. teleangiectodes), rarely showing malignantdegeneration (=I. sarcomatodes, liposarcoma). A lipoma can becategorized as pathological because they grow and their connectivetissue envelope may be painful per se, as well as the compressionderived therefrom on blood vessels, which may cause neuralgia.

In some embodiments, the compositions can be used to treat an adiposecondition, adipose tissue disorder, lipodystrophy, or adipose tissuetumor in various areas of a subject. For example, the compositions canbe used to reduce or remove fat deposits localized under the eyes, inthe lower face and jowls, under chin, under arm, buttock, calf, back,thigh, ankle, stomach, cheek, brow, “love-handles”, ankles, lips, ortrachea of a subject. In some embodiments, the compositions can be usedto treat omental adipocyte hypertrophy. In some embodiments, areas oflaxity with adjacent fat can be treated, such as the vagina, urethra,and uvula, with the compositions.

The total volume, unit dose and number of treatments administered mayvary depending on the amount of fat in a target site, the location ofthe target site, type of fat composition, the degree of tissue laxity,and desired results. In general, the greater the amount of fat beingtreated, the greater the dose that is administered. The type of compoundused will depend on the relative degree of fatty hypertrophy versustissue laxity. The compositions and unit dosages herein may beadministered to a subject as part of a treatment regimen or as anindividual treatment session.

In some embodiments according to any one of the methods describedherein, the method further includes a step of ascertaining theeffectiveness of the method. In some embodiments, the effectiveness isdetermined by a physical measurement, such as MRI, high resolutionultrasound, or caliper. In some embodiments, the localized fat isreduced by at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% of thevolume, or by at least 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, or 10% of itsthickness, as determined by MRI or by caliper measurement. The % of thevolume reduction can be determined by subtracting the volume aftertreatment (volume after treatment: Vf) and that of the baseline (initialvolume or volume before treatment: Vi), divided by Vi and multiplied by100. Similarly the % of the thickness reduction can be determined bysubtracting the thickness after treatment (thickness after treatment:Tf) and that of the baseline (initial volume or volume before treatment:Ti), divided by Ti and multiplied by 100. As an example to determinepercentage reduction in volume, if Vi is 6346.8 cc, Vf is 5376.6 cc,then the volume is reduced by 18%. Similarly to determine percentagereduction in thickness, if Ti is 17.2 mm, Tf is 14.1 mm, then thethickness is reduced by 15%.

The present disclosure provides for a method for decreasing submentalfat deposit under a skin area in a subject comprising administering to atarget site in the fat deposit a composition comprising an indolecompound (such as a compound of Formula (I)). In some embodiments, themethod comprises administering a compound of any one of Formula (II),(III), (IV), (V) and (VI) or any one of Compounds 2, 10, 29, 38, 40, 41,43, and 44. In some embodiments, there is provided a method fordecreasing submental fat deposit under a skin area in a subjectcomprising administering to a target site in the fat deposit acomposition comprising a compound of Formula (II). In some embodiments,there is provided a method for decreasing submental fat deposit under askin area in a subject comprising administering to a target site in thefat deposit a composition comprising a compound of Formula (III). Insome embodiments, there is provided a method for decreasing submentalfat deposit under a skin area in a subject comprising administering to atarget site in the fat deposit a composition comprising a compound ofFormula (IV). In some embodiments, there is provided a method fordecreasing submental fat deposit under a skin area in a subjectcomprising administering to a target site in the fat deposit acomposition comprising a compound of Formula (V). In some embodiments,there is provided a method for decreasing submental fat deposit under askin area in a subject comprising administering to a target site in thefat deposit a composition comprising a compound of Formula (VI). In someembodiments, there is provided a method for decreasing submental fatdeposit under a skin area in a subject comprising administering to atarget site in the fat deposit a composition comprising compound 2. Insome embodiments, there is provided a method for decreasing submentalfat deposit under a skin area in a subject comprising administering to atarget site in the fat deposit a composition comprising compound 10. Insome embodiments, there is provided a method for decreasing submentalfat deposit under a skin area in a subject comprising administering to atarget site in the fat deposit a composition comprising compound 29. Insome embodiments, there is provided a method for decreasing submentalfat deposit under a skin area in a subject comprising administering to atarget site in the fat deposit a composition comprising compound 38. Insome embodiments, there is provided a method for decreasing submentalfat deposit under a skin area in a subject comprising administering to atarget site in the fat deposit a composition comprising compound 40. Insome embodiments, there is provided a method for decreasing submentalfat deposit under a skin area in a subject comprising administering to atarget site in the fat deposit a composition comprising compound 41. Insome embodiments, there is provided a method for decreasing submentalfat deposit under a skin area in a subject comprising administering to atarget site in the fat deposit a composition comprising compound 43. Insome embodiments, there is provided a method for decreasing submentalfat deposit under a skin area in a subject comprising administering to atarget site in the fat deposit a composition comprising compound 44.

The methods described herein, in some embodiments, are useful for one ormore of the following: 1) enhancing facial aesthetics through reductionof submental fat; and/or 2) decreasing submental fat deposit under askin area in a subject, for enhancing the cosmetic appearance of asubject, or for providing a facial cosmetic benefit to a subject.

In some embodiments, the submental fat deposit treated by the methods ofthe present disclosure is cosmetically unappealing but isnon-pathological and the reduction of it is to improve the appearance ofthe subject. In certain embodiments, the result is reduction of theappearance of a double chin. In some embodiments, the method isnon-surgical and does not include liposuction.

In some embodiments, the method can further include a step ofascertaining the effectiveness of the method. In some embodiments, theeffectiveness is determined by a physical measurement, such as MRI, highresolution ultrasound, or caliper. A thickness and/or volume of thesubmental fat deposit can be measured with magnetic resonance imaging(MRI), high resolution ultrasound, or by a caliper. The thicknessesand/or volumes of the submental fat deposit can be compared before andafter the treatment to assess the effectiveness of the treatment. Insome embodiments, the thickness and/or volume is reduced by at leastabout 10%, or by at least about 15%, 20%, 25%, 30%, 35%, 40%, 45%, or50%.

The reduction of submental fat can enhance the facial appearance of saidsubject. In some embodiments, the enhanced facial appearance is due tothe reduction of prominence of a double chin. In some embodiments, theeffectiveness of the treatment can be assessed by visual inspection fora reduction of prominence of a double chin or lack of a double chin. Thelessening of the double chin appearance may be determined by theimprovement in the degree of the submental convexity of the area underthe chin.

The present disclosure provides for a method for preventing or reducinga skin condition associated with aging in a subject comprising locallyadministering to the subject a composition comprising an indole compound(such as a compound of Formula (I)). The present disclosure alsoprovides for a method for the treatment or improvement of skin and softtissue laxity due to aging, weight loss, genetic determinants or otherdisorder. In some embodiments, the method comprises administering acompound of any one of Formula (II), (III), (IV), (V) and (VI) or anyone of Compounds 2, 10, 29, 38, 40, 41, 43, and 44. In some embodiments,there is provided a method for preventing or reducing a skin conditionassociated with aging in a subject comprising locally administering tothe subject a composition comprising a compound of Formula (II). In someembodiments, there is provided a method for preventing or reducing askin condition associated with aging in a subject comprising locallyadministering to the subject a composition comprising a compound ofFormula (III). In some embodiments, there is provided a method forpreventing or reducing a skin condition associated with aging in asubject comprising locally administering to the subject a compositioncomprising a compound of Formula (VI). In some embodiments, there isprovided a method for preventing or reducing a skin condition associatedwith aging in a subject comprising locally administering to the subjecta composition comprising a compound of Formula (V). In some embodiments,there is provided a method for preventing or reducing a skin conditionassociated with aging in a subject comprising locally administering tothe subject a composition comprising a compound of Formula (VI). In someembodiments, there is provided a method for preventing or reducing askin condition associated with aging in a subject comprising locallyadministering to the subject a composition comprising compound 2. Insome embodiments, there is provided a method for preventing or reducinga skin condition associated with aging in a subject comprising locallyadministering to the subject a composition comprising compound 10. Insome embodiments, there is provided a method for preventing or reducinga skin condition associated with aging in a subject comprising locallyadministering to the subject a composition comprising compound 29. Insome embodiments, there is provided a method for preventing or reducinga skin condition associated with aging in a subject comprising locallyadministering to the subject a composition comprising compound 38. Insome embodiments, there is provided a method for preventing or reducinga skin condition associated with aging in a subject comprising locallyadministering to the subject a composition comprising compound 40. Insome embodiments, there is provided a method for preventing or reducinga skin condition associated with aging in a subject comprising locallyadministering to the subject a composition comprising compound 41. Insome embodiments, there is provided a method for preventing or reducinga skin condition associated with aging in a subject comprising locallyadministering to the subject a composition comprising compound 43. Insome embodiments, there is provided a method for preventing or reducinga skin condition associated with aging in a subject comprising locallyadministering to the subject a composition comprising compound 44. Forexample, skin conditions associated with aging include loose skin,irregularities of the skin, and wrinkles.

The methods described herein, in some embodiments, are useful for one ormore of the following: 1) rejuvenating skin; 2) skin and subcutaneoustissue tightening; 3) causing skin and soft tissue retraction in a bodyregion containing fat deposits, such as localized fat, cellulite, or apostlipoplasty deformity; 4) alleviating skin conditions, includingcellulite, rippling, divots (skin contour irregularities followinglipoplasty), and protuberances; 5) removing localized excess skin;and/or 6) firming the skin and soft tissue.

In some embodiments, the compositions are administered locally to atarget area to create an inflammatory response causing subcutaneouscollagen deposition with subsequent soft tissue retraction. Theformation of a scar results in skin and soft tissue tighteningespecially in areas where the skin is under little or no tension andprovides little resistance to fibroseptal contraction. Such treatmentmay be relevant in a number of clinical scenarios such as, for example,commonly performed fat treatments, including, but not limited to, largevolume liposuction. The latter may be associated with post-liposuction,or weight loss induced skin and soft tissue laxity. Thus, in someembodiments, a composition comprising a therapeutically effective amountof an indole compound may be administered to a liposuction site aftercompletion of the liposuction procedure. In some embodiments, the indolecompound is a compound of Formula (I). In some embodiments, the methodcomprises administering a compound of any one of Formula (II), (III),(IV), (V) and (VI) or any one of Compounds 2, 10, 29, 38, 40, 41, 43,and 44. In some embodiments, there is provided a method for localadministration to a target area to create an inflammatory responsecausing subcutaneous collagen deposition with subsequent soft tissueretraction of a compound of Formula (II). In some embodiments, there isprovided a method for local administration to a target area to create aninflammatory response causing subcutaneous collagen deposition withsubsequent soft tissue retraction of a compound of Formula (III). Insome embodiments, there is provided a method for local administration toa target area to create an inflammatory response causing subcutaneouscollagen deposition with subsequent soft tissue retraction of a compoundof Formula (IV). In some embodiments, there is provided a method forlocal administration to a target area to create an inflammatory responsecausing subcutaneous collagen deposition with subsequent soft tissueretraction of a compound of Formula (V). In some embodiments, there isprovided a method for local administration to a target area to create aninflammatory response causing subcutaneous collagen deposition withsubsequent soft tissue retraction of a compound of Formula (VI). In someembodiments, there is provided a method for local administration to atarget area to create an inflammatory response causing subcutaneouscollagen deposition with subsequent soft tissue retraction of compound2. In some embodiments, there is provided a method for localadministration to a target area to create an inflammatory responsecausing subcutaneous collagen deposition with subsequent soft tissueretraction of compound 10. In some embodiments, there is provided amethod for local administration to a target area to create aninflammatory response causing subcutaneous collagen deposition withsubsequent soft tissue retraction of compound 29. In some embodiments,there is provided a method for local administration to a target area tocreate an inflammatory response causing subcutaneous collagen depositionwith subsequent soft tissue retraction of compound 38. In someembodiments, there is provided a method for local administration to atarget area to create an inflammatory response causing subcutaneouscollagen deposition with subsequent soft tissue retraction of compound40. In some embodiments, there is provided a method for localadministration to a target area to create an inflammatory responsecausing subcutaneous collagen deposition with subsequent soft tissueretraction of compound 41. In some embodiments, there is provided amethod for local administration to a target area to create aninflammatory response causing subcutaneous collagen deposition withsubsequent soft tissue retraction of compound 43. In some embodiments,there is provided a method for local administration to a target area tocreate an inflammatory response causing subcutaneous collagen depositionwith subsequent soft tissue retraction of compound 44.

In some embodiments, the target area is an area under eye, under chin,under arm, buttock, calf, back, thigh, stomach, cheek, brow, or anyother skin regions showing aging, wrinkles, loose skin or skinirregularity.

In some embodiments, the method can further include a step ofascertaining the effectiveness of the method. The present disclosurealso provides a method for ascertaining the effectiveness of a therapyfor preventing or reducing a skin condition associated with aging in asubject, comprising comparing the skin condition of the subject beforetherapy with the skin condition of the subject after therapy, whereinsmooth skin retraction without rippling, crease, or local indentation inthe subject after therapy indicates effective therapy. The comparisoncan be done by visual inspection or patient satisfaction surveys. Othermethods of ascertaining the effectiveness of the method include highresolution ultrasound, MRI dermatological wrinkle scale, Canfield Vectra3D® imaging system, and calipers. High resolution ultrasound can be usedto measure the thickness of a fatty deposit at certain sites. MRI iscurrently the “gold standard” in measuring the depth and width ofsubcutaneous fat deposits in a given region. Canfield Vectra 3D® imagingsystem is a mathematical way of determine smoothness of skin. The systemuses a quadratic equation to determine positive and negative variationsto form a computer-generated ideal of smooth curved surface for a givenphotographed region. The “smoothness index” is a way to measure thepre-treatment variation from the ideal surface. After treatment, another3D photo is taken. The treatment region is identified, and the equationcan be used to determine the change/improvement in surface contourirregularity.

The present disclosure provides for a method for treating obstructivesleep apnea comprising locally administering to the subject acomposition comprising an indole compound (such as a compound of Formula(I)). In some embodiments, the method comprises administering a compoundof any one of Formula (II), (III), (IV), (V) and (VI) or any one ofCompounds 2, 10, 29, 38, 40, 41, 43, and 44. In some embodiments, thereis provided a method for a method for treating obstructive sleep apneacomprising locally administering to the subject a composition comprisinga compound of Formula (II). In some embodiments, there is provided amethod for a method for treating obstructive sleep apnea comprisinglocally administering to the subject a composition comprising a compoundof Formula (III). In some embodiments, there is provided a method for amethod for treating obstructive sleep apnea comprising locallyadministering to the subject a composition comprising a compound ofFormula (IV). In some embodiments, there is provided a method for amethod for treating obstructive sleep apnea comprising locallyadministering to the subject a composition comprising a compound ofFormula (V). In some embodiments, there is provided a method for amethod for treating obstructive sleep apnea comprising locallyadministering to the subject a composition comprising a compound ofFormula (VI). In some embodiments, there is provided a method for amethod for treating obstructive sleep apnea comprising locallyadministering to the subject a composition comprising compound 2. Insome embodiments, there is provided a method for a method for treatingobstructive sleep apnea comprising locally administering to the subjecta composition comprising compound 10. In some embodiments, there isprovided a method for a method for treating obstructive sleep apneacomprising locally administering to the subject a composition comprisingcompound 29. In some embodiments, there is provided a method for amethod for treating obstructive sleep apnea comprising locallyadministering to the subject a composition comprising compound 38. Insome embodiments, there is provided a method for a method for treatingobstructive sleep apnea comprising locally administering to the subjecta composition comprising compound 40. In some embodiments, there isprovided a method for a method for treating obstructive sleep apneacomprising locally administering to the subject a composition comprisingcompound 41. In some embodiments, there is provided a method for amethod for treating obstructive sleep apnea comprising locallyadministering to the subject a composition comprising compound 43. Insome embodiments, there is provided a method for a method for treatingobstructive sleep apnea comprising locally administering to the subjecta composition comprising compound 44. Obstructive sleep apnea ischaracterized by repetitive pauses in breathing during sleep due to theobstruction and/or collapse of an upper airway (throat), usuallyaccompanied by a reduction in blood oxygen saturation, and followed byan awakening to breathe. It is a dangerous (sometimes life threatening)condition that often affects obese people. Obese people have a largeamount of fat around their trachea, and this fat may cause their airwayto collapse when their muscles relax during sleep. In some embodiments,the compositions are used to treat obstructive sleep apnea by reducingfat around the trachea. In such embodiments, the composition isadministered locally (e.g., via injection) to a target site of fataround the trachea in a therapeutically effective amount.

In the above methods, in some embodiments, the subject being treated isa mammal. Such mammal can be a human or an animal such as a primate(e.g., a monkey, chimpanzee, etc.), a domesticated animal (e.g., a dog,cat, horse, etc.), farm animal (e.g., goat, sheep, pig, cattle, etc.),or laboratory animal (e.g., mouse, rat, etc.). In some embodiments, asubject being treated is a human, a horse, a dog, or a cat. In someembodiments, a subject can be a male or female human. A subject can be ahuman of any age, such as young age, adolescent age, adult age, middleage, or old age. In some embodiments, the subject can be an age of 1-4,5-9, 10-19, 20-29, 30-39, 40-49, 50-59, 60-69, 70-79, 80-89, or 90-100years.

In some embodiments, a subject is overweight or obese. In someembodiments, a subject is of normal weight or underweight. Overweight orobesity can be assessed, for example, by BMI (body mass index). A methodfor calculating BMI includes dividing a person's body weight inkilograms by their height in meters squared (weight [kg]/height [m]²). ABMI of 30 or more is considered obese; a BMI between 25 to 29.9 isconsidered overweight; a BMI between 18.5 to 24.9 is considered normalweight; a BMI under 18.5 is considered underweight. In some embodiments,a subject has a BMI over about 30, such as about 30 to about 50. In someembodiments, a subject has a BMI of about 25 to about 29.9. In someembodiments, a subject has a BMI under about 25.

In some embodiments, the subject has a fat deposit. In some embodiments,the subject has skin and soft tissue laxity. In some embodiments, thesubject has a fat deposit and skin and soft tissue laxity.

A “target site’ used herein refers to an area of the body at which thecomposition is applied. The target site can be located at the fatdeposit and/or the skin area to be affected. The target site can be atdifferent levels of the skin, such as epidermis, dermis, or hypodermis.The target site can be intradermal (within or between layers of skin).

In some embodiments, the compound is administered locally. “Localadministration” used herein refers to administration of a substance toan area where the action of the substance is desired. Sometimes,administration of the substance is directly to the area where the actionof the substance is desired. In some embodiments, the compositions areadministered via a localized injection. However, other means ofadministering the compositions are also contemplated. For example, thecompositions may be administered via a transdermal pump, a transdermalpatch, or a subdermal depot. In some embodiments, the compositions areadministered topically.

In some embodiments, the composition is administered transdermally orsubcutaneously, via e.g., a subcutaneous injection using a syringe to atarget site. In some embodiments, the composition is administered byinjection at hypodermis level, injection into the superficial level tomid-layer of subcutaneous fat, mid-layer or deep layer of subcutaneousfat, or injection into the lipodystrophic region. The compositions maybe administered at the same, adjacent, or nearby target sites at variousintervals, dosages, volumes, as disclosed herein.

In some embodiments, a target site can be, for example, 0.1 cm×0.1 cm,to about 5 cm×5 cm before the procedure. In some embodiments, the targetsite can be 0.1 cm×0.1 cm, 0.5 cm×0.5 cm, 1 cm×1 cm, 2 cm×2 cm, 3 cm×3cm, 4 cm×4 cm, or 5 cm×5 cm.

The compositions may be administered once or multiple times into thetarget site. In some embodiments, the compositions are administered atleast 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 times to a target site. More thanone administration can occur in a single week, month, year, 2-5 years,or 5-10 years. In some embodiments, the subject is given 1-100, 2-50,3-30, 4-20, or 5-10 injections at a target site. This number ofinjections can occur over a period of 1 week, 2 weeks, 3 weeks, 1 month,2 months, 3 months, 4 months, 5 months, 6 months, 7 months, 8 months, 9months, 10 months, 11 months, 1 year, 2 years, 3 years, 4 years, 5years, 6 years, 7 years, 8 years, 9 years, or 10 years. In someembodiments, the compositions are administered weekly or 1-8 weeksapart.

In some embodiments, the subject is given 1 to 10 injections withintervals of 1 to 12 weeks; or 2 to 8 injections with intervals of 2 to10 weeks; or 2 to 6 injections with intervals of 2 to 8 weeks. In someembodiments, the subject is given 2 to 4 injections with intervals of 4to 8 weeks.

The compositions can be administered at various levels below the dermis.In some embodiments, the compositions can be administered with a 2-15 mminjection depth. In some embodiments, the injection depth is 2-4, 4-6,6-8, 8-10, 10-12, or 12-15 mm. In some embodiments, the injection depthis 4-10, 6-10, 2-8, or 6-8 mm.

The compositions can be administered anywhere within the fatty layer.Because some of the compositions have certain dispersion when injectedin a depot manner, in some embodiments, the compositions areadministered with multilevel depots. For example, one administrationcould be immediately under the skin in the superficial hypodermis; andanother administration could be halfway through the hypodermis; andanother administration could be deep, just above the fascia. The presentdisclosure provides a multilevel injection approach, using needles ofdifferent lengths.

The dose can depend on the following factors—the amount of fat present,the desired effect desire, and the concentration of the drug. In someembodiments, a solution for injection comprises about 1-100 mg/ml of theindole composition. In some embodiments, a solution for injectioncomprises about 1-5, 6-10, 11-15, or 16-20 mg/ml of the indolecomposition. In some embodiments, a solution for injection comprisesabout 21-30, 31-40, 41-50, 51-60, 61-70, 71-80, 81-90, or 91-100 mg/mlof the indole composition. In some embodiments, a solution for injectioncomprises about 8-12 or 10 mg/ml of the indole composition.

In some embodiments, the volume for each injection is about 0.1 ml toabout 0.5 ml. In some embodiments, the total of an indole compoundadministered is between about 50 mg to about 100 mg, or from about 60mg, 70 mg to about 90 mg, 80 mg, without limitation.

In some embodiments, the method comprises local injection to the targetsite, through a plurality of injection sites on the skin area, acomposition comprising an effective amount of an indole compound,wherein the effective amount is from about 0.01 mg to about 10 mg perinjection site. In some embodiments, the effective amount is at leastabout 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10 mg per injection site. Insome embodiments, the effective amount if no more than about 0.5, 1, 2,3, 4, 5, 6, 7, 8, 9, or 10 mg per injection site.

In some embodiments, the plurality of injection sites is substantiallyevenly distributed on the skin area. The term “substantially evenly” asused here, refers to injection sites in an area where there aresubstantially the same number of injection sites per unit of area. Inone aspect, a number is substantially the same as another number is theyare with about 5% or 10%, or 15% or 20%, or 25% difference.

In some embodiments, each injection site is from about 0.8 cm to about1.2 cm distant from an adjacent injection site. In some embodiments,each injection site is from about 0.9 cm to about 1.1 cm distant from anadjacent injection site. In some embodiments, each injection site isabout 1 cm distant from an adjacent injection site.

In some embodiments, the plurality of injection sites comprises at least20 injection sites, or alternatively at least 25, 30, 35, 40, 45, 50,55, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, or 500injection sites. In some embodiments, the plurality of injection siteshas of no more than about 100, 90, 80, 70, 60, 50, 45, 40, 35, 30, or 25injection sites. In some embodiments, the plurality of injection siteshas from about 40 to about 60 injection sites, or about 50 injectionsites.

In some embodiments, each injection site receives from about 0.1 ml toabout 0.5 ml of the composition. In some embodiments, each injectionsite receives from about 0.1 ml to about 0.25 ml, or alternatively fromabout 0.26 to about 0.5, or from about 0.2 to about 0.4 ml of thecomposition.

In some embodiments, the method utilizes a grid comprising a pluralityof injection sites, each of which is from about 0.8 cm to about 1.5 cmdistant from an adjacent injection site of the grid; and injecting, witha suitable needle, through each of the plurality of injection sites,into about half way into the target site, an effective amount of acomposition comprising from about 0.5% to about 1% (w/w) of an indolecompound, wherein each injection constitutes delivery of from about 0.1ml to about 0.3 ml of the composition.

In some embodiments, the grid comprises at least 20 injection sites, orat least 25, 30, 35, 40, 45, 50, 55, 60, 70, 80, 90, or 100 injectionsites. In some embodiments, the grid comprises no more than about 100,90, 80, 70, 60, 50, 45, 40, 35, 30, or 25 injection sites. In someembodiments, the grid comprises from about 40 to about 60 injectionsites, or about 50 injection sites.

An alternative pattern would be a multi-level injection, using anunder-the-skin type delivery. These would be performed from a singleentry site, and would be executed in a ray-type distribution, similar toliposuction. The value of treating multiple levels of adiposity has beenrecently shown, so a better and more uniform response can be obtainedwith this method. Also, drugs with poor dispersion can be betterdelivered to the target tissue this way.

In some embodiments, the method further comprises pretreating the areaaround the injection sites with a local anesthetic. Various anestheticsindividually or in combination may be included in the composition suchas: ropivacaine, articaine, benzocaine bupivacaine, chloroprocaine,etidocaine, hexylcaine, lontocaine, lidocatine, levobuivaciaine,mepivacaine, prilocaine, procaine, and tetracaine. In some embodiments,co-administration of an anesthetic either the composition can reduce thenumber of injections

Indole Compounds and Compositions

The present disclosure provides various indole compounds andcompositions which are useful for the methods disclosed herein. Anindole compound is a compound comprising an indole core. An indole coreis shown below:

Formula (I)

The present disclosure provides a compound of Formula (I) andcompositions comprising a compound of Formula (I):

wherein

R¹ is hydrogen, C₁₋₆ alkyl, hydroxyl, or —(CH₂)_(x)—CONH₂;

R², R³, R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen,C₁₋₆alkyl, C₁₋₆alkoxy, amino, substituted amino, halogen, heteroaryl,substituted heteroaryl, —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl, —(CH₂)_(x)—OH,—(CH₂)_(x)—CN, —OCH₂C₆H₅, —OCOCH₃, —(CH₂)_(x)—CONH₂, —CHO,—(CH₂)_(x)—COOH, —(CH₂)_(x)—COOC₁₋₆ alkyl, —(CH₂)_(y)—CO—COOH, and—(CH₂)_(y)—C(H)(OH)—COOH; or

any two adjacent R⁴, R⁵, R⁶, and R⁷, together with the atoms they attachto, form a five to seven-membered carbocyclic ring; or

R² and R³, together with the atoms they attach to, form an unsubstitutedor substituted five to seven-membered heterocyclyl ring;

x is a number from zero to six; and

y is a number from zero to six;

or a pharmaceutically acceptable salt thereof.

In some embodiments of Formula (I), R¹ is hydrogen. In some embodiments,R¹ is C₁₋₆ alkyl. In some embodiments, R¹ is methyl. In someembodiments, R¹ is hydroxy. In some embodiments, R¹ is —(CH₂)_(x)—CONH₂,wherein x is a number from zero to six. In some embodiments, R¹ is—(CH₂)CONH₂.

In some embodiments of Formula (I), at least one of R², R³, R⁴, R⁵, R⁶,and R⁷ is selected from halogen, —CHO, and —(CH₂)_(x)—COOH.

In some embodiments of Formula (I), at least one of R², R³, R⁴, R⁵, R⁶,and R⁷ is a halogen. In some embodiments, at least one of R², R³, R⁴,R⁵, R⁶, and R⁷ is bromo. In some embodiments, R² is bromo. In someembodiments, R³ is bromo. In some embodiments, R⁴ is bromo. In someembodiments, R⁵ is bromo. In some embodiments, R⁶ is bromo. In someembodiments, R⁷ is bromo.

In some embodiments of Formula (I), at least one of R², R³, R⁴, R⁵, R⁶,and R⁷ is —CHO. In some embodiments, R² is —CHO. In some embodiments, R³is —CHO. In some embodiments, R⁴ is —CHO. In some embodiments, R⁵ is—CHO. In some embodiments, R⁶ is —CHO. In some embodiments, R⁷ is —CHO.

In some embodiments of Formula (I), at least one of R², R³, R⁴, R⁵, R⁶,and R⁷ is —(CH₂)_(x)—COOH. In some embodiments, R² is —(CH₂)_(x)—COOH.In some embodiments, R³ is —(CH₂)_(x)—COOH. In some embodiments, R⁴ is—(CH₂)_(x)—COOH. In some embodiments, R⁵ is —(CH₂)_(x)—COOH. In someembodiments, R⁶ is —(CH₂)_(x)—COOH. In some embodiments, R⁷ is—(CH₂)_(x)—COOH. In some embodiments, x is one to three. In someembodiments, x is one.

In some embodiments of Formula (I), at least one of R², R³, R⁴, R⁵, R⁶,and R⁷ is heteroaryl or substituted heteroaryl. In some embodiments, atleast one of R², R³, R⁴, R⁵, R⁶, and R⁷ is benzimidazole or substitutedbenzimidazole. In some embodiments, one of R² and R³ is benzimidazole orsubstituted benzimidazole. In some embodiments, the benzimidazole issubstituted with C₁₋₆alkyl, halogen, —COOH, or —CHO.

In some embodiments of Formula (I), at least one of R², R³, R⁴, R⁵, R⁶,and R⁷ is —OCH₂C₆H₅. In some embodiments, at least one of R², R³, R⁴,R⁵, R⁶, and R⁷ is —OCOCH₃. In some embodiments, at least one of R², R³,R⁴, R⁵, R⁶, and R⁷ is —(CH₂)_(x)—CONH₂. In some embodiments, at leastone of R², R³, R⁴, R⁵, R⁶, and R⁷ is —(CH₂)_(x)—COOC₁₋₆ alkyl.

In some embodiments of Formula (I), one of R², R³, R⁴, R⁵, R⁶, and R⁷ ishalogen, and the rest are hydrogen. In some embodiments, the halogen isbromo.

In some embodiments of Formula (I), one of R², R³, R⁴, R⁵, R⁶, and R⁷ ishalogen; and one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —CHO or—(CH₂)_(x)—COOH. In some embodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷is bromo; and one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —CHO or—(CH₂)_(x)—COOH. In some embodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷is bromo; and one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —(CH₂)_(x)—COOH. Insome embodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷ is bromo; and one ofR², R³, R⁴, R⁵, R⁶, and R⁷ is —(CH₂)_(x)—COOH.

In some embodiments of Formula (I), one of R², R³, R⁴, R⁵, R⁶, and R⁷ ishalogen; one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —CHO or —(CH₂)_(x)—COOH;and the rest are hydrogen. In some embodiments, one of R², R³, R⁴, R⁵,R⁶, and R⁷ is bromo; one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —CHO or—(CH₂)_(x)—COOH; and the rest are hydrogen. In some embodiments, one ofR², R³, R⁴, R⁵, R⁶, and R⁷ is bromo; one of R², R³, R⁴, R⁵, R⁶, and R⁷is —(CH₂)_(x)—COOH; and the rest are hydrogen. In some embodiments, oneof R², R³, R⁴, R⁵, R⁶, and R⁷ is bromo; one of R², R³, R⁴, R⁵, R⁶, andR⁷ is —(CH₂)_(x)—COOH; and the rest are hydrogen.

In some embodiments of Formula (I), one of R², R³, R⁴, R⁵, R⁶, and R⁷ is—CHO or —(CH₂)_(x)—COOH, and the rest are hydrogen. In some embodiments,one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —CHO and the rest are hydrogen. Insome embodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —(CH₂)_(x)—COOHand the rest are hydrogen.

In some embodiments of Formula (I), one of R², R³, R⁴, R⁵, R⁶, and R⁷ is—CHO or —(CH₂)_(x)—COOH; and one of R², R³, R⁴, R⁵, R⁶, and R⁷ ishalogen or —OCH₂C₆H₅. In some embodiments, one of R², R³, R⁴, R⁵, R⁶,and R⁷ is —CHO; and one of R², R³, R⁴, R⁵, R⁶, and R⁷ is halogen or—OCH₂C₆H₅. In some embodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷ is—(CH₂)_(x)—COOH; and one of R², R³, R⁴, R⁵, R⁶, and R⁷ is halogen or—OCH₂C₆H₅.

In some embodiments of Formula (I), one of R², R³, R⁴, R⁵, R⁶, and R⁷ is—CHO or —(CH₂)_(x)—COOH; one of R², R³, R⁴, R⁵, R⁶, and R⁷ is halogen or—OCH₂C₆H₅; and the rest are hydrogen. In some embodiments, one of R²,R³, R⁴, R⁵, R⁶, and R⁷ is —CHO; one of R², R³, R⁴, R⁵, R⁶, and R⁷ ishalogen or —OCH₂C₆H₅; and the rest are hydrogen. In some embodiments,one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —(CH₂)_(x)—COOH; one of R², R³, R⁴,R⁵, R⁶, and R⁷ is halogen or —OCH₂C₆H₅; and the rest are hydrogen.

In some embodiments of Formula (I), R² and R³, together with the atomsthey attach to, form a substituted six-membered heterocyclyl ring. Insome embodiments, R² and R³, together with the atoms they attach to,form a substituted six-membered heterocyclyl ring containing onenitrogen. In some embodiments, R² and R³, together with the atoms theyattach to, form

wherein R⁸, R¹⁰, and R¹¹ are independently selected from hydrogen,halogen, —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl, —(CH₂)_(x)—OH, —(CH₂)_(x)—CN,—OCH₂C₆H₅, —OCOCH₃, —(CH₂)_(x)—CONH₂, —CHO, —(CH₂)_(x)—COOH,—(CH₂)_(y)—CO—COOH, —(CH₂)_(y)—C(H)(OH)—COOH, phenyl, and substitutedphenyl; wherein the substituted phenyl is substituted with 1-4substituents selected from hydroxyl, C₁₋₆alkoxy, and C₁₋₆alkyl; and R⁹is hydrogen or C₁₋₆ alkyl.

In some embodiments of Formula (I), R² is selected from halogen, —CHO,and —(CH₂)_(x)—COOH and R¹ and R³ are hydrogen. In some embodiments, R³is selected from halogen, —CHO, and —(CH₂)_(x)—COOH and R¹, R², and R⁴are hydrogen. In some embodiments, R⁴ is selected from halogen, —CHO,and —(CH₂)_(x)—COOH and R³, R⁵, and R⁶ are hydrogen. In someembodiments, R⁵ is selected from halogen, —CHO, and —(CH₂)_(x)—COOH andR⁴, R⁶, and R⁷ are hydrogen. In some embodiments, R⁶ is selected fromhalogen, —CHO, and —(CH₂)_(x)—COOH and R⁴, R⁵, and R⁷ are hydrogen. Insome embodiments, R⁷ is selected from halogen, —CHO, and —(CH₂)_(x)—COOHand R¹ and R⁶ are hydrogen.

In some embodiments of Formula (I), R², R³, R⁴, R⁵, R⁶, and R⁷ arehydrogen.

In some embodiments of Formula (I), R² is hydrogen. In some embodimentsof Formula (I), R² is —CHO. In some embodiments of Formula (I), R² is—(CH₂)_(x)—COOH. In some embodiments of Formula (I), R² is—(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (I), R² ishalogen. In some embodiments of Formula (II), R² is bromo. In someembodiments of Formula (I), R² is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (I), R² is—OCH₂C₆H₅. In some embodiments of Formula (I), R² is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (I), R² is heteroaryl orsubstituted heteroaryl. In some embodiments of Formula (I), R² is—OCOCH₃ or —(CH₂)_(x)—CONH₂. In some embodiments of Formula (I), R² isC₁₋₆alkyl, C₁₋₆alkoxy, amino, or substituted amino. In some embodimentsof Formula (I), R² is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (I), R³ is hydrogen. In some embodimentsof Formula (I), R³ is —CHO. In some embodiments of Formula (I), R³ is—(CH₂)_(x)—COOH. In some embodiments of Formula (I), R³ is—(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (I), R³ ishalogen. In some embodiments of Formula (I), R³ is bromo. In someembodiments of Formula (I), R³ is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (I), R³ is—OCH₂C₆H₅. In some embodiments of Formula (I), R³ is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (I), R³ is heteroaryl orsubstituted heteroaryl. In some embodiments of Formula (I), R³ is—OCOCH₃ or —(CH₂)_(x)—CONH₂. In some embodiments of Formula (I), R³ isC₁₋₆alkyl, C₁₋₆alkoxy, amino, or substituted amino. In some embodimentsof Formula (I), R³ is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (I), R² and R³, together with the atomsthey attach to, form an unsubstituted five to seven-memberedheterocyclyl ring. In some embodiments, R² and R³, together with theatoms they attach to, form a substituted five to seven-memberedheterocyclyl ring. In some embodiments, R² and R³, together with theatoms they attach to, form a five-membered heterocyclyl ring. In someembodiments, R² and R³, together with the atoms they attach to, form asix-membered heterocyclyl ring. In some embodiments, R² and R³, togetherwith the atoms they attach to, form a seven-membered heterocyclyl ring.

In some embodiments of Formula (I), R⁴ is hydrogen. In some embodimentsof Formula (I), R⁴ is —CHO. In some embodiments of Formula (I), R⁴ is—(CH₂)_(x)—COOH. In some embodiments of Formula (I), R⁴ is—(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (I), R⁴ ishalogen. In some embodiments of Formula (I), R⁴ is bromo. In someembodiments of Formula (I), R⁴ is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (I), R⁴ is—OCH₂C₆H₅. In some embodiments of Formula (I), R⁴ is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (I), R⁴ is heteroaryl orsubstituted heteroaryl. In some embodiments of Formula (I), R⁴ is—OCOCH₃ or —(CH₂)_(x)—CONH₂. In some embodiments of Formula (I), R⁴ isC₁₋₆alkyl, C₁₋₆alkoxy, amino, or substituted amino. In some embodimentsof Formula (I), R⁴ is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (I), R⁵ is hydrogen. In some embodimentsof Formula (I), R⁵ is —CHO. In some embodiments of Formula (I), R⁵ is—(CH₂)_(x)—COOH. In some embodiments of Formula (I), R⁵ is—(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (I), R⁵ ishalogen. In some embodiments of Formula (I), R⁵ is bromo. In someembodiments of Formula (I), R⁵ is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (I), R⁵ is—OCH₂C₆H₅. In some embodiments of Formula (I), R⁵ is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (I), R⁵ is heteroaryl orsubstituted heteroaryl. In some embodiments of Formula (I), R⁵ is—OCOCH₃ or —(CH₂)_(x)—CONH₂. In some embodiments of Formula (I), R⁵ isC₁₋₆alkyl, C₁₋₆alkoxy, amino, or substituted amino. In some embodimentsof Formula (I), R⁵ is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (I), R⁶ is hydrogen. In some embodimentsof Formula (I), R⁶ is —CHO. In some embodiments of Formula (I), R⁶ is—(CH₂)_(x)—COOH. In some embodiments of Formula (I), R⁶ is—(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (I), R⁶ ishalogen. In some embodiments of Formula (I), R⁶ is bromo. In someembodiments of Formula (I), R⁶ is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (I), R⁶ is—OCH₂C₆H₅. In some embodiments of Formula (I), R⁶ is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (I), R⁶ is heteroaryl orsubstituted heteroaryl. In some embodiments of Formula (I), R⁶ is—OCOCH₃ or —(CH₂)_(x)—CONH₂. In some embodiments of Formula (I), R⁶ isC₁₋₆alkyl, C₁₋₆alkoxy, amino, or substituted amino. In some embodimentsof Formula (I), R⁶ is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (I), R⁷ is hydrogen. In some embodimentsof Formula (I), R⁷ is —CHO. In some embodiments of Formula (I), R⁷ is—(CH₂)_(x)—COOH. In some embodiments of Formula (I), R⁷ is—(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (I), R⁷ ishalogen. In some embodiments of Formula (I), R⁷ is bromo. In someembodiments of Formula (I), R⁷ is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (I), R⁷ is—OCH₂C₆H₅. In some embodiments of Formula (I), R⁷ is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (I), R⁷ is heteroaryl orsubstituted heteroaryl. In some embodiments of Formula (I), R⁷ is—OCOCH₃ or —(CH₂)_(x)—CONH₂. In some embodiments of Formula (I), R⁷ isC₁₋₆alkyl, C₁₋₆alkoxy, amino, or substituted amino. In some embodimentsof Formula (I), R⁷ is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (I), R⁶ and R⁷, together with the atomsthey attach to, form a five to seven-membered carbocyclic ring. In someembodiments, R⁶ and R⁷, together with the atoms they attach to, form afive-membered carbocyclic ring.

In some embodiments of Formula (I), R⁵ and R⁶, together with the atomsthey attach to, form a five to seven-membered carbocyclic ring. In someembodiments, R⁵ and R⁶, together with the atoms they attach to, form afive-membered carbocyclic ring.

In some embodiments of Formula (I), R⁴ and R⁵, together with the atomsthey attach to, form a five to seven-membered carbocyclic ring. In someembodiments, R⁴ and R⁵, together with the atoms they attach to, form afive-membered carbocyclic ring.

Formula (II)

The present disclosure provides a compound of Formula (II) andcompositions comprising a compound of Formula (II):

wherein

R¹ is hydrogen, C₁₋₆ alkyl, or hydroxy;

R², R³, R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen,C₁₋₆alkyl, C₁₋₆alkoxy, amino, substituted amino, halogen,—(CH₂)_(x)—C(O)—OC₁₋₆ alkyl, —(CH₂)_(x)—OH, —(CH₂)_(x)—CN, —OCH₂C₆H₅,—CHO, —(CH₂)_(x)—COOH, —(CH₂)_(x)—COOC₁₋₆ alkyl, —(CH₂)_(y)—CO—COOH, and—(CH₂)_(y)—C(H)(OH)—COOH; or

any two adjacent R⁴, R⁵, R⁶, and R⁷, together with the atoms they attachto, form a five to seven-membered carbocyclic ring;

x is a number from zero to six; and

y is a number from zero to six;

or a pharmaceutically acceptable salt thereof.

In some embodiments of Formula (II), R¹ is hydrogen. In someembodiments, R¹ is C₁₋₆ alkyl. In some embodiments, R¹ is methyl. Insome embodiments, R¹ is hydroxy.

In some embodiments of Formula (II), at least one of R², R³, R⁴, R⁵, R⁶,and R⁷ is selected from halogen, —CHO, and —(CH₂)_(x)—COOH.

In some embodiments of Formula (II), at least one of R², R³, R⁴, R⁵, R⁶,and R⁷ is a halogen. In some embodiments, at least one of R², R³, R⁴,R⁵, R⁶, and R⁷ is bromo. In some embodiments, R² is bromo. In someembodiments, R³ is bromo. In some embodiments, R⁴ is bromo. In someembodiments, R⁵ is bromo. In some embodiments, R⁶ is bromo. In someembodiments, R⁷ is bromo.

In some embodiments of Formula (II), at least one of R², R³, R⁴, R⁵, R⁶,and R⁷ is —CHO. In some embodiments, R² is —CHO. In some embodiments, R³is —CHO. In some embodiments, R⁴ is —CHO. In some embodiments, R⁵ is—CHO. In some embodiments, R⁶ is —CHO. In some embodiments, R⁷ is —CHO.

In some embodiments of Formula (II), at least one of R², R³, R⁴, R⁵, R⁶,and R⁷ is —(CH₂)_(x)—COOH. In some embodiments, R² is —(CH₂)_(x)—COOH.In some embodiments, R³ is —(CH₂)_(x)—COOH. In some embodiments, R⁴ is—(CH₂)_(x)—COOH. In some embodiments, R⁵ is —(CH₂)_(x)—COOH. In someembodiments, R⁶ is —(CH₂)_(x)—COOH. In some embodiments, R⁷ is—(CH₂)_(x)—COOH. In some embodiments, x is one to three. In someembodiments, x is one.

In some embodiments of Formula (II), at least one of R², R³, R⁴, R⁵, R⁶,and R⁷ is —OCH₂C₆H₅. In some embodiments, at least one of R², R³, R⁴,R⁵, R⁶, and R⁷ is —(CH₂)_(x)—COOC₁₋₆alkyl.

In some embodiments of Formula (II), one of R², R³, R⁴, R⁵, R⁶, and R⁷is halogen, and the rest are hydrogen. In some embodiments, the halogenis bromo.

In some embodiments of Formula (II), one of R², R³, R⁴, R⁵, R⁶, and R⁷is halogen; and one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —CHO or—(CH₂)_(x)—COOH. In some embodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷is bromo; and one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —CHO or—(CH₂)_(x)—COOH. In some embodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷is bromo; and one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —(CH₂)_(x)—COOH. Insome embodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷ is bromo; and one ofR², R³, R⁴, R⁵, R⁶, and R⁷ is —(CH₂)_(x)—COOH.

In some embodiments of Formula (II), one of R², R³, R⁴, R⁵, R⁶, and R⁷is halogen; one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —CHO or—(CH₂)_(x)—COOH; and the rest are hydrogen. In some embodiments, one ofR², R³, R⁴, R⁵, R⁶, and R⁷ is bromo; one of R², R³, R⁴, R⁵, R⁶, and R⁷is —CHO or —(CH₂)_(x)—COOH; and the rest are hydrogen. In someembodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷ is bromo; one of R², R³,R⁴, R⁵, R⁶, and R⁷ is —(CH₂)_(x)—COOH; and the rest are hydrogen. Insome embodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷ is bromo; one of R²,R³, R⁴, R⁵, R⁶, and R⁷ is —(CH₂)_(x)—COOH; and the rest are hydrogen.

In some embodiments of Formula (II), one of R², R³, R⁴, R⁵, R⁶, and R⁷is —CHO or —(CH₂)_(x)—COOH, and the rest are hydrogen. In someembodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —CHO and the rest arehydrogen. In some embodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷ is—(CH₂)_(x)—COOH and the rest are hydrogen.

In some embodiments of Formula (II), one of R², R³, R⁴, R⁵, R⁶, and R⁷is —CHO or —(CH₂)_(x)—COOH; and one of R², R³, R⁴, R⁵, R⁶, and R⁷ ishalogen or —OCH₂C₆H₅. In some embodiments, one of R², R³, R⁴, R⁵, R⁶,and R⁷ is —CHO; and one of R², R³, R⁴, R⁵, R⁶, and R⁷ is halogen or—OCH₂C₆H₅. In some embodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷ is—(CH₂)_(x)—COOH; and one of R², R³, R⁴, R⁵, R⁶, and R⁷ is halogen or—OCH₂C₆H₅.

In some embodiments of Formula (II), one of R², R³, R⁴, R⁵, R⁶, and R⁷is —CHO or —(CH₂)_(x)—COOH; one of R², R³, R⁴, R⁵, R⁶, and R⁷ is halogenor —OCH₂C₆H₅; and the rest are hydrogen. In some embodiments, one of R²,R³, R⁴, R⁵, R⁶, and R⁷ is —CHO; one of R², R³, R⁴, R⁵, R⁶, and R⁷ ishalogen or —OCH₂C₆H₅; and the rest are hydrogen. In some embodiments,one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —(CH₂)_(x)—COOH; one of R², R³, R⁴,R⁵, R⁶, and R⁷ is halogen or —OCH₂C₆H₅; and the rest are hydrogen.

In some embodiments of Formula (II), R² is selected from halogen, —CHO,and —(CH₂)_(x)—COOH and R¹ and R³ are hydrogen. In some embodiments, R³is selected from halogen, —CHO, and —(CH₂)_(x)—COOH and R¹, R², and R⁴are hydrogen. In some embodiments, R⁴ is selected from halogen, —CHO,and —(CH₂)_(x)—COOH and R³, R⁵, and R⁶ are hydrogen. In someembodiments, R⁵ is selected from halogen, —CHO, and —(CH₂)_(x)—COOH andR⁴, R⁶, and R⁷ are hydrogen. In some embodiments, R⁶ is selected fromhalogen, —CHO, and —(CH₂)_(x)—COOH and R⁴, R⁵, and R⁷ are hydrogen. Insome embodiments, R⁷ is selected from halogen, —CHO, and —(CH₂)_(x)—COOHand R¹ and R⁶ are hydrogen.

In some embodiments of Formula (II), R², R³, R⁴, R⁵, R⁶, and R⁷ arehydrogen.

In some embodiments of Formula (II), R² is hydrogen. In some embodimentsof Formula (II), R² is —CHO. In some embodiments of Formula (II), R² is—(CH₂)_(x)—COOH. In some embodiments of Formula (II), R² is—(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (II), R² ishalogen. In some embodiments of Formula (II), R² is bromo. In someembodiments of Formula (II), R² is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (II), R² is—OCH₂C₆H₅. In some embodiments of Formula (II), R² is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (II), R² is C₁₋₆alkyl,C₁₋₆alkoxy, amino, or substituted amino. In some embodiments of Formula(II), R² is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (II), R³ is hydrogen. In some embodimentsof Formula (II), R³ is —CHO. In some embodiments of Formula (II), R³ is—(CH₂)_(x)—COOH. In some embodiments of Formula (II), R³ is—(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (II), R³ ishalogen. In some embodiments of Formula (II), R³ is bromo. In someembodiments of Formula (II), R³ is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (II), R³ is—OCH₂C₆H₅. In some embodiments of Formula (II), R³ is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (II), R³ is C₁₋₆alkyl,C₁₋₆alkoxy, amino, or substituted amino. In some embodiments of Formula(II), R³ is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (II), R⁴ is hydrogen. In some embodimentsof Formula (II), R⁴ is —CHO. In some embodiments of Formula (II), R⁴ is—(CH₂)_(x)—COOH. In some embodiments of Formula (II), R⁴ is—(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (II), R⁴ ishalogen. In some embodiments of Formula (II), R⁴ is bromo. In someembodiments of Formula (II), R⁴ is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (II), R⁴ is—OCH₂C₆H₅. In some embodiments of Formula (II), R⁴ is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (II), R⁴ is C₁₋₆alkyl,C₁₋₆alkoxy, amino, or substituted amino. In some embodiments of Formula(II), R⁴ is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (II), R⁵ is hydrogen. In some embodimentsof Formula (II), R⁵ is —CHO. In some embodiments of Formula (II), R⁵ is—(CH₂)_(x)—COOH. In some embodiments of Formula (II), R⁵ is—(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (II), R⁵ ishalogen. In some embodiments of Formula (II), R⁵ is bromo. In someembodiments of Formula (II), R⁵ is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (II), R⁵ is—OCH₂C₆H₅. In some embodiments of Formula (II), R⁵ is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (II), R⁵ is C₁₋₆alkyl,C₁₋₆alkoxy, amino, or substituted amino. In some embodiments of Formula(II), R⁵ is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (II), R⁶ is hydrogen. In some embodimentsof Formula (II), R⁶ is —CHO. In some embodiments of Formula (II), R⁶ is—(CH₂)_(x)—COOH. In some embodiments of Formula (II), R⁶ is—(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (II), R⁶ ishalogen. In some embodiments of Formula (II), R⁶ is bromo. In someembodiments of Formula (II), R⁶ is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (II), R⁶ is—OCH₂C₆H₅. In some embodiments of Formula (II), R⁶ is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (II), R⁶ is C₁₋₆alkyl,C₁₋₆alkoxy, amino, or substituted amino. In some embodiments of Formula(II), R⁶ is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (II), R⁷ is hydrogen. In some embodimentsof Formula (II), R⁷ is —CHO. In some embodiments of Formula (II), R⁷ is—(CH₂)_(x)—COOH. In some embodiments of Formula (II), R⁷ is—(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (II), R⁷ ishalogen. In some embodiments of Formula (II), R⁷ is bromo. In someembodiments of Formula (II), R⁷ is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (II), R⁷ is—OCH₂C₆H₅. In some embodiments of Formula (II), R⁷ is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (II), R⁷ is C₁₋₆alkyl,C₁₋₆alkoxy, amino, or substituted amino. In some embodiments of Formula(II), R⁷ is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (II), R⁶ and R⁷, together with the atomsthey attach to, form a five to seven-membered carbocyclic ring. In someembodiments, R⁶ and R⁷, together with the atoms they attach to, form afive-membered carbocyclic ring.

In some embodiments of Formula (II), R⁵ and R⁶, together with the atomsthey attach to, form a five to seven-membered carbocyclic ring. In someembodiments, R⁵ and R⁶, together with the atoms they attach to, form afive-membered carbocyclic ring.

In some embodiments of Formula (II), R⁴ and R⁵, together with the atomsthey attach to, form a five to seven-membered carbocyclic ring. In someembodiments, R⁴ and R⁵, together with the atoms they attach to, form afive-membered carbocyclic ring.

Formula (III)

The present disclosure provides a compound of Formula (III) andcompositions comprising a compound of Formula (III):

wherein

R¹ is hydrogen, C₁₋₆ alkyl, or hydroxy;

R², R³, R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen,C₁₋₆alkyl, C₁₋₆alkoxy, amino, substituted amino, halogen,—(CH₂)_(x)—C(O)—OC₁₋₆ alkyl, —(CH₂)_(x)—OH, —(CH₂)_(x)—CN, —OCH₂C₆H₅,—CHO, —(CH₂)_(x)—COOH, —(CH₂)_(x)—COOC₁₋₆ alkyl, —(CH₂)_(y)—CO—COOH, and—(CH₂)_(y)—C(H)(OH)—COOH; or

any two adjacent R⁴, R⁵, R⁶, and R⁷, together with the atoms they attachto, form a five to seven-membered carbocyclic ring;

x is a number from zero to six; and

y is a number from zero to six;

or a pharmaceutically acceptable salt thereof;

provided that at least one of R², R³, R⁴, R⁵, R⁶, and R⁷ is bromo.

In some embodiments of Formula (III), R¹ is hydrogen. In someembodiments, R¹ is C₁₋₆ alkyl. In some embodiments, R¹ is methyl. Insome embodiments, R¹ is hydroxy.

In Formula (III), at least one of R², R³, R⁴, R⁵, R⁶, and R⁷ is bromo.In some embodiments, R² is bromo. In some embodiments, R³ is bromo. Insome embodiments, R⁴ is bromo. In some embodiments, R⁵ is bromo. In someembodiments, R⁶ is bromo. In some embodiments, R⁷ is bromo.

In some embodiments of Formula (III), one of R², R³, R⁴, R⁵, R⁶, and R⁷is bromo, and the rest are hydrogen.

In some embodiments of Formula (III), one of R², R³, R⁴, R⁵, R⁶, and R⁷is bromo and at least one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —CHO,—(CH₂)_(x)—COOH, or —OCH₂C₆H₅. In some embodiments, one of R², R³, R⁴,R⁵, R⁶, and R⁷ is bromo and at least one of R², R³, R⁴, R⁵, R⁶, and R⁷is —CHO. In some embodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷ is bromoand at least one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —(CH₂)_(x)—COOH. Insome embodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷ is bromo and atleast one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —OCH₂C₆H₅.

In some embodiments of Formula (III), one of R², R³, R⁴, R⁵, R⁶, and R⁷is bromo; one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —CHO, —(CH₂)_(x)—COOH, or—OCH₂C₆H₅; and the rest are hydrogen. In some embodiments, one of R²,R³, R⁴, R⁵, R⁶, and R⁷ is bromo; one of R², R³, R⁴, R⁵, R⁶, and R⁷ is—CHO; and the rest are hydrogen. In some embodiments, one of R², R³, R⁴,R⁵, R⁶, and R⁷ is bromo; one of R², R³, R⁴, R⁵, R⁶, and R⁷ is—(CH₂)_(x)—COOH; and the rest are hydrogen. In some embodiments, one ofR², R³, R⁴, R⁵, R⁶, and R⁷ is bromo; one of R², R³, R⁴, R⁵, R⁶, and R⁷is —OCH₂C₆H₅; and the rest are hydrogen.

In some embodiments of Formula (III), R² is bromo and R¹ and R³ arehydrogen. In some embodiments, R³ is bromo and R¹, R², and R⁴ arehydrogen. In some embodiments, R⁴ is bromo and R³, R⁵, and R⁶ arehydrogen. In some embodiments, R⁵ is bromo and R⁴, R⁶, and R⁷ arehydrogen. In some embodiments, R⁶ is bromo and R⁴, R⁵, and R⁷ arehydrogen. In some embodiments, R⁷ is bromo and R¹ and R⁶ are hydrogen.

In some embodiments of Formula (III), R² is hydrogen. In someembodiments of Formula (III), R² is —CHO. In some embodiments of Formula(III), R² is —(CH₂)_(x)—COOH. In some embodiments of Formula (III), R²is —(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (III), R² ishalogen. In some embodiments of Formula (III), R² is bromo. In someembodiments of Formula (III), R² is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (III), R² is—OCH₂C₆H₅. In some embodiments of Formula (III), R² is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (III), R² is C₁₋₆alkyl,C₁₋₆alkoxy, amino, or substituted amino. In some embodiments of Formula(III), R² is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (III), R³ is hydrogen. In someembodiments of Formula (III), R³ is —CHO. In some embodiments of Formula(III), R³ is —(CH₂)_(x)—COOH. In some embodiments of Formula (III), R³is —(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (III), R³ ishalogen. In some embodiments of Formula (III), R³ is bromo. In someembodiments of Formula (III), R³ is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (III), R³ is—OCH₂C₆H₅. In some embodiments of Formula (III), R³ is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (III), R³ is C₁₋₆alkyl,C₁₋₆alkoxy, amino, or substituted amino. In some embodiments of Formula(III), R³ is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (III), R⁴ is hydrogen. In someembodiments of Formula (III), R⁴ is —CHO. In some embodiments of Formula(III), R⁴ is —(CH₂)_(x)—COOH. In some embodiments of Formula (III), R⁴is —(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (III), R⁴ ishalogen. In some embodiments of Formula (III), R⁴ is bromo. In someembodiments of Formula (III), R⁴ is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (III), R⁴ is—OCH₂C₆H₅. In some embodiments of Formula (III), R⁴ is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (III), R⁴ is C₁₋₆alkyl,C₁₋₆alkoxy, amino, or substituted amino. In some embodiments of Formula(III), R⁴ is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (III), R⁵ is hydrogen. In someembodiments of Formula (III), R⁵ is —CHO. In some embodiments of Formula(III), R⁵ is —(CH₂)_(x)—COOH. In some embodiments of Formula (III), R⁵is —(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (III), R⁵ ishalogen. In some embodiments of Formula (III), R⁵ is bromo. In someembodiments of Formula (III), R⁵ is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (III), R⁵ is—OCH₂C₆H₅. In some embodiments of Formula (III), R⁵ is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (III), R⁵ is C₁₋₆alkyl,C₁₋₆alkoxy, amino, or substituted amino. In some embodiments of Formula(III), R⁵ is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (III), R⁶ is hydrogen. In someembodiments of Formula (III), R⁶ is —CHO. In some embodiments of Formula(III), R⁶ is —(CH₂)_(x)—COOH. In some embodiments of Formula (III), R⁶is —(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (III), R⁶ ishalogen. In some embodiments of Formula (III), R⁶ is bromo. In someembodiments of Formula (III), R⁶ is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (III), R⁶ is—OCH₂C₆H₅. In some embodiments of Formula (III), R⁶ is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (III), R⁶ is C₁₋₆alkyl,C₁₋₆alkoxy, amino, or substituted amino. In some embodiments of Formula(III), R⁶ is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (III), R⁷ is hydrogen. In someembodiments of Formula (III), R⁷ is —CHO. In some embodiments of Formula(III), R⁷ is —(CH₂)_(x)—COOH. In some embodiments of Formula (III), R⁷is —(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (III), R⁷ ishalogen. In some embodiments of Formula (III), R⁷ is bromo. In someembodiments of Formula (III), R⁷ is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (III), R⁷ is—OCH₂C₆H₅. In some embodiments of Formula (III), R⁷ is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (III), R⁷ is C₁₋₆alkyl,C₁₋₆alkoxy, amino, or substituted amino. In some embodiments of Formula(III), R⁷ is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (III), R⁶ and R⁷, together with the atomsthey attach to, form a five to seven-membered carbocyclic ring. In someembodiments, R⁶ and R⁷, together with the atoms they attach to, form afive-membered carbocyclic ring.

In some embodiments of Formula (III), R⁵ and R⁶, together with the atomsthey attach to, form a five to seven-membered carbocyclic ring. In someembodiments, R⁵ and R⁶, together with the atoms they attach to, form afive-membered carbocyclic ring.

In some embodiments of Formula (III), R⁴ and R⁵, together with the atomsthey attach to, form a five to seven-membered carbocyclic ring. In someembodiments, R⁴ and R⁵, together with the atoms they attach to, form afive-membered carbocyclic ring.

Formula (IV)

The present disclosure provides a compound of Formula (IV) andcompositions comprising a compound of Formula (IV):

wherein

R¹ is hydrogen, C₁₋₆ alkyl, or hydroxy;

R², R³, R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen,C₁₋₆alkyl, C₁₋₆alkoxy, amino, substituted amino, halogen,—(CH₂)_(x)—C(O)—OC₁₋₆ alkyl, —(CH₂)_(x)—OH, —(CH₂)_(x)—CN, —OCH₂C₆H₅,—CHO, —(CH₂)_(x)—COOH, —(CH₂)_(x)—COOC₁₋₆ alkyl, —(CH₂)_(y)—CO—COOH, and—(CH₂)_(y)—C(H)(OH)—COOH; or

any two adjacent R⁴, R⁵, R⁶, and R⁷, together with the atoms they attachto, form a five to seven-membered carbocyclic ring;

x is a number from zero to six; and

y is a number from zero to six;

or a pharmaceutically acceptable salt thereof;

provided that at least one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —CHO or—(CH₂)_(x)—COOH.

In some embodiments of Formula (IV), R¹ is hydrogen. In someembodiments, R¹ is C₁₋₆ alkyl. In some embodiments, R¹ is methyl. Insome embodiments, R¹ is hydroxy.

In Formula (IV), at least one of R², R³, R⁴, R⁵, R⁶, and R⁷ is selectedfrom —CHO, and —(CH₂)_(x)—COOH.

In some embodiments of Formula (IV), at least one of R², R³, R⁴, R⁵, R⁶,and R⁷ is —CHO. In some embodiments, R² is —CHO. In some embodiments, R³is —CHO. In some embodiments, R⁴ is —CHO. In some embodiments, R⁵ is—CHO. In some embodiments, R⁶ is —CHO. In some embodiments, R⁷ is —CHO.

In some embodiments of Formula (IV), at least one of R², R³, R⁴, R⁵, R⁶,and R⁷ is —(CH₂)_(x)—COOH. In some embodiments, R² is —(CH₂)_(x)—COOH.In some embodiments, R³ is —(CH₂)_(x)—COOH. In some embodiments, R⁴ is—(CH₂)_(x)—COOH. In some embodiments, R⁵ is —(CH₂)_(x)—COOH. In someembodiments, R⁶ is —(CH₂)_(x)—COOH. In some embodiments, R⁷ is—(CH₂)_(x)—COOH. In some embodiments, x is one to three. In someembodiments, x is one.

In some embodiments of Formula (IV), at least one of R², R³, R⁴, R⁵, R⁶,and R⁷ is —OCH₂C₆H₅. In some embodiments of Formula (IV), at least oneof R², R³, R⁴, R⁵, R⁶, and R⁷ is halogen. In some embodiments of Formula(IV), at least one of R², R³, R⁴, R⁵, R⁶, and R⁷ is -bromo. In someembodiments of Formula (IV), at least one of R², R³, R⁴, R⁵, R⁶, and R⁷is —(CH₂)_(x)—COOC₁₋₆alkyl.

In some embodiments of Formula (IV), one of R², R³, R⁴, R⁵, R⁶, and R⁷is —CHO or —(CH₂)_(x)—COOH, and the rest are hydrogen. In someembodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —CHO and the rest arehydrogen. In some embodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷ is—(CH₂)_(x)—COOH and the rest are hydrogen.

In some embodiments of Formula (IV), one of R², R³, R⁴, R⁵, R⁶, and R⁷is —CHO or —(CH₂)_(x)—COOH and at least one of R², R³, R⁴, R⁵, R⁶, andR⁷ is bromo or —OCH₂C₆H₅. In some embodiments, one of R², R³, R⁴, R⁵,R⁶, and R⁷ is —CHO and at least one of R², R³, R⁴, R⁵, R⁶, and R⁷ isbromo. In some embodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —CHOand at least one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —OCH₂C₆H₅. In someembodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —(CH₂)_(x)—COOH and atleast one of R², R³, R⁴, R⁵, R⁶, and R⁷ is bromo. In some embodiments,one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —(CH₂)_(x)—COOH and at least one ofR², R³, R⁴, R⁵, R⁶, and R⁷ is —OCH₂C₆H₅.

In some embodiments of Formula (IV), one of R², R³, R⁴, R⁵, R⁶, and R⁷is —CHO or —(CH₂)_(x)—COOH; one of R², R³, R⁴, R⁵, R⁶, and R⁷ is halogenor —OCH₂C₆H₅; and the rest are hydrogen. In some embodiments, one of R²,R³, R⁴, R⁵, R⁶, and R⁷ is —CHO; one of R², R³, R⁴, R⁵, R⁶, and R⁷ ishalogen or —OCH₂C₆H₅; and the rest are hydrogen. In some embodiments,one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —(CH₂)_(x)—COOH; one of R², R³, R⁴,R⁵, R⁶, and R⁷ is halogen or —OCH₂C₆H₅; and the rest are hydrogen.

In some embodiments of Formula (IV), R² is selected from —CHO and—(CH₂)_(x)—COOH and R¹ and R³ are hydrogen. In some embodiments, R³ isselected from —CHO and —(CH₂)_(x)—COOH and R¹, R², and R⁴ are hydrogen.In some embodiments, R⁴ is selected from —CHO, and —(CH₂)_(x)—COOH andR³, R⁵, and R⁶ are hydrogen. In some embodiments, R⁵ is selected from—CHO, and —(CH₂)_(x)—COOH and R⁴, R⁶, and R⁷ are hydrogen. In someembodiments, R⁶ is selected from —CHO and —(CH₂)_(x)—COOH and R⁴, R⁵,and R⁷ are hydrogen. In some embodiments, R⁷ is selected from —CHO and—(CH₂)_(x)—COOH and R¹ and R⁶ are hydrogen.

In some embodiments of Formula (IV), R², R³, R⁴, R⁵, R⁶, and R⁷ arehydrogen.

In some embodiments of Formula (IV), R² is hydrogen. In some embodimentsof Formula (IV), R² is —CHO. In some embodiments of Formula (IV), R² is—(CH₂)_(x)—COOH. In some embodiments of Formula (IV), R² is—(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (IV), R² ishalogen. In some embodiments of Formula (IV), R² is bromo. In someembodiments of Formula (IV), R² is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (IV), R² is—OCH₂C₆H₅. In some embodiments of Formula (IV), R² is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (IV), R² is C₁₋₆alkyl,C₁₋₆alkoxy, amino, or substituted amino. In some embodiments of Formula(IV), R² is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (IV), R³ is hydrogen. In some embodimentsof Formula (IV), R³ is —CHO. In some embodiments of Formula (IV), R³ is—(CH₂)_(x)—COOH. In some embodiments of Formula (IV), R³ is—(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (IV), R³ ishalogen. In some embodiments of Formula (IV), R³ is bromo. In someembodiments of Formula (IV), R³ is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (IV), R³ is—OCH₂C₆H₅. In some embodiments of Formula (IV), R³ is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (IV), R³ is C₁₋₆alkyl,C₁₋₆alkoxy, amino, or substituted amino. In some embodiments of Formula(IV), R³ is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (IV), R⁴ is hydrogen. In some embodimentsof Formula (IV), R⁴ is —CHO. In some embodiments of Formula (IV), R⁴ is—(CH₂)_(x)—COOH. In some embodiments of Formula (IV), R⁴ is—(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (IV), R⁴ ishalogen. In some embodiments of Formula (IV), R⁴ is bromo. In someembodiments of Formula (IV), R⁴ is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (IV), R⁴ is—OCH₂C₆H₅. In some embodiments of Formula (IV), R⁴ is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (IV), R⁴ is C₁₋₆alkyl,C₁₋₆alkoxy, amino, or substituted amino. In some embodiments of Formula(IV), R⁴ is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (IV), R⁵ is hydrogen. In some embodimentsof Formula (IV), R⁵ is —CHO. In some embodiments of Formula (IV), R⁵ is—(CH₂)_(x)—COOH. In some embodiments of Formula (IV), R⁵ is—(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (IV), R⁵ ishalogen. In some embodiments of Formula (IV), R⁵ is bromo. In someembodiments of Formula (IV), R⁵ is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (IV), R⁵ is—OCH₂C₆H₅. In some embodiments of Formula (IV), R⁵ is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (IV), R⁵ is C₁₋₆alkyl,C₁₋₆alkoxy, amino, or substituted amino. In some embodiments of Formula(IV), R⁵ is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (IV), R⁶ is hydrogen. In some embodimentsof Formula (IV), R⁶ is —CHO. In some embodiments of Formula (IV), R⁶ is—(CH₂)_(x)—COOH. In some embodiments of Formula (IV), R⁶ is—(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (IV), R⁶ ishalogen. In some embodiments of Formula (IV), R⁶ is bromo. In someembodiments of Formula (IV), R⁶ is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (IV), R⁶ is—OCH₂C₆H₅. In some embodiments of Formula (IV), R⁶ is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (IV), R⁶ is C₁₋₆alkyl,C₁₋₆alkoxy, amino, or substituted amino. In some embodiments of Formula(IV), R⁶ is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (IV), R⁷ is hydrogen. In some embodimentsof Formula (IV), R⁷ is —CHO. In some embodiments of Formula (IV), R⁷ is—(CH₂)_(x)—COOH. In some embodiments of Formula (IV), R⁷ is—(CH₂)_(x)—COOC₁₋₆ alkyl. In some embodiments of Formula (IV), R⁷ ishalogen. In some embodiments of Formula (IV), R⁷ is bromo. In someembodiments of Formula (IV), R⁷ is —(CH₂)_(y)—CO—COOH or—(CH₂)_(y)—C(H)(OH)—COOH. In some embodiments of Formula (IV), R⁷ is—OCH₂C₆H₅. In some embodiments of Formula (IV), R⁷ is —(CH₂)_(x)—OH or—(CH₂)_(x)—CN. In some embodiments of Formula (IV), R⁷ is C₁₋₆alkyl,C₁₋₆alkoxy, amino, or substituted amino. In some embodiments of Formula(IV), R⁷ is —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl.

In some embodiments of Formula (IV), R⁶ and R⁷, together with the atomsthey attach to, form a five to seven-membered carbocyclic ring. In someembodiments, R⁶ and R⁷, together with the atoms they attach to, form afive-membered carbocyclic ring.

In some embodiments of Formula (IV), R⁵ and R⁶, together with the atomsthey attach to, form a five to seven-membered carbocyclic ring. In someembodiments, R⁵ and R⁶, together with the atoms they attach to, form afive-membered carbocyclic ring.

In some embodiments of Formula (IV), R⁴ and R⁵, together with the atomsthey attach to, form a five to seven-membered carbocyclic ring. In someembodiments, R⁴ and R⁵, together with the atoms they attach to, form afive-membered carbocyclic ring.

Formula (V)

The present disclosure provides a compound of Formula (V) andcompositions comprising a compound of Formula (V):

wherein

R¹ is hydrogen or C₁₋₆ alkyl;

R², R³, R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen,C₁₋₆alkyl, C₁₋₆alkoxy, —OCH₂C₆H₅, halogen, —CHO, —(CH₂)_(x)—COOH; and

x is a number from zero to six;

or a pharmaceutically acceptable salt thereof.

In some embodiments of Formula (V), R¹ is hydrogen. In some embodiments,R¹ is C₁₋₆ alkyl. In some embodiments, R¹ is methyl.

In some embodiments of Formula (V), at least one of R², R³, R⁴, R⁵, R⁶,and R⁷ is halogen, —CHO or —(CH₂)_(x)—COOH. In some embodiments, atleast one of R², R³, R⁴, R⁵, R⁶, and R⁷ is bromo, —CHO or—(CH₂)_(x)—COOH. In some embodiments, at least one of R², R³, R⁴, R⁵,R⁶, and R⁷ is bromo. In some embodiments, at least one of R², R³, R⁴,R⁵, R⁶, and R⁷ is —CHO. In some embodiments, at least one of R², R³, R⁴,R⁵, R⁶, and R⁷ is —(CH₂)_(x)—COOH.

In some embodiments of Formula (V), at least one of R², R³, R⁴, R⁵, R⁶,and R⁷ is a halogen. In some embodiments, at least one of R², R³, R⁴,R⁵, R⁶, and R⁷ is bromo. In some embodiments, R² is bromo. In someembodiments, R³ is bromo. In some embodiments, R⁴ is bromo. In someembodiments, R⁵ is bromo. In some embodiments, R⁶ is bromo. In someembodiments, R⁷ is bromo.

In some embodiments of Formula (V), at least one of R², R³, R⁴, R⁵, R⁶,and R⁷ is —CHO. In some embodiments, R² is —CHO. In some embodiments, R³is —CHO. In some embodiments, R⁴ is —CHO. In some embodiments, R⁵ is—CHO. In some embodiments, R⁶ is —CHO. In some embodiments, R⁷ is —CHO.

In some embodiments of Formula (V), at least one of R², R³, R⁴, R⁵, R⁶,and R⁷ is —(CH₂)_(x)—COOH. In some embodiments, R² is —(CH₂)_(x)—COOH.In some embodiments, R³ is —(CH₂)_(x)—COOH. In some embodiments, R⁴ is—(CH₂)_(x)—COOH. In some embodiments, R⁵ is —(CH₂)_(x)—COOH. In someembodiments, R⁶ is —(CH₂)_(x)—COOH. In some embodiments, R⁷ is—(CH₂)_(x)—COOH. In some embodiments, x is one to three. In someembodiments, x is one.

In some embodiments of Formula (V), at least one of R², R³, R⁴, R⁵, R⁶,and R⁷ is —OCH₂C₆H₅.

In some embodiments of Formula (V), one of R², R³, R⁴, R⁵, R⁶, and R⁷ ishalogen, and the rest are hydrogen. In some embodiments, the halogen isbromo.

In some embodiments of Formula (V), one of R², R³, R⁴, R⁵, R⁶, and R⁷ ishalogen; and one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —CHO or—(CH₂)_(x)—COOH. In some embodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷is bromo; and one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —CHO or—(CH₂)_(x)—COOH. In some embodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷is bromo; and one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —(CH₂)_(x)—COOH. Insome embodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷ is bromo; and one ofR², R³, R⁴, R⁵, R⁶, and R⁷ is —(CH₂)_(x)—COOH.

In some embodiments of Formula (V), one of R², R³, R⁴, R⁵, R⁶, and R⁷ ishalogen; one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —CHO or —(CH₂)_(x)—COOH;and the rest are hydrogen. In some embodiments, one of R², R³, R⁴, R⁵,R⁶, and R⁷ is bromo; one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —CHO or—(CH₂)_(x)—COOH; and the rest are hydrogen. In some embodiments, one ofR², R³, R⁴, R⁵, R⁶, and R⁷ is bromo; one of R², R³, R⁴, R⁵, R⁶, and R⁷is —(CH₂)_(x)—COOH; and the rest are hydrogen. In some embodiments, oneof R², R³, R⁴, R⁵, R⁶, and R⁷ is bromo; one of R², R³, R⁴, R⁵, R⁶, andR⁷ is —(CH₂)_(x)—COOH; and the rest are hydrogen.

In some embodiments of Formula (V), one of R², R³, R⁴, R⁵, R⁶, and R⁷ is—CHO or —(CH₂)_(x)—COOH, and the rest are hydrogen. In some embodiments,one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —CHO and the rest are hydrogen. Insome embodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —(CH₂)_(x)—COOHand the rest are hydrogen.

In some embodiments of Formula (V), one of R², R³, R⁴, R⁵, R⁶, and R⁷ is—CHO or —(CH₂)_(x)—COOH; and one of R², R³, R⁴, R⁵, R⁶, and R⁷ ishalogen or —OCH₂C₆H₅. In some embodiments, one of R², R³, R⁴, R⁵, R⁶,and R⁷ is —CHO; and one of R², R³, R⁴, R⁵, R⁶, and R⁷ is halogen or—OCH₂C₆H₅. In some embodiments, one of R², R³, R⁴, R⁵, R⁶, and R⁷ is—(CH₂)_(x)—COOH; and one of R², R³, R⁴, R⁵, R⁶, and R⁷ is halogen or—OCH₂C₆H₅.

In some embodiments of Formula (V), one of R², R³, R⁴, R⁵, R⁶, and R⁷ is—CHO or —(CH₂)_(x)—COOH; one of R², R³, R⁴, R⁵, R⁶, and R⁷ is halogen or—OCH₂C₆H₅; and the rest are hydrogen. In some embodiments, one of R²,R³, R⁴, R⁵, R⁶, and R⁷ is —CHO; one of R², R³, R⁴, R⁵, R⁶, and R⁷ ishalogen or —OCH₂C₆H₅; and the rest are hydrogen. In some embodiments,one of R², R³, R⁴, R⁵, R⁶, and R⁷ is —(CH₂)_(x)—COOH; one of R², R³, R⁴,R⁵, R⁶, and R⁷ is halogen or —OCH₂C₆H₅; and the rest are hydrogen.

In some embodiments of Formula (V), R² is selected from halogen, —CHO,and —(CH₂)_(x)—COOH and R¹ and R³ are hydrogen. In some embodiments, R³is selected from halogen, —CHO, and —(CH₂)_(x)—COOH and R¹, R², and R⁴are hydrogen. In some embodiments, R⁴ is selected from halogen, —CHO,and —(CH₂)_(x)—COOH and R³, R⁵, and R⁶ are hydrogen. In someembodiments, R⁵ is selected from halogen, —CHO, and —(CH₂)_(x)—COOH andR⁴, R⁶, and R⁷ are hydrogen. In some embodiments, R⁶ is selected fromhalogen, —CHO, and —(CH₂)_(x)—COOH and R⁴, R⁵, and R⁷ are hydrogen. Insome embodiments, R⁷ is selected from halogen, —CHO, and —(CH₂)_(x)—COOHand R¹ and R⁶ are hydrogen.

In some embodiments of Formula (V), R², R³, R⁴, R⁵, R⁶, and R⁷ arehydrogen.

In some embodiments of Formula (V), R² is hydrogen. In some embodimentsof Formula (V), R² is —CHO. In some embodiments of Formula (V), R² is—(CH₂)_(x)—COOH. In some embodiments of Formula (V), R² is halogen. Insome embodiments of Formula (V), R² is bromo. In some embodiments ofFormula (V), R² is —OCH₂C₆H₅. In some embodiments of Formula (V), R² isC₁₋₆alkyl or C₁₋₆alkoxy.

In some embodiments of Formula (V), R³ is hydrogen. In some embodimentsof Formula (V), R³ is —CHO. In some embodiments of Formula (V), R³ is—(CH₂)_(x)—COOH. In some embodiments of Formula (V), R³ is halogen. Insome embodiments of Formula (V), R³ is bromo. In some embodiments ofFormula (V), R³ is —OCH₂C₆H₅. In some embodiments of Formula (V), R³ isC₁₋₆alkyl or C₁₋₆alkoxy.

In some embodiments of Formula (V), R⁴ is hydrogen. In some embodimentsof Formula (V), R⁴ is —CHO. In some embodiments of Formula (V), R⁴ is—(CH₂)_(x)—COOH. In some embodiments of Formula (V), R⁴ is halogen. Insome embodiments of Formula (V), R⁴ is bromo. In some embodiments ofFormula (V), R⁴ is —OCH₂C₆H₅. In some embodiments of Formula (V), R⁴ isC₁₋₆alkyl or C₁₋₆alkoxy.

In some embodiments of Formula (V), R⁵ is hydrogen. In some embodimentsof Formula (V), R⁵ is —CHO. In some embodiments of Formula (V), R⁵ is—(CH₂)_(x)—COOH. In some embodiments of Formula (V), R⁵ is halogen. Insome embodiments of Formula (V), R⁵ is bromo. In some embodiments ofFormula (V), R⁵ is —OCH₂C₆H₅. In some embodiments of Formula (V), R⁵ isC₁₋₆alkyl or C₁₋₆alkoxy.

In some embodiments of Formula (V), R⁶ is hydrogen. In some embodimentsof Formula (V), R⁶ is —CHO. In some embodiments of Formula (V), R⁶ is—(CH₂)_(x)—COOH. In some embodiments of Formula (V), R⁶ is halogen. Insome embodiments of Formula (V), R⁶ is bromo. In some embodiments ofFormula (V), R⁶ is —OCH₂C₆H₅. In some embodiments of Formula (V), R⁶ isC₁₋₆alkyl or C₁₋₆alkoxy.

In some embodiments of Formula (V), R⁷ is hydrogen. In some embodimentsof Formula (V), R⁷ is —CHO. In some embodiments of Formula (V), R⁷ is—(CH₂)_(x)—COOH. In some embodiments of Formula (V), R⁷ is halogen. Insome embodiments of Formula (V), R⁷ is bromo. In some embodiments ofFormula (V), R⁷ is —OCH₂C₆H₅. In some embodiments of Formula (V), R⁷ isC₁₋₆alkyl or C₁₋₆alkoxy.

Formula (VI)

The present disclosure provides a compound of Formula (VI) andcompositions comprising a compound of Formula (VI):

wherein

R¹ is hydrogen or C₁₋₆ alkyl;

R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen, C₁₋₆alkyl,C₁₋₆alkoxy, amino, substituted amino, halogen, heteroaryl, substitutedheteroaryl, —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl, —(CH₂)_(x)—OH, —(CH₂)_(x)—CN,—OCH₂C₆H₅, —OCOCH₃, —(CH₂)_(x)—CONH₂, —CHO, —(CH₂)_(x)—COOH,—(CH₂)_(x)—COOC₁₋₆ alkyl, —(CH₂)_(y)—CO—COOH, and—(CH₂)_(y)—C(H)(OH)—COOH;

R⁸, R¹⁰, and R¹¹ are independently selected from hydrogen, halogen,—(CH₂)_(x)—C(O)—OC₁₋₆ alkyl, —(CH₂)_(x)—OH, —(CH₂)_(x)—CN, —OCH₂C₆H₅,—OCOCH₃, —(CH₂)_(x)—CONH₂, —CHO, —(CH₂)_(x)—COOH, —(CH₂)_(x)—COOC₁₋₆alkyl, —(CH₂)_(y)—CO—COOH, —(CH₂)_(y)—C(H)(OH)—COOH, phenyl, andsubstituted phenyl; wherein the substituted phenyl is substituted with1-4 substituents selected from hydroxyl, C₁₋₆alkoxy, and C₁₋₆alkyl;

R⁹ is hydrogen or C₁₋₆ alkyl;

x is a number from zero to six; and

y is a number from zero to six;

or a pharmaceutically acceptable salt thereof.

In some embodiments of Formula (VI), R¹ is hydrogen. In someembodiments, R¹ is C₁₋₆ alkyl. In some embodiments, R¹ is methyl.

In some embodiments of Formula (VI), at least one of R⁴, R⁵, R⁶, R⁷, R⁸,R¹⁰, and R¹¹ is halogen, —CHO or —(CH₂)_(x)—COOH. In some embodiments,at least one of R⁴, R⁵, R⁶, R⁷, R⁸, R¹⁰, and R¹¹ is bromo, —CHO or—(CH₂)_(x)—COOH. In some embodiments, at least one of R⁴, R⁵, R⁶, R⁷,R⁸, R¹⁰, and R¹¹ is bromo. In some embodiments, at least one of R⁴, R⁵,R⁶, R⁷, R⁸, R¹⁰, and R¹¹ is —CHO. In some embodiments, at least one ofR⁴, R⁵, R⁶, R⁷, R⁸, R¹⁰, and R¹¹ is —(CH₂)_(x)—COOH. In someembodiments, at least one of R⁴, R⁵, R⁶, R⁷, R⁸, R¹⁰, and R¹¹ is—(CH₂)_(x)—COOC₁₋₆alkyl.

In some embodiments of Formula (VI), R⁴, R⁵, R⁶, and R⁷ areindependently selected from hydrogen and halogen. In some embodiments ofFormula (VI), R⁴, R⁵, R⁶, and R⁷ are hydrogen.

In some embodiments of Formula (VI), R⁸, R¹⁰, and R¹¹ are independentlyselected from hydrogen, halogen, —(CH₂)_(x)—C(O)—OC₁₋₆ alkyl, —OCH₂C₆H₅,—OCOCH₃, —(CH₂)_(x)—CONH₂, —CHO, —(CH₂)_(x)—COOH, —(CH₂)_(x)—COC₁₋₆alkyl, phenyl, and substituted phenyl; wherein the substituted phenyl issubstituted with 1-4 substituents selected from hydroxyl, C₁₋₆alkoxy,and C₁₋₆alkyl. In some embodiments, R⁸, R¹⁰, and R¹¹ are independentlyselected from hydrogen, halogen, —CHO, —(CH₂)_(x)—COOH,—(CH₂)_(x)—COOC₁₋₆ alkyl, phenyl, and substituted phenyl; wherein thesubstituted phenyl is substituted with 1-4 substituents selected fromhydroxyl, C₁₋₆alkoxy, and C₁₋₆alkyl.

Compounds and Compositions

In some embodiments, the present disclosure provides a compound andpharmaceutically acceptable salts thereof and compositions comprising acompound and pharmaceutically acceptable salts thereof for use in thepresent methods, wherein the compound is selected from the following:

TABLE 1 Compound Structure Chemical Name 1

1H-indole-3-carbaldehyde 2

1H-indole-2-carbaldehyde 3

1H-indole-5-carbaldehyde 4

1H-indole-7-carbaldehyde 5

1H-indole-4-carbaldehyde 6

1H-indole-6-carbaldehyde 7

1,6,7,8- tetrahydrocyclopenta[g]indole-3- carbaldehyde 8

1-methyl-1H-indole-3-carbaldehyde 9

5-methoxy-1-methyl-1H-indole-3- carbaldehyde 10

4-(1H-indol-3-yl)butanoic acid 11

3-(1H-indol-3-yl)-2-oxopropanoic acid 12

(R)-2-hydroxy-3-(1H-indol-3- yl)propanoic acid 13

5-methyl-1H-indole-3-carbaldehyde 14

3-methyl-1H-indole-7-carbaldehyde 15

5-ethyl-1H-indole-3-carbaldehyde 16

6-amino-1H-indole-3-carbaldehyde 17

6-isopropyl-1H-indole-3- carbaldehyde 18

5,7-dimethyl-1H-indole-3- carbaldehyde 19

5-hydroxy-1H-indole-3- carbaldehyde 20

3-formyl-1H-indole-6-carbonitrile 21

6-bromo-1H-indole-3-carbaldehyde 22

6-chloro-1H-indole-3-carbaldehyde 23

1-hydroxy-1H-indole-3- carbaldehyde 24

7-bromo-1H-indole-3-carbaldehyde 25

3-formyl-1H-indole-7-carboxylic acid 26

4-hydroxy-1H-indole-3- carbaldehyde 27

1H-indole-4-carboxylic acid 28

1H-indole-5-carboxylic acid 29

1H-indole-2-carboxylic acid 30

1H-indole-3-carboxylic acid 31

6-methoxy-1H-indole-3-carboxylic acid 32

(S)-2-amino-3-(1H-indol-3- yl)propanoic acid; L-tryptophan 33

1H-indole 34

methyl 1H-indole-4-carboxylate 35

(1H-indol-3-yl)methanol 36

5-(benzyloxy)-1H-indole-3- carbaldehyde 37

5-bromo-1H-indole-3-carbaldehyde 38

5-bromo-1H-indole 39

4-bromo-1H-indole 40

5-bromo-1H-indole-2-carboxylic acid 41

2-(5-bromo-1H-indol-3-yl)acetic acid 42

2-(1H-indol-3-yl)acetonitrile 43

4-(benzyloxy)-1H-indole-3- carbaldehyde 44

6-(benzyloxy)-1H-indole-3- carbaldehyde 45

2-(2-methyl-3-(7-methyl-1H- benzo[d]imidazol-2-yl)-1H-indol-1-yl)acetamide 46

2-(2-methyl-3-(1-methyl-1H- benzo[d]imidazol-2-yl)-1H-indol-1-yl)acetamide 47

2-(1-(2-amino-2-oxoethyl)-2- methyl-1H-indol-3-yl)-1H-benzo[d]imidazole-6-carboxylic acid 48

2-(3-(6-chloro-1H- benzo[d]imidazol-2-yl)-2-methyl-1H-indol-1-yl)acetamide 49

Indole-6-carboxylic acid 50

6-bromoindole-2-carboxylic acid 51

5-fluoroindole-3-acetic acid 52

7-benzyloxyindole 53

5-benzyloxyindole-3-acetic acid 54

Indole-4-carboxylic acid 55

6-bromoindole 56

7-bromoindole 57

5-benzyloxyindole 58

5-benzyloxyindole-3 carboxaldehyde 59

5-bromoindole-3-acetamide 60

6-benzyloxyindole 61

4-benzyloxyindole 62

5-bromo-7-methylindole-3- carboxyaldehyde 63

3-bromoindole-2-carboxylic acid 64

Indole-3-acetic acid 65

5-hydroxyindole-3-acetic acid 66

5-benzyloxyindole-3-acetamide 67

6-benzyloxyindole-3-carboxaldehyde 68

7-amino-5-bromoindole 69

5-bromoindoxyl acetate; 3-Acetoxy-5-bromoindole 71

Ethyl 5-bromoindole-2-carboxylate 73

(1R,3R)-6-bromo-1-(4- isopropylphenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid 74

(1R,3S)-1-(3-hydroxyphenyl)- 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid 75

(1R,3R)-1-(2-hydroxy-5- methoxyphenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid 76

(1R,3R)-1-(4-hydroxy-3,5- dimethoxyphenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole- 3-carboxylic acid 77

(1R,3R)-1-(2-methoxyphenyl)- 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid 78

(1R,3R)-1-(2,4-dihydroxyphenyl)- 2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylic acid 79

Ethyl-5-hydroxy-1H-indole-2- carboxylate 80

3-methyl-1H-indole-2-carboxylic acid 81

4-methoxy-1H-indole-2-carboxylic acid

In some embodiments, the present disclosure provides Compounds 2, 10,29, 38, 40, 41, 43, and 44 and pharmaceutically acceptable salts thereoffor use in the present methods.

Compound Structure Chemical Name  2

1H-indole-2-carbaldehyde 10

4-(1H-indol-3-yl)butanoic acid 29

1H-indole-2-carboxylic acid 38

5-bromo-1H-indole 40

5-bromo-1H-indole-2-carboxylic acid 41

2-(5-bromo-1H-indol-3-yl)acetic acid 43

4-(benzyloxy)-1H-indole-3-carbaldehyde 44

6-(benzyloxy)-1H-indole-3-carbaldehyde

In some embodiments, the indole compound is apoptotic. In someembodiments, the indole compound is cytolytic. In some embodiments, theindole compound is pyroptotic. Such properties can be determined, forexample, through histology with fresh ex-vivo fat tissues. The presenceof cell wall lysis, “ghosting,” and loss of integrity of regions ofconfluent adipocytes can indicate that an indole compound has activityagainst adipocytes. Signs of apoptosis, histologically, include“ghosting” and regions of shrinking or much smaller cells. Signs ofcytolysis include disruption of cell walls, and with aggressivecompositions and the detergent controls, large “moth-eaten” regionswhere no cells exist; they have all been lysed. Signs of pyroptosisinclude a combination of both findings. In a live animal or human,cytolysis can produce inflammatory changes.

In some embodiments, the indole compounds are inflammatory. In someembodiments, the indole compounds are non-inflammatory. In someembodiments, the indole compounds are moderately inflammatory. Dependingon the mechanism of action, the level of inflammation induced by indolecompounds varies. Inflammatory response is generated when the cell wallis mechanically lysed or the cell dies an ischemic death. Release of thecell contents and lysozymes triggers significant local swelling, and acytokine and histamine response. An early indicator is the presence ofneutrophils or lymphocytes in the affected target tissue. With anaggressive composition, large areas of viable cells are missing, and theregion is filled with ground substance. Fibrosis is indicated bythickening of the fibrous septae. Macrophages infiltrate, and“crown-like” structures—noted by the presence of macrophages at theverge of an adipocyte cell wall—are also hallmarks of fattyinflammation. Cytolytic indoles can generate an inflammatory response.Apoptosis is noninflammatory. There are no macrophages, nor is there anapoptotic target. Apoptosis occurs when the cell is programmed to die.The cell shrinks and “ghosting—the residual intact cell wall withoutmuch cytoplasm—can be seen.

In some embodiments, the indole compound is at least about 25% (such asat least about any of 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%) morespecific to adipocytes than to muscle cells (such as skeletal musclecells). In some embodiments, the indole compound is at least about 80%more specific to adipocytes than to muscle cells (such as skeletalmuscle cells). In some embodiments, the indole compound is at leastabout 2×, 3×, or 4× more specific to adipocytes than to muscle cells(such as skeletal muscle cells).

In some embodiments, the indole compound is at least about 25% (such asat least about any of 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%) morespecific to adipocytes than to nerve cells (such as peripheral nervecells). In some embodiments, the indole compound is at least about 80%more specific to adipocytes than to nerve cells (such as peripheralnerve cells). In some embodiments, the indole compound is at least about2×, 3×, or 4× more specific to adipocytes than to nerve cells (such asperipheral nerve cells).

In some embodiments, the indole compound is at least about 25% (such asat least about any of 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%) morespecific to adipocytes than to dermal cells (such as dermalfibroblasts). In some embodiments, the indole compound is at least about80% more specific to adipocytes than to dermal cells (such as dermalfibroblasts). In some embodiments, the indole compound is at least about2×, 3×, or 4× more specific to adipocytes than to dermal cells (such asdermal fibroblasts).

In some embodiments, the indole compound is selected from the groupconsisting of Compounds 2 and 43. In some embodiments, the indolecompound has a cell killing activity and tissue specificity that are atleast as high as those of an indole compound selected from the groupconsisting of Compounds 2 and 43.

In some embodiments, the indole compound is selected from the groupconsisting of Compounds 40 and 41. In some embodiments, the indolecompound has a cell killing activity and tissue specificity that are atmost as high as those of an indole compound selected from the groupconsisting of Compounds 40 and 41.

In some embodiments, the indole compound is selected from the groupconsisting of Compounds 10 and 29. In some embodiments, the indolecompound has a cell killing activity and tissue specificity that are atleast as high as those of an indole compound selected from the groupconsisting of Compounds 27 and 28.

In some embodiments, the indole compound is a compound having a cellkilling activity that is between the cell killing activity of Compounds2 or 43 and Compounds 10 or 29. In some embodiments, the indole compoundis a compound having a cell killing activity that is between the cellkilling activity of Compounds 10 or 29 and Compounds 40 and 41. In someembodiments, the indole compound is a compound having a cell killingactivity that is between the cell killing activity of Compounds 2 or 43and Compounds 40 or 41.

Also provided herein are methods of selecting an indole compound for anyof the therapeutic methods described herein comprising assessing theactivity, tissue specificity, and/or cell killing mechanism (apoptotic,cytolytic, pyroptotic, etc.) of the compound. In some embodiments, thereis provided a method of determining whether an indole compound issuitable for any of the therapeutic methods described herein comprisingassessing the activity, tissue specificity, and/or cell killingmechanism (apoptotic, cytolytic, pyroptotic, etc.) of the compound. Insome embodiments, the compound is selected (or deemed suitable for use)if the compound has high activity against adipocytes and high tissuespecificity. In some embodiments, the compound is selected (or deemedsuitable for use) if the compound has high activity against adipocytesand moderate tissue specificity. In some embodiments, the compound isselected (or deemed suitable for use) if the compound has moderateactivity against adipocytes and high tissue specificity. In someembodiments, the compound is selected (or deemed suitable for use) ifthe compound is apoptotic. In some embodiments, the compound is selected(or deemed suitable for use if the compound is cytolytic. In someembodiments, the compound is selected (or deemed suitable for use) ifthe compound is pyroptotic.

Pharmaceutical Formulations

The disclosed pharmaceutical compositions can be formulated as apharmaceutically acceptable salt of a disclosed compound.Pharmaceutically acceptable salts are non-toxic salts of a free baseform of a compound that possesses the desired pharmacological activityof the free base. These salts may be derived from inorganic or organicacids. Non-limiting examples of pharmaceutically acceptable saltsinclude sulfates, pyrosulfates, bisulfates, sulfites, bisulfites,phosphates, monohydrogen-phosphates, dihydrogenphosphates,metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates,propionates, decanoates, caprylates, acrylates, formates, isobutyrates,caproates, heptanoates, propiolates, oxalates, malonates, succinates,suberates, sebacates, fumarates, maleates, butyne-1,4-dioates,hexyne-1,6-dioates, benzoates, chlorobenzoates, methylbenzoates,dinitrobenzoates, hydroxybenzoates, methoxybenzoates, phthalates,sulfonates, methylsulfonates, propylsulfonates, besylates,xylenesulfonates, naphthalene-1-sulfonates, naphthalene-2-sulfonates,phenylacetates, phenylpropionates, phenylbutyrates, citrates, lactates,γ-hydroxybutyrates, glycolates, tartrates, and mandelates. Lists ofother suitable pharmaceutically acceptable salts are found inRemington's Pharmaceutical Sciences, 17th Edition, Mack PublishingCompany, Easton, Pa., 1985.

The compositions can be formulated for various types of delivery e.g.,topical, subcutaneous, subdermal, intralesional, or hypodermal, etc. byany means known in the art. Such formulations can be in the form of atablet, powder, gel, solution, cream, vapor, ointment, etc. In someembodiments, an indole compound is formulated into a solution. In someembodiments, such solution is aqueous. The term “aqueous” as used hereinrefers to a solution which is a homogenous mixture prepared bydissolving a solid or a liquid in water such that the molecules of thesolute or dissolved substance are dispersed among those of water.

Pharmacologically acceptable aqueous vehicles for the compositions ofthe present invention can include, for example, any liquid solution thatis capable of dissolving an indole compound and is not toxic to theparticular individual receiving the formulation. Examples ofpharmaceutically acceptable aqueous vehicles include, withoutlimitation, saline, water and acetic acid. Typically, pharmaceuticallyacceptable aqueous vehicles are sterile. In some embodiments, the indolecompound is in an aqueous solution buffered at a pH of between about 8.0and about 8.5.

In some embodiments, compositions are formulated for veterinaryapplications with one or more veterinary excipients. In someembodiments, compositions are formulated for cosmetic applications withone or more cosmetic excipients. For delivery into humans, thecompositions are formulated with one or more pharmaceutical excipients.

A “pharmaceutically acceptable excipient” or “pharmaceutical excipient”may be used herein, and refers to a compound that is useful in preparinga pharmaceutical composition that is generally safe, non-toxic andneither biologically nor otherwise undesirable, and includes excipientsthat are acceptable for veterinary use or human pharmaceutical use. Apharmaceutically acceptable excipient as used herein includes both oneand more than one such excipient. Some examples of suitable excipientsinclude lactose, dextrose, sucrose, sorbitol, mannitol, starches, gumacacia, calcium phosphate, alginates, tragacanth, gelatin, calciumsilicate, microcrystalline cellulose, polyvinylpyrrolidone,phosphatidylcholine, cellulose, sterile water, syrup, and methylcellulose. The formulations can additionally include: lubricating agentssuch as talc, magnesium stearate, and mineral oil; wetting agents;emulsifying and suspending agents; and preserving agents such as methyl-and propylhydroxy-benzoates and benzyl alcohol. In some embodiments,suitable excipients include cyclodextrins (such ashydroxypropyl-cyclodextrin and sulfobutylether-cyclodextrin),polyethylene glycol, polyethylene glycol-400 (PEG-400), Tween 80,ethanol, and DMSO. The compositions of the present invention can beformulated so as to provide quick, sustained or delayed release of theindole compound after administration to the subject by employingprocedures known in the art.

Additional excipients suitable for formulation with an indole compoundinclude penetration enhancers and dispersion agents. Non-limitingexamples of dispersion agents which allow the dispersion of drugs intissue include hyaluronidase and collagenase. Hyaluronidase functions toaugment tissue permeability and spread or dispersion of other drugs.Collagenase has been used to isolate adipocytes from subcutaneous fatand does not have lytic effects on adipocytes themselves. Additionallyhyaluronidase and collagenase can facilitate healing by acceleratingreduction of necrotic tissue after treatment with the indole compoundformulations of the present invention.

In some embodiments, a formulation comprising an indole compound isadministered by injection, for example, by bolus injection. In someembodiments, the formulation can have direct contact with the fattissue. The formulation can be injected subcutaneously or infuseddirectly into the fat. In some embodiments, the formulation can havedirect contact with the skin tissue for skin and soft tissue tightening.The formulation can be injected or infused directly into the skintissue. Formulations for injection can be presented in unit dosage form,for example, in ampoules or in multi-dose containers, with or without anadded preservative. The compositions can take such forms as suspensions,solutions, or emulsions in oily or aqueous vehicles, and can containformulatory agents such as suspending, stabilizing and/or dispersingagents.

Unit Dose

A unit dose comprises an amount of a compound of an indole compound. Insome embodiments, the indole compound is a compound of Formula (I). Asan injectable solution, a unit dose has an amount of an indole compoundin a volume of solution.

In some embodiments, a unit dose comprises of more than 0.1% w/w, w/v orv/v of an indole compound and the unit dose has a total volume of morethan 0.2 ml and less than 500 ml. In some embodiments, a unit dosecomprises of more than 0.1% w/w, w/v or v/v of an indole compound andthe unit dose has a total volume of more than 0.1 ml and less that 0.2ml. In some embodiments, a unit dose comprises of more than 0.1% w/w,w/v or v/v of an indole compound and the unit dose has a total volume ofless than 0.1 ml.

The dose can depend on the following factors—the amount of fat present,the desired effect, and the concentration of the drug. In someembodiments, a solution for injection comprises about 1-20 mg/ml of anindole compound. In some embodiments, a solution for injection comprisesabout 1-5, 6-10, 11-15, or 16-20 mg/ml of an indole compound. In someembodiments, a solution for injection comprises about 8-12 or 10 mg/mlof an indole compound.

In some embodiments, unit doses are in a container or a syringe. Suchunit doses can have, for example, a total volume of up to 100, 90, 80,70, 60, 50, 40, 30, 20, 10, 9, 8, 7, 6, 5, 4, 3, 2, 1, 0.9, 0.8, 0.7,0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.09, 0.08, 0.07, 0.06, 0.05, 0.04, 0.03,0.02, 0.01, 0.009, 0.008, 0.007, 0.006, 0.005, 0.004, 0.003, 0.002,0.001, 0.0009, 0.0008, 0.0007, 0.0006, 0.0005, 0.0004, 0.0003, 0.0002,or 0.0001 ml. In some embodiments, a unit dose has a total volume in therange of 0.0001-100, 0.0005-90, 0.001-80, 0.005-70, 0.01-60, 0.05-50,0.06-40, 0.07-30, 0.08-20, 0.09-10, or 0.1-5 ml. Other embodimentscontemplate a unit dose with a total volume in the range of 0.01-2,0.05-1 or 0.1-0.5 ml total volume. In some embodiments, a unit dose hasa total volume greater 0.0001, 0.0002, 0.0005, 0.001, 0.002, 0.005,0.01, 0.02, 0.05, 0.1, 0.2, 0.5, 1, 2, 5, 10, 20, 50, 100 ml. In someembodiments, a unit dose has a total volume of up to 1.0, 0.9. 0.8, 0.7,0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.05, or 0.01 ml.

In some embodiments, a unit dose includes up to 10, 9, 8, 7, 6, 5, 4, 3,2, 1, 0.9, 0.8, 0.7, 0.6, 0.5, 0.4, 0.3, 0.2, 0.1, 0.09, 0.08, 0.07,0.06, 0.05, 0.04, 0.03, 0.02, 0.01, 0.009, 0.008, 0.007, 0.006, 0.005,0.004, 0.003, 0.002, 0.001, 0.0009, 0.0008, 0.0007, 0.0006, 0.0005,0.0004, 0.0003, 0.0002, or 0.0001 grams of an indole compound. In someembodiments, a unit dose includes a range of approximately 0.00001 to20, 0.00005 to 15, 0.0001 to 12.5, 0.0005 to 10, 0.001 to 7.5, or 0.005to 5 grams. In some embodiments, a unit dose comprises about 0.01, 0.1,1, or 2 grams of an indole compound.

Second Therapeutic Agents

The present disclosure provides compositions that can be co-formulated,co-administered, and/or co-marketed with a second therapeutic agent. Insome embodiments, the second therapeutic agent is co-formulated with anindole compound and administered simultaneously with the indolecompound. In some embodiments, the second therapeutic agent isadministered prior to or after the administration of an indole compound.The second therapeutic agent can be administered locally, regionally, orsystemically.

In some embodiments, the second therapeutic agent is a detergent, a bileacid, bile salt, deoxycholic acid or a salt thereof. In someembodiments, the second therapeutic agent is phosphatidylcholine ordeoxycholate or mixtures thereof. These compositions are described in US2005/0267080, WO 2008/066775 and US 2009/0233885, which are hereinincorporated by reference in their entireties.

Non-limiting examples of second therapeutic agents include: anesthetics,anti-microbial agents, vasoconstrictors, anti-thrombotic agents,anti-coagulation agents, anti-inflammatory agents, analgesics,dispersion agents, anti-dispersion agents, penetration enhancers,steroids, tranquilizers, muscle relaxants, anti-diarrhea agents, betaadrenergic stimulators, and collagenase.

In some embodiments, the compositions can further comprise an amount ofbeta adrenergic stimulator. A beta adrenergic stimulator can bind eitherdirectly or indirectly to the beta-receptor, thereby stimulating it. Thestimulated receptor triggers a complex series of events involvingmultiple enzyme systems which results in an accumulation of cyclic AMPwithin the cell and decreased ATP. These conditions can activate lipaseswhich break down triglyceride fats in the adipocytes into free fattyacids, which can be used by the cell for growth and metabolism, or maybe discharged extracellularly. Various beta adrenergic stimulatorsindividually or in combination can be included in the compositions, suchas isoproterenol hydrochloride (ISUPREL®), isoproterenol hydrochloride,forskolin, norepinephrine, guarana and clenbuterol, or otherbeta-receptor specific agonist (or nonspecific agonists such asephedrine as to certain applications)

In some embodiments, the compositions can further comprise, individuallyor in various permutations or combinations, an amount of collagenase,such as Clostridial collagenase or an amount of one or more of nicotinicacid, clofibrate, tannic acid, scorpion toxin, snake venom, beta adrenicstimulants, dimethlyaminoethanol, hyaluronic acid,penta-O-galloyl-alpha-D-glucose, hormone sensitive lipase, human adiposetriglyceride lipase, TNF-alpha, raspberry ketone, ethanol,rosiglitazone, peroxisome-proliferator activated receptor gamma, Y-9738(ethyl 2(4-chlorophenyl)-5-ethoxy-4-oxazoleacetate) oliphen, fish oil,scallop shell extract, peanut shell extract, caffeine, or bee venom.

Anti-microbial agents suitable for use with the compositions, methods,and kits herein include, but not limited to, anti-bactericidal agents,anti-fungal agents, anti-viral agents or the like, and are efficaciousagainst a broad spectrum of microbes.

Examples of anti-bacterial agents include, but not limited to,benzalkonium chloride, benzoic acid, benzoxonium chloride, benzylalcohol, 2-bromo-2-nitropropane-1,3-diol, 5-bromo-5-nitro-1,3-dioxane,bromochlorophene, camphor benzalkonium methosulfate, captan, cetrimoniumbromide, cetrimonium chloride, cetylpyridinium chloride, climbazol,chloracetamide, chlorhexidine and its salts, p-chloro-m-cresol,chlorphenesin, chloroxylenol, chlorophen, chlorobutanol, o-cymen-5-ol,dehydroacetic acid, dibromodicyanobutan, dibromohexamidin,dibromopropamidin, dichlorobenzyl alcohol, dichlorophenylimidazoldioxolan, dimethyloxazolidin, DMDM hydantoin, dodecylguanidineacetate, hexamidine diisothionate, hexachlorophen, hexetidin,iodopropynyl butylcarbamate, lauryl isoquinolinium bromide,methyldibromo glutaronitrile, methylolchloracetamide, phenethyl alcohol,phenoxyethanol, phenoxypropanol, o-phenylphenol, piroctone olamine,polyaminopropyl biguanide, potassium sorbate, potassium undecylenoylhydrolyzed collagen, quaternium-15, salicylic acid, sodium benzoate,sodium dehydroacetate, sodium hydroxymethylglycinate, sodiumo-phenylphenate, sorbic acid, triclocarban, triclosan, undecylenic acidand its derivatives, zinc cysteate, zinc gluconate, zinc pyrithione, orzinc sulfate. Derivatives of undecylenic acid useful as anti-microbialagents are e.g. esters, such as methyl ester, isopropyl ester, glycerylester, ethoxylated soya sterol ester, or ethoxylated PHB ester, oramides, such as monoethanolamide, monoethanolamide derivatives such asmonoethanolamide (MEA) sulfosuccinate salts, diethanolamide, proteincondensates, e.g. potassium undecylenoyl hydrolyzed animal collagen, andquaternized 3-aminopropyl-amide, e.g. undecylenamidopropyltrimoniummethosulfate. Specific examples of suitable fungicidal/fungistaticagents include, without limitation, dithiocarbamates, phthalimides,dicarboximides, organophosphates, benzimidazoles, carboxanilides,phenylamides, phosphites, and the like.

Other examples of anti-bacterial agents include, but are not limited to,erythromycin, clarithromycin, penicillins, cephalosporins,aminoglycosides, sulfonamides, macrolides, tetracyclins, lincosides,quinolones, chloramphenicol, vancomycin, metronidazole, rifampin,isoniazid, spectinomycin, trimethoprim, sulfamethoxazole, penems,carbapenems, monobactams mupirocin, neomycin sulfate bacitracin,polymyxin B, 1-ofloxacin, tetracyclines (chlortetracyclinehydrochloride, oxytetracycline hydrochloride and tetrachcyclinehydrochoride), clindamycin phsphate, gentamicin sulfate, benzalkoniumchloride, benzethonium chloride, hexylresorcinol, methylbenzethoniumchloride, phenol, quaternary ammonium compounds, triclocarbon,triclosan, tea tree oil, and their pharmaceutically acceptable salts.

Other examples of anti-bacterial agents include, but are not limited to,Acrofloxacin, Amoxicillin plus clavulonic acid (i.e. Augmentin),Amikacin, Amplicillin, Apalcillin, Apramycin, Astromicin, Arbekacin,Aspoxicillin, Azidozillin, Azithromycin, Aziocillin, Bacitracin,Benzathine penicillin, Benzylpenicillin, Carbencillin, Cefaclor,Cefadroxil, Cefalexin, Cefamandole, Cefaparin, Cefatrizine, Cefazolin,Cefbuperazone, Cefcapene, Cefdinir, Cefditoren, Cefepime, Cefetamet,Cefixime, Cefinetazole, Cefminox, Cefoperazone, Ceforamide, Cefotaxime,Cefotetan, Cefotiam, Cefoxitin, Cefpimizole, Cefpiramide, Cefpodoxime,Cefprozil, Cefradine, Cefroxadine, Cefsulodin, Ceftazidime, Ceftriaxone,Cefuroxime, Chlorampenicol, Chlortetracycline, Ciclacillin, Cinoxacin,Ciprofloxacin, Clarithromycin, Clemizole penicillin, Clindamycin,Cloxacillin, Daptomycin, Demeclocycline, Desquinolone, Dibekacin,Dicloxacillin, Dirithromycin, Doxycycline, Enoxacin, Epicillin,Erthromycin, Ethambutol, Fleroxacin, Flomoxef, Flucloxacillin,Flumequine, Flurithromycin, Fosfomycin, Fosmidomycin, Fusidic acid,Gatifloxacin, Gemifloxaxin, Gentamicin, Imipenem, Imipenem plusCilistatin combination, Isepamicin, Isoniazid, Josamycin, Kanamycin,Kasugamycin, Kitasamycin, Latamoxef, Levofloxacin, Lincomycin,Linezolid, Lomefloxacin, Loracarbaf, Lymecycline, Mecillinam, Meropenem,Methacycline, Methicillin, Metronidazole, Meziocillin, Midecamycin,Minocycline, Miokamycin, Moxifloxacin, Nafcillin, Nafcillin, Nalidixicacid, Neomycin, Netilmicin, Norfloxacin, Novobiocin, Oflaxacin,Oleandomycin, Oxacillin, Oxolinic acid, Oxytetracycline, Paromycin,Pazufloxacin, Pefloxacin, Penicillin G, Penicillin V, Phenethicillin,Phenoxymethyl penicillin, Pipemidic acid, Piperacillin, Piperacillin andTazobactam combination, Piromidic acid, Procaine penicillin,Propicillin, Pyrimethamine, Rifabutin, Rifamide, Rifampicin, RifamycinSV, Rifapentene, Rokitamycin, Rolitetracycline, Roxithromycin,Rufloxacin, Sitafloxacin, Sparfloxacin, Spectinomycin, Spiramycin,Sulfadiazine, Sulfadoxine, Sulfamethoxazole, Sisomicin, Streptomycin,Sulfamethoxazole, Sulfisoxazole, Synercid (Quinupristan-Dalfopristancombination), Teicoplanin, Telithromycin, Temocillin, Tetracycline,Tetroxoprim, Thiamphenicol, Ticarcillin, Tigecycline, Tobramycin,Tosufloxacin, Trimethoprim, Trimetrexate, Trovafloxacin, Vancomycin, andVerdamicin.

Vasoconstrictor agents suitable for use with the compositions of thepresent invention can include, for example, dihydroergotamine,ergotamine and methysergide, epinephrine, norepinephrine, andpharmaceutically-acceptable salts thereof.

Anti-thrombotic agents suitable for use with the compositions of thepresent invention can include, for example, argatroban, iloprost,lamifiban, taprostene, tirofiban, tissue plasminogen activator (naturalor recombinant), tenecteplase (TNK), and lanoteplase (nPA); factor Vilainhibitors; factor Xa inhibitors; thrombin inhibitors (such as hirudinand argatroban); PAI-1 inhibitors (i.e., inactivators of tissueplasminogen activator inhibitors); alpha2-antiplasmin inhibitors;streptokinase, urokinase and prourokinase; and anisoylated plasminogenstreptokinase activator complex, anti-coagulants (e.g. hirudin, heparin,etc.), plasminogen activators (e.g. t-PA, urokinase, etc.), fibrinolyticenzymes (e.g. plasmin, subtilisin, etc.), anti-platelet-aggregationagents (e.g. prostacyclin, aspirin, etc.) and the like.

Anti-coagulation agents suitable for use with the compositions of thepresent invention can include, for example, cilostazol (PLETAL®,Otsuka), clopidogrel (PLAVIX®, Sanofi), ticlopidine (TICLID®, Syntex),tirofiban (AGGRASTAT®, Merck), eptifibatide (INTEGRILIN®, CORTherapeutics), abciximab (REOPRO®, Eli Lilly), anagrelide (AGRYLIN®,Roberts), dipyridamole (PERSANTIN®, Boehringer Ingelheim), aspirin(ECOTR®, and others), dipyridamole/aspirin (AGGRENOX®, BoehringerIngelheim), dalteparin (FRAGMIN®, Pharmacia), enoxaparin (LOVENOX®,Aventis), tinzaparin (INNOHE®, DuPont), heparin (various), danaparoid(ORGANON®, Organon), antithrombin III (THROMBATE®, Bayer), lepirudin(REFLUDAN®, Hoechst-Marion Roussel), argatroban (ACOVA®,SmithKlineBeecham), bivalirudin (ANGIOMAX®, Medicines Company), warfarin(COUMADIN®, DuPont) anisidione (MIRADON®, Schering), alteplase(ACTIVASE®, Genentech), reteplase (RETAVASE®, Boehringer Mannheim),tenecteplase (TNKASE®, Genentech), drotrecogin (XIGRIS®, Eli Lilly),anistreplase (EMINASE®, Roberts), streptokinase (STREPTASE®, Astra),urokinase (ABBOKINASE®, Abbott) and combinations thereof.

Examples of anti-dispersion agents include, but are not limited to,sucrose, glyercerol, and glycerin.

Steroids suitable for use with the compositions of the present inventioncan include, for example, betamethasone, chloroprednisone, clocortolone,cortisone, desonide, dexamethasone, desoximetasone, difluprednate,estradiol, fludrocortisone, flumethasone, flunisolide, fluocortolone,fluprednisolone, hydrocortisone, meprednisone, methylprednisolone,paramethasone, prednisolone, prednisone, pregnan-3-alpha-ol-20-one,testosterone, and triamcinolone, estradiol, estron, estriol,polyestradiol, polyestriol, dienestrol, diethylstilbestrol,dihydroergosterone, cyproterone, danazol, testosterone, progesterone,norethindrone, levonorgestrol, ethynodiol, norgestimate, gestanin, 3keton-desogestrel, demegestone, promethoestrol, testosterone,spironolactone, and esters thereof, budesonide, rofleponide, rofleponidepalmitate, ciclesonide, momethasone furoate, fluticasone propionate,tipredane, fluocinolone acetonide, flunisolide, flumethasone,dexamethasone, beclomethasone dipropionate, deflazacort, cortivazol, orcortisol and/or hydrocortisol, prednisone, fluorometholone acetate,dexamethasone sodium phosphate, suprofen, fluorometholone, andmedrysone, optionally in their pure isomeric forms (where such formsexist) and in the forms of their pharmaceutically acceptable salts.

Anti-inflammatory agents suitable for use with the compositions of thepresent invention can include both steroidal anti-inflammatory agentsand non-steroidal anti-inflammatory agents. Suitable steroidalanti-inflammatory agent can include, although are not limited to,corticosteroids such as hydrocortisone, hydroxyltriamcinolonealphamethyl dexamethasone, dexamethasone-phosphate, beclomethasonedipropionate, clobetasol valerate, desonide, desoxymethasone,desoxycorticosterone acetate, dexamethasone, dichlorisone, diflorasonediacetate, diflucortolone valerate, fluadrenolone, fluclaroloneacetonide, fludrocortisone, flumethasone pivalate, fluosinoloneacetonide, fluocinonide, flucortine butylester, fluocortolone,fluprednidene (fluprednylidene)acetate, flurandrenolone, halcinonide,hydrocortisone acetate, hydrocortisone butyrate, methylprednisolone,triamcinolone acetonide, cortisone, cortodoxone, flucetonide,fludrocortisone, difluorosone diacetate, fluradrenalone acetonide,medrysone, amciafel, amcinafide, betamethasone and the balance of itsesters, chlorprednisone, chlorprednisone acetate, clocortelone,clescinolone, dichlorisone, difluprednate, flucloronide, flunisolide,fluoromethalone, fluperolone, fluprednisolone, hydrocortisone valerate,hydrocortisone cyclopentylproprionate, hydrocortamate, meprednisone,paramethasone, prednisolone, prednisone, beclomethasone dipropionate,betamethasone dipropionate, triamcinolone, and mixtures thereof can beused.

A second class of anti-inflammatory agents which is useful in thecompositions of the present invention includes the nonsteroidalanti-inflammatory agents. A variety of compounds encompassed by thisgroup are well-known to those skilled in the art. Suitable non-steroidalanti-inflammatory agents useful in the compositions of the presentinvention include, but are not limited to: the oxicams, such aspiroxicam, isoxicam, tonexicam, sudoxicam, and CP-14,304; thesalicylates, such as salicylic acid, aspirin, disalcid, benorylate,trilisate, safapryn, solprin, diflunisal, and fendosal; the acetic acidderivatives, such as diclofenac, fenclofenac, indomethacin, sulindac,tolmetin, isoxepac, furofenac, tiopinac, zidometacin, acematacin,fentiazac, zomepiract, clidanac, oxepinac, and felbinac; the fenamates,such as mefenamic, meclofenamic, flufenamic, niflumic, and tolfenamicacids; the propionic acid derivates, such as ibuprofen, naproxen,benoxaprofen, flurbiprofen, ketoprofen, fenoprofen, fenbufen,indoprofen, pirprofen, carprofen, oxaprozin, pranoprofen, miroprofen,tioxaprofen, suprofen, alminoprofen, and tiaprofenic; and the pyrazoles,such as phenybutazone, oxyphenbutazone, feprazone, azapropazone, andtrimethazone. Mixtures of these nonsteroidal anti-inflammatory agentscan also be employed, as well as the pharmaceutically-acceptable saltsand esters of these agents.

Analgesics suitable for use with the composition of the presentinvention to reduce discomfort due to inflammation after subcutaneousinjection of the formulation of the present invention include, but arenot limited to, injectable local amine and ester anesthetics.Non-limiting examples of analgesics include ropivacaine, lidocaine,mepivacaine, bupivacaine, procaine, chloroprocaine, etidocaine,prilocalne dyclonine, hexylcaine, procaine, cocaine, ketamine,pramoxine, propophol, phenol and tetracaine. Mixtures of theseanalgesics can also be employed, as well as the pharmaceuticallyacceptable salts and esters or these agents. Other examples ofanalgesics include opioids. Examples of opioids include morphine, or asalt thereof, such as the sulphate, chloride, or hydrochloride. Other1,4-hydroxymorphinan opioid analgesics that may be used herein includethose such as naloxone, meperidine, butorphanol or pentazocine, ormorphine-6-glucuronide, codeine, dihydrocodeine, diamorphine,dextropropoxyphene, pethidine, fentanyl, alfentanil, alphaprodine,buprenorphine, dextromoramide, diphenoxylate, dipipanone, heroin(diacetylmorphine), hydrocodone (dihydrocodeinone), hydromorphone(dihydromorphinone), levorphanol, meptazinol, methadone, metopon(methyldihydromorphinone), nalbuphine, oxycodone(dihydrohydroxycodeinone-), oxymorphone (dihydrohydroxymorphinone),phenadoxone, phenazocine, remifentanil, tramadol, or a salt of any ofthese. The opioid used in the method of the invention may comprise anycombination of the aforementioned compounds. Naloxone is also includedwithin the definition of an opioid. In certain embodiments, theanalgesic is hydromorphone, oxycodone, or morphine, e.g. morphinesulphate and fentanyl and/or pharmaceutically-acceptable salts thereof.

Suitable tranquilizer and sedative drugs that may included in the kitsor compositions of the present invention include chlordiazepoxide,benactyzine, benzquinamide, flurazepam, hydroxyzine, loxapine,promazine, and/or acceptable salts and esters thereof.

Suitable muscle relaxant drugs that may be included in the kits orcompositions of the present invention include cinnamedrine,cyclobenzaprine, flavoxate, orphenadrine, papaverine, mebeverine,idaverine, ritodrine, dephenoxylate, dantrolene, azumolene, and/orpharmaceutically-acceptable salts thereof.

Suitable anti-diarrhea drugs may be included in the kits or compositionsof the present invention include, for example, loperamide, and/orpharmaceutically-acceptable salts thereof.

Second therapeutic agents may be co-formulated and/or co-administeredwith an indole compound. In such co-formulations, a second therapeuticagent may be at a concentration of less than 20%, 19%, 18%, 17%, 16%,15%, 14%, 13%, 12%, 11%, 10%, 9%, 8%, 7%, 6%, 5%, 4%, 3%, 2%, 1%, 0.5%,0.4%, 0.3%, 0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%,0.02%, 0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%,0.002%, 0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%,0.0003%, 0.0002%, or 0.0001% w/w, w/v or v/v.

In some embodiments, a second therapeutic agent may be co-formulatedwith an indole compound. In such co-formulation, the second therapeuticagent may be at a concentration greater than 20%, 19.75%, 19.50%, 19.25%19%, 18.75%, 18.50%, 18.25% 18%, 17.75%, 17.50%, 17.25% 17%, 16.75%,16.50%, 16.25% 16%, 15.75%, 15.50%, 15.25% 15%, 14.75%, 14.50%, 14.25%14%, 13.75%, 13.50%, 13.25% 13%, 12.75%, 12.50%, 12.25% 12%, 11.75%,11.50%, 11.25% 11%, 10.75%, 10.50%, 10.25% 10%, 9.75%, 9.50%, 9.25% 9%,8.75%, 8.50%, 8.25% 8%, 7.75%, 7.50%, 7.25% 7%, 6.75%, 6.50%, 6.25% 6%,5.75%, 5.50%, 5.25% 5%, 4.75%, 4.50%, 4.25%, 4%, 3.75%, 3.50%, 3.25%,3%, 2.75%, 2.50%, 2.25%, 2%, 1.75%, 1.50%, 125%, 1%, 0.5%, 0.4%, 0.3%,0.2%, 0.1%, 0.09%, 0.08%, 0.07%, 0.06%, 0.05%, 0.04%, 0.03%, 0.02%,0.01%, 0.009%, 0.008%, 0.007%, 0.006%, 0.005%, 0.004%, 0.003%, 0.002%,0.001%, 0.0009%, 0.0008%, 0.0007%, 0.0006%, 0.0005%, 0.0004%, 0.0003%,0.0002%, or 0.0001% w/w, w/v or v/v.

In some embodiments, a second therapeutic agent may be co-formulatedwith an indole compound such that the final formulation has aconcentration of the second therapeutic agent that is in the range offrom approximately 0.001% to approximately 50%, approximately 0.001% toapproximately 40%, approximately 0.01% to approximately 30%,approximately 0.02% to approximately 29%, approximately 0.03% toapproximately 28%, approximately 0.04% to approximately 27%,approximately 0.05% to approximately 26%, approximately 0.06% toapproximately 25%, approximately 0.07% to approximately 24%,approximately 0.08% to approximately 23%, approximately 0.09% toapproximately 22%, approximately 0.1% to approximately 21%,approximately 0.2% to approximately 20%, approximately 0.3% toapproximately 19%, approximately 0.4% to approximately 18%,approximately 0.5% to approximately 17%, approximately 0.6% toapproximately 16%, approximately 0.7% to approximately 15%,approximately 0.8% to approximately 14%, approximately 0.9% toapproximately 12%, approximately 1% to approximately 10% w/w, w/v orv/v. It is understood that the final concentration is dependent on manyfactors known to persons skilled in the art including, but not limitedto, location and size of the treatment site.

In some embodiments, a composition herein comprises less than 10 g, 9.5g, 9.0 g, 8.5 g, 8.0 g, 7.5 g, 7.0 g, 6.5 g, 6.0 g, 5.5 g, 5.0 g, 4.5 g,4.0 g, 3.5 g, 3.0 g, 2.5 g, 2.0 g, 1.5 g, 1.0 g, 0.95 g, 0.9 g, 0.85 g,0.8 g, 0.75 g, 0.7 g, 0.65 g, 0.6 g, 0.55 g, 0.5 g, 0.45 g, 0.4 g, 0.35g, 0.3 g, 0.25 g, 0.2 g, 0.15 g, 0.1 g, 0.09 g, 0.08 g, 0.07 g, 0.06 g,0.05 g, 0.04 g, 0.03 g, 0.02 g, 0.01 g, 0.009 g, 0.008 g, 0.007 g, 0.006g, 0.005 g, 0.004 g, 0.003 g, 0.002 g, 0.001 g, 0.0009 g, 0.0008 g,0.0007 g, 0.0006 g, 0.0005 g, 0.0004 g, 0.0003 g, 0.0002 g, or 0.0001 gof the one or more second therapeutic agents herein.

In some embodiments, a composition herein comprises more than 0.0001 g,0.0002 g, 0.0003 g, 0.0004 g, 0.0005 g, 0.0006 g, 0.0007 g, 0.0008 g,0.0009 g, 0.001 g, 0.0015 g, 0.002 g, 0.0025 g, 0.003 g, 0.0035 g, 0.004g, 0.0045 g, 0.005 g, 0.0055 g, 0.006 g, 0.0065 g, 0.007 g, 0.0075 g,0.008 g, 0.0085 g, 0.009 g, 0.0095 g, 0.01 g, 0.015 g, 0.02 g, 0.025 g,0.03 g, 0.035 g, 0.04 g, 0.045 g, 0.05 g, 0.055 g, 0.06 g, 0.065 g, 0.07g, 0.075 g, 0.08 g, 0.085 g, 0.09 g, 0.095 g, 0.1 g, 0.15 g, 0.2 g, 0.25g, 0.3 g, 0.35 g, 0.4 g, 0.45 g, 0.5 g, 0.55 g, 0.6 g, 0.65 g, 0.7 g,0.75 g, 0.8 g, 0.85 g, 0.9 g, 0.95 g, 1 g, 1.5 g, 2 g, 2.5, 3 g, 3.5, 4g, 4.5 g, 5 g, 5.5 g, 6 g, 6.5 g, 7 g, 7.5 g, 8 g, 8.5 g, 9 g, 9.5 g, or10 g of the one or more second therapeutic agents herein.

In some embodiments, a composition herein comprises 0.0001-10 g,0.0005-9 g, 0.001-8 g, 0.005-7 g, 0.01-6 g, 0.05-5 g, 0.1-4 g, 0.5-4 g,or 1-3 g of the one or more second therapeutic agents herein.

Kits

The present disclosure provides a kit for the reduction or removal oflocalized fat deposits and/or skin and soft tissue tightening in thesubject. The kit can provide a non-surgical method of reduction orremoval of localized fat deposits and/or skin and subcutaneous tissuetightening in the subject. The kit includes one or more containers. Acontainer comprises any of the compositions herein. For example, acontainer can comprise an indole compound. In certain embodiments, asyringe can comprise an indole compound. In some embodiments, the indolecompound is a compound of Formula (I).

In some embodiments, an indole compound may be prepared in a solution orin an injectable solution. A container comprising such a solution mayhave sufficient volume to hold one or more unit doses. For example, acontainer may be adapted to hold a less than 500 ml, 100 ml solution, 20ml solution 10 ml solution or 5 ml solution. In some embodiments, acontainer can hold a volume of about 0.01 ml to about 100 ml, about 0.1ml to about 90 ml, about 0.5 ml to about 80 ml, about 1 ml to about 70ml, about 2 ml to about 60 ml, about 3 ml to about 50 ml, about 4 ml toabout 40 ml, about 5 ml to about 30 ml, about 6 ml to about 20 ml, andabout 7 ml to about 10 ml. In certain embodiments, a container is anampule having a volume capacity of about 10 to about 20 ml.

In some embodiments, an indole compound is formulated in a transdermalpatch or a subdermal depot for sustained release. Dosages in a patch ordepot can be the same as those discussed herein.

The container can optionally include one or more second therapeuticagents. In certain embodiments, a container includes an analgesic,antimicrobial agent, or anti-inflammatory agent. The kit may furtherinclude a second container comprising a second active agent. Examples ofa second therapeutic agent in a second container include, for example,an antimicrobial agent, an anti-thrombotic agent, an anti-coagulationagent, an anti-inflammatory agent, an analgesic, an anesthetic, ananti-dispersion agent, a dispersion agent, a penetration enhancer, asteroid, a tranquilizer, a muscle relaxant, and an anti-diarrhea agent.

The solution of container is administered according to the instructionsfor use. Instructions for use can provide dosing instructions which maydepend upon, for example, location of target site, animal being treated,desired results, size of target site, concentration of the indolecompound in composition, etc. In certain embodiments, instructions foruse are for the treatment of an animal such as a human, a dog, a cat, ora horse. Instructions for use can also include information for treatmentof other domesticated animals and/or farm animals. Instruction for usemay also include information on the use of the compositions herein totreat specific target sites, such as, e.g., fat deposits or areas ofloose skin localized under eye, under chin, under arm, buttock, cheek,brow, calf, back, thigh, ankle, or stomach. In some embodiments,instruction for use detail an explanation for use of the compositionsherein to treat a fat condition of obesity, fat redistribution syndrome,dorsocervical fat, visceral adiposity, breast enlargement, breastptosis, localized lipodystrophy with or without associated pendulosity,hyperadiposity, eyelid fat herniation, lipomas, lipodystrophy, buffalohump lipodystrophy, diffused body fat around trunk and arms, or fatdeposits associated with cellulite.

In some embodiments, instructions for use detail an explanation for useof the compositions herein to prevent or reduce a skin conditionassociated with aging, such as lax skin, and subcutaneous tissue, alocalized pendulous overhang of skin and subcutaneous tissue,irregularities of the skin, and wrinkles.

Instruction for use may include information regarding proper diluentsand volumes for dilution, if any, of the container. The instructions foruse may also provide information regarding the proper administration ofthe compositions herein, such as frequency and dosage of administration.

The kit may further comprise a syringe or other suitable delivery device(e.g., transdermal pump, transdermal patch, or subdermal depot) fordelivering the compositions in the container to a localized fat depositor loose skin. In some embodiments, a syringe or delivery device may bepreloaded with a unit dose of a solution of the present invention. Incertain embodiments, a syringe or delivery device may be preloaded witha fat-dissolving or skin-tightening effective amount of an indolecompound.

EXAMPLES

The following examples are offered to illustrate but not to limit theinvention.

Example 1

The time and concentration dependent effects of drug substance on bothcell viability and toxicity were evaluated using a two-colorfluorescence assay that measures plasma membrane integrity andintracellular enzyme activity. Live cells are determined by the strongfluorescence of calcein AM upon enzymatic conversion. In contrast,ethidium bromide signal is dramatically increased upon entering a cellwith damaged membranes and binding to nucleic acids. The ratio ofethidium to calcein fluorescence is an excellent measure of the relativeamount of live and dead cells.

Test compounds are commercially available. Test compounds includecompounds from Table 1. Comparative non-indole compounds were alsotested: C-8, C-19, C-20, C21, C-56, C-57, C-58, C-60, and C-61. Positivecontrols include 1% sodium deoxycholate (DC) (MasterPharm, RichmondHill, N.Y.), phosphatidylcholine 25 mg/ml plus deoxycholate 12 mg/ml(MasterPharm, Richmond Hill, N.Y.), PC 50/DC24 (Network Lipolysis,Drensteinfurt, Germany) and Aqualyx®, a sodium deoxycholate in a lactosecarrier. Compound 44H is a high concentration version of Compound 44.

The effects of various test compounds were compared to currentlyavailable known cytotoxic compounds (positive controls) includingAqualyx, deoxycholic acid (DC), and the two combinations ofphosphatidylcholine and deoxycholic acid (PC/DC) on cell viability andtoxicity. Saline was used as a negative control. All compounds wereincubated with approximately 1-2 million cells/ml for varying amounts oftime to induce cell death and/or disrupt membrane integrity. Thecompounds tested showed a gradient of adipocyte killing behavior as afunction of time ranging from very aggressive to modest cell death(FIGS. 1 and 2). FIG. 1 suggests that there are multiple compounds thathave more aggressive, intermediate, and less aggressive cell killingbehavior as compared to the positive controls Aqualyx, DC, and PC/DC(FIGS. 1 and 2).

In a separate study, the influence of both test compound concentrationand incubation time on cell viability and cytotoxicity of adipocytes wasevaluated (FIGS. 3 and 4). FIGS. 3 and 4 shown that increasing testcompound concentration generally increases the ethidium bromide signal(cell death). Similar to the previous time dependent study, an initialincrease in cell death followed by a plateau and a diverse range of testcompound activity from aggressive to non-aggressive cell cytotoxicitywas observed.

Example 2

Indole compounds were tested in immediate ex-vivo tissue. Test compoundsinclude a negative control (saline) which shows no response, or normaladipocyte architecture. In all specimens, some shearing (linear tears)and compression artifacts (rectangular fat cells rather than round) werepresent, as fatty tissue is notoriously difficult to keep fromfragmenting during histologic processing. In order to preventinterpretation errors, the treatment zone located in the center of thespecimen was evaluated from the dermal/fat junction distally, and onlyif adjacent to a section of normal appearing fat.

Test compounds included indole compounds in Table 1. Compounds to betested for tissue preference were first screened for adipocytecytoxicity in order to qualify. In addition to normal saline andcompound diluent (DMSO plus PBS) (negative controls), positive controlsinclude 1% sodium deoxycholate (MasterPharm, Richmond Hill, N.Y.),phosphatidylcholine 25 mg/ml plus deoxycholate 12 mg/ml (MasterPharm,Richmond Hill, N.Y.), PC 50/DC24 (Network Lipolysis, Drensteinfurt,Germany) and Aqualyx®, a sodium deoxycholate in a lactose carrier(Marllor International, Italy).

Initial screening was performed using a variety of cell viability andcytotoxicity assays, including Presto Blue® (Invitrogen, Grand Island,N.Y.), Alamar Blue® (Invitrogen, Grand Island, N.Y.), Cyto-Tox One®(Promega, Madison, Wis.), and Cell Titer Glo® (Promega, Madison, Wis.).Due to reaction of several test compounds with the blue dye, the redoxassays were discontinued. An MTT terazolium assay was performed, as wellas LDH and ATP based assays. It was determined that the most consistencyoccurred with the dual function assays, Multi-Tox Fluor® (Promega,Madison, Wis.) and LIVE/DEAD® for mammalian cells (Invitrogen, GrandIsland, N.Y.). The LIVE/DEAD® for mammalian cells assay was used.LIVE/DEAD® for mammalian cells assay is a calcein (live read)/ethidiumbromide (dead) multiplex assay.

There was a wide range of tissue preference ranging from none—allcompounds were indiscriminately cytotoxic—to about 90%. Indole (Compound33) was fairly tissue preferential at about 53-56%. Ethidium results forindole for dermis, muscle, and endothelial cells showed that indole wasless than half toxic for those cells than for adipocytes at 4 timepoints over 24 hours. FIG. 5 shows results for test compounds foradipocytes, dermis, muscle, and endothelial cells for Compound A(Aqualyx®) and Compounds 2, 29, 40, 41, and 43.

As shown in FIG. 5, the most strongly tissue preferential group includedsix tested compounds, Compounds 2 and 43 in the aggressive category,Compounds 40 and 41 in the moderate range, and Compounds 29 in the lessaggressive range. (Compound 10 is not shown in FIG. 5.) These compoundshad adipocyte cytotoxicity numbers that are 3 to 4 times stronger thanthose noted with other tissue types. Additional data for tissuespecificity results are shown in the table below.

In general, the PC/DC compositions were indiscriminate. Aqualyx® hadslight tissue specificity toward nerve tissue and endothelial tissue.The deoxycholate composition was indiscriminate.

FIG. 6 shows results for test compounds for adipocytes, dermis, andmuscle cells for Compound B (saline control) and Compounds 1, 2, 3, 4,5, and 10. All the bars in FIG. 6 indicate kill rate (ethidium). In thecompound number, “a” refers to compound tissue preference at 2 hours. Inthe compound number, “b” refers to compound tissue preference at 5hours.

As shown in FIG. 6, Compounds 2 and 10 were the most aggressive in thisgroup of compounds. Compound 4 was less aggressive, but showsspecificity for adipocyte killing. Compound 1 showed no preference forcells over time. Compound 5 showed more nerve preservation, but a latedermal spike appeared.

FIG. 7 shows results for test compounds for adipocytes, dermis, andmuscle cells for Compound C (saline control), Compounds D and E(deoxycholate), and Compounds 29, 7, 33, 38, and 40. All the bars inFIG. 7 indicate kill rate (ethidium). In the compound number, “a” refersto compound tissue preference at 2 hours. In the compound number, “b”refers to compound tissue preference at 5 hours.

In FIG. 7, Compound C is a saline control; Compound D isphosphatidylcholine 25 mg/ml plus deoxycholate 12 mg/ml; and Compound Eis phosphatidylcholine 25 mg/ml plus deoxycholate 24 mg/ml. Both ofCompounds D and E are detergents that showed no tissue specificity.Recent reports following clinical trials of 1% deoxycholate show twoinstances of facial nerve palsy and numbness with paresthesias in up to40% of patients treated. Compounds D and E are toxic to nerve and dermalfibroblasts as they are to adipocytes.

As shown in FIG. 7, Compound 29 is strongly adipocyte preferential,while the adipocyte kill rate is equivalent to that of Compounds D andE. Compound 7 showed not tissue preference. Compound 33 showed definitetissue specificity at two time points. While the specificity is not asstrong as other compounds tested, there is much more tissue specificitythan with Compounds D and E. Compound 38 was an aggressive adipocytekiller and is also toxic to nerve cells, although not nearly as toxic todermal fibroblasts. Compound 40 showed tissue specificity at two timepoints. In FIG. 7, Compounds 29 and 40 showed the most specificity foradipocyte killing among the compounds tested in this group. Compound 33showed moderate tissue specificity, but a fairly low adipocyte killrate.

FIG. 8 shows results for test compounds for adipocytes, dermis, andmuscle cells for Compound F (saline control), Compounds G (Aqualyx®),and Compounds 41, 43, and 44. All the bars in FIG. 8 indicate kill rate(ethidium). In the compound number, “a” refers to compound tissuepreference at 2 hours. In the compound number, “b” refers to compoundtissue preference at 5 hours.

In FIG. 8, Compound F is a saline control; Compound G is Aqualyx®.Compound G showed no tissue specificity. Compounds H and I are diluentcontrols, which include cells and DMSO/PBS. CellDMpb is a diluent havingDMSO and PBS and cells.

As shown in FIG. 8, Compound 41 had a high tissue preference index andstrong adipocytolytic capability. Compound 41 is not as aggressive asCompounds 2, 38, or 43. Compound 43 is adipolytic, yet has a low killrate for nerve cells and dermis. It is a more aggressive than Compound41. Compound 41 would be effective in areas where there is a large fatdeposit. Compound 44 is not as specific as the other compounds tested inthis group.

The following table shows tissue specificity results for the testedcompounds. A sample of DMSO/PBS was a negative control. A sample ofAqualyx® was a positive control. In the table, 24M isphosphatidylcholine 25 mg/ml plus deoxycholate 12 mg/and 25N is C50/DC24; these were positive controls. The numbers in the table refer toaveraged ethidium numbers. The percentages represent the relative killrate for each cell type when rated against the adipocyte kill rate forthat compound. All tissue types were tested on the same plate againstadipocytes in order to standardize results.

Compound # Adipocyte Nerve Dermis Muscle Endothelial DMSO/PBS 17.7 15 16  15.5   14.5 24M 72   69.5 76 74   76.5 25N 65.5 66 70   68.5 67Aqualyx ® 124 105 (85%)  123  120  111 (90%)  78 29.5 n/a 8.3 (28%)  8.7(29%)  9.8 (33%)  1 53 60 56 82 98 2 360 124 (39%)  101 (28%)  93 (26% 116 (32%)  5 36 17 (47%) 17 (47%) 27 (75%) 16 (44%) 3 42.5 26 (61%) 26.5(62%)  25 (59%) 25 (59%) 4 127 66 (52%) 79 (62%) 99 (78%) 86 (63%) 10 4512 (27%) 10 (22%) 13 (29%) 16.5 (37%)  29 83 15 (18%)  9 (11%) 14 (17%)8.5 (10%)  7 196 56 (30%) 103 (53%)  119 (61%)  69 (35%) 33 32 17 (53%)17 (53%) 18 (56%) 18 (56%) 38 558 551 (99%)  148 (27%)  362 (65%)  289(50%)  40 123 61 (50%) 33 (27%) 36 (29%) 40 (33%) 41 149 32 (20%) 27(18%) 40 (27%) 44 (30%) 43 340 58 (17%) 74 (22%) 73 (21%) 92.5 (27%)  44218 103 (47%)  134 (61%)  172 (79%)  129 (59%) 

Compounds 28, 91 and 94 showed high kill rate for adipocytes and highspecificity for adipocytes over nerve cells, dermal cells, muscle cells,and endothelial cells. Compounds 78, 2, 27, and 40 showed highspecificity for adipocytes over nerve cells, dermal cells, muscle cells,and endothelial cells. Compounds 5, 4, 30, 33, and 44 showed about 50%preferential for adipocytes over nerve cells, dermal cells, musclecells, and endothelial cells. Compounds 3 and 38 showed moderatepreference of adipocytes over nerve cells, dermal cells, muscle cells,and endothelial cells.

Example 3

As the indole group has not been previously used for intralesional fatreduction, a method of obtaining histologic specimens had to bemodified. In 1978, May et al (Plast. Reconstr. Sug. 1978 February;61(2): 256-67) noted that segments of human tissue remained viable andcould be reattached to the body using microvascular techniques for up to12 hours after separation. After 12 hours, a phenomenon called“no-reflow” occurred, and the tissue was no longer viable.

The tissue model described herein, therefore, was immediate ex-vivoabdominoplasty tissue that had been permitted for use by the surgicalpatient. Segments of abdominal skin and subcutaneous fat were injectedwith identified test compounds, plus a negative saline control and threepositive controls: 1% deoxycholate, the commercial preparation ofAqualyx®, and the Network Lipolysis PC/DC formula.

In compounds that were identified and confirmed as adipolytic usingthree separate sessions of the Live/Dead cell viability assay(Invitrogen), specimens were injected and then placed into formalin at 1hour, 4 hours, and 12 hours. Because there was no host; inflammatorychanges would not be expected. This study was only performed to assessthe immediacy of adipocyte changes, and to determine the method ofaction of each compound.

As a whole, the compounds of the embodiments appear to have a pyroptoticmechanism of action. Pyroptosis is a relatively new category of celldeath mechanism. While apoptosis is programmed cell death and bydefinition, there is no inflammation, cytolysis causes cell membranerupture followed by an immediate onset of swelling and inflammation inthe affected area. Pyroptosis is defined as a combination of these twomechanisms, in which some cells die as a programmed function, and somecells die due to mitochondrial dysfunction or cell wall lysis or both.Pyroptosis is the central continuum between apoptosis and cell walllysis, with some clinical and microscopic manifestations of both.

FIG. 9A shows a saline control with adipocytes intact.

FIG. 9B shows a histology test sample with 1% deoxycholate at 4 hours.Cell wall lysis with a large area of “missing” tissue is present. Thecentral oblique line of injection shows significant cell damage whilenormal fat can be seen at the periphery, in the lower left and upperright corners. This is a classic appearance, showing the limiteddispersion of the deoxycholate compound.

FIG. 9C shows a histology test sample with PC50/DC 24 at 12 hours. Minorapoptotic changes such as pyknotic nuclei and “ghosting” can be seen. Nocell wall lysis is present.

FIG. 9D shows a histology test sample with Compound 88 at 4 hours. Theappearance is very similar to that of PC/DC. Pyknotic nuclei arepresent. Both ghosting and quite shrunken cells are noted with foldingof the cytoplasmic membrane. This is an example of a compound withsimilar efficacy as PC/DC, with a primarily apoptotic mechanism ofaction.

FIG. 9E shows a histology test sample with Compound 41 at twelve hours.Pyroptotic mechanism is well demonstrated here. Two areas of cytolysisare shown using dark arrows. Pyknotic nuclei are strongly present, asare ghosting and shrunken intact cells.

FIG. 9F shows a histology test sample with Compound 38 at four hours.The mechanism of action of this compound is primarily cytolysis, as seenby fragmentation of multiple cell walls, and empty area where adipocytesused to be. Some signs of apoptosis are present. In some embodiments, itis difficult to assign an exclusively cytolytic or apoptotic mechanism,as both are most commonly seen.

FIG. 9G shows a histology test sample with Compound 2 at 1 hour. Thiscompound is aggressive, and cases more cytolysis than apoptosis.

FIG. 9H shows a histology test sample with Compound 29 at 12 hours. Thiscompound exhibits primarily an apoptotic mechanism.

FIG. 9I shows a histology test sample with Compound 33 at 4 hours.Indole, the parent compound, shows pyroptotic activity when injectedinto adipose tissue. A tattoo marking the injection site is seen in theupper left margin. Dark arrows show regions of cytolysis. Ghosting ofapoptotic cells is also visible.

In summary, the compounds of the embodiments have a variety of effectson adipocytes, with some compounds inducing more programmed cell death,and some more aggressive compounds primarily working by lysing cellmembranes the majority of compounds are pyroptotic; evidence of bothmechanisms of cell death is seen.

Example 4

The diagram in FIG. 10 shows an injection pattern for basic level usersof an injectable lipolytic composition. This pattern presupposes somedispersion of the injectable composition. In the facial region, a gridor ruler was used to measure the distance between injection points.

In Palmer and Duncan's article on the standard of practice for injectionlipolysis (Duncan D I, Palmer M: Fat reduction usingphosphatidylcholine/sodium deoxycholate injections: standard ofpractice. Aesthetic Plast. Surg. 2008; 32: 858-72), these points weredescribed as being 1 cm apart for facial regions, and 1.5 cm apart inbody regions. Facial injections should be performed with a meso needlethat is 6 mm long, in order to standardize the depth of injection. Adose of 0.2 to 0.4 cc of a 10 mg/ml product is the standard dose perpre-marked injection site in facial regions. In body regions, a dose of0.4 to 0.5 cc of the same concentration would be used, and the gridpattern would show injection points 1.5 cm apart.

An alternative pattern would be a multi-level injection, using anunder-the-skin type delivery. These would be performed from a singleentry site, and would be executed in a ray-type distribution, similar toliposuction. The value of treating multiple levels of adiposity has beenrecently shown, so a better and more uniform response can be obtainedwith this method. Also, drugs with poor dispersion can be betterdelivered to the target tissue this way.

Example 5

This example reports exemplary compounds reported in Example 1. Overseventy compounds of the embodiments were tested for adipocytolysis,then for tissue preference. A consistent assay with multiplexinformation was a calcein/ethidium bromide assay that assesses cellviability and cell death simultaneously. Cell viability was checkedusing the Countess device. All plates were inoculated with 100microliters of the appropriate cell types. A 6 well repeat was used toverify results. Cell types used included cultured human adult derivedadipocytes, dermal fibroblasts, skeletal muscle cells, and endothelialcells (Cell Applications, Inc., San Diego, Calif.). Human peripheralnerve cells (Innoprot, Spain) were also used.

Compounds were formulated using a DMSO/PBS excipient. A 10 mg/mlconcentration was used. One hundred microliters of test compound wasinserted into 6 wells of 5 cell types, placed in adjacent rows. Theplates were incubated for 4 hours. Indicator was added to each well, andplates were read at 45 minutes using a fluorescence spectrophotometer(Molecular Devices, Sunnyvale, Calif.).

FIG. 11 shows results for adipocytes, dermal cells, nerve cells, musclecells, and endothelial cells for control compounds. Normal saline was anegative control. Excipient was DMSO/PBS excipient. Positive controlsincluded phosphatidylcholine 25 mg/ml plus deoxycholate 12 mg/ml (PC/DC,MasterPharm, Richmond Hill, N.Y.), and Aqualyx®, a sodium deoxycholatein a lactose carrier (Marllor International, Italy). All the bars inFIG. 11 indicate kill rate (ethidium). The tissue preference assays inFIG. 11 were repeated three times, one month apart, to verify consistentfindings. As shown in FIG. 11, the control compounds were indiscriminatefor adipocytes, dermal cells, nerve cells, muscle cells, and endothelialcells.

FIG. 12 shows results for adipocytes, dermal cells, nerve cells, musclecells, and endothelial cells for control compounds and test compounds.All the bars in FIG. 12 indicate kill rate (ethidium). As shown in FIG.12, Compounds A, B, C, D, and E showed high specificity for adipocytesover dermal cells, nerve cells, muscle cells, and endothelial cells.PC/DC shows uniform cell death with all tissue types. The parent indolecompound (Compound 33) showed about 50% tissue preference.

FIG. 13 shows results for adipocytes, dermal cells, nerve cells, musclecells, and endothelial cells for control compounds and test compounds.All the bars in FIG. 13 indicate kill rate (ethidium). As shown in FIG.13, Compounds F, G, H, I, and J showed high specificity for adipocytesover dermal cells, nerve cells, muscle cells, and endothelial cells.There was no tissue preference for either control (saline and Aqualyx®).

Example 6

This example reports exemplary compounds reported in Example 1. A mousestudy was performed to test compounds of the embodiments. Eight testcompounds were injected. In addition to normal saline and compounddiluent (DMSO plus excipients) (negative controls), positive controlsincluded 1% sodium deoxycholate (DC, MasterPharm, Richmond Hill, N.Y.),phosphatidylcholine 25 mg/ml plus deoxycholate 12 mg/ml (PC/DC,PC25/DC12, MasterPharm, Richmond Hill, N.Y.), and Aqualyx®, a sodiumdeoxycholate in a lactose carrier (Marllor International, Italy).

Seventy nude mice were chosen for a study of safety and efficacy ofinjectable lipolytic compounds. Human fat was harvested one hour priorto the injection procedure. 0.5 cc of fat was loaded into microsyringes. Engraftment took place under general anesthesia. Four weekslater, the fat pad size was measured and compounds injected preciselyusing a 6 mm meso needle in the center and 0.5 cm cephalad and caudad tothe midpoint. Mice were sacrificed at one day, one week, two weeks and 4weeks. One mouse died following injection. This same mouse exhibited SRP(sick rodent posture) following engraftment. Three mice developed SRPand were euthanized according to protocol.

Each fat pad was measured and weighed on the analytical balance at thetime of sacrifice. Photos were taken and histology was performed. SEMwas performed at two weeks and 4 weeks. Gross characteristics of the fatwere documented.

At four weeks, clinical size reduction was just becoming visible withPC/DC and DC injectables. Visible and measurable fat reduction was notedwith DC and three test compounds, although the number of mice with eachcompound sacrificed at 4 weeks could not give any statisticallysignificant numbers. The two compounds that induced death or SRP weredeleted, as clinical performance for either was not strong.

Details of injection of compounds into the mice and results arediscussed below. Each mouse was given general anesthesia. Previous toinjection of compounds, the fat pad was remeasured as not all fat takesas a graft. Mean graft take was 68%.

Size reduction after compound injection was measured against themeasurement taken just previous to injection of compounds. The fatgrafts migrated laterally in all but one case. Compound dose wascalculated based on the average weight of each mouse and was based onthe maximum safe dose of PC/DC. At 0.4 mg/gram, maximum dose wasestimated to be 10 mg. Actual dose was 6 mg per mouse.

Three injections were performed and were perpendicularly given to adepth of 0.6 cm using a 30 gauge meso needle, spaced 0.5 cm apart. Eighttest compounds were injected. Negative control was saline and the DMSOexcipient. Two positive controls, Aqualyx® and PC25/DC12, were injected.Five mice exhibited small excoriations at the injection site. All haddisappeared within one day.

Mice were given a special antibiotic diet. No mouse became infected.After the first 24 hours, all recovered well and seemed to ignore thefat pads. Sacrifice of mice took place as schedule. A limited postmortemat 24 hours showed no apparent systemic effects.

FIG. 14 shows a sample mouse at one day postinjection. No effect fromthe compound was noted. Neovascularization of the graft was visiblebeneath the thin skin of this mouse. No effect on adjacent tissue norvital organs was noted.

FIG. 15 shows a mouse, injected with Compound B, which had a lobulatedgraft. The most cephalad pad was not injected. The central pad wasinjected with 0.1 cc or 1 mg of compound. The most caudal fat pad wasinjected with 0.2 cc or 2 mg of compound. As early as one week, fatnecrosis had been induced with Compound B. FIG. 15 shows that fatnecrosis occurred prevalently on the most caudal pad and to a lesserdegree on the central pad.

FIG. 16 shows deoxycholate injected fat pad at Day 1. Immediate necrosiswas apparent in the injected segment. The lack of dispersion was madeclear in this specimen.

FIG. 17 shows gross appearance of Compound D (above) as compared toexcipient control (below), at one week postinjection. Tested compoundsof the embodiments appeared to induce some type of fat reaction. Visiblegross changes included discoloration as early as one week. Someliquefaction was seen at two weeks. A soft granular appearance with sizereduction was noted at 4 weeks.

FIG. 18 shows a mouse at one week postinjection. The mouse was treatedwith Compound H. There was discoloration and textural changes in the fatpad after injection of Compound H, as shown in FIG. 18.

FIG. 19 shows the effect of Compound I at two weeks. There is someliquefaction and textural change. Definite fat necrosis was present.FIG. 20 shows the effect of Compound I at four weeks. Dispersion wasgood; the entire fat pad was been affected. A measured 33% reduction infat pad size was noted. Compound I showed good results and is anexcellent test compound in this study.

FIG. 21 shows PC/DC treated fat pad at 4 weeks. There was almost novisible change from its original condition.

A clinical outcome view was taken to test compounds for fat killingpotential. A final arbiter of success is visible reduction in the sizeof the fat pad following treatment. This endpoint is best observed byclinicians.

Example 7

Scanning electron microscopy (SEM) can provide images of a sample'stopography and composition. SEM was performed on various adipose cells.

This example reports exemplary compounds reported in Example 1.

FIG. 22 shows the appearance of normal fat cells with saline control.There was a very thin, fibrous “netting” that holds the cells together.As shown in FIG. 23, the fibrous scar response generated by deoxycholatewas massive. There are very few live cells left in this tissue segment;most was fibrous scar response. An ideal response would be either anapoptotic response with little inflammation in cases where only fatreduction is needed, or a combination of fat reduction and moderateinflammation when tissue tightening is the desired response. Thecompounds of the embodiments can generate these desired responses.

FIG. 24 shows SEM of an untreated cultured adipocyte. The physicalcharacteristics of adipose cells were easily identified when culturedcells are treated. Intact adipocytes were round, with a mean diameter ofabout 100 microns. There was great variability in the size ofadipocytes, which can range from 30 microns to over 200 microns. Thesurface of the cell membrane was not slick and smooth. FIG. 25 showsintact adipocytes in vivo. These were not perfectly round. Their shapewas affected by its neighbors.

FIG. 26 shows SEM of cultured adipocytes treated with PC/DC at fourhours. There was blebbing, a hallmark of apoptosis. Bleb is an irregularbulge in the plasma membrane of a cell. Cell wall injuries can have twooutcomes. If a large enough defect is created, the cell cannot repairitself and it undergoes necrosis, with the creation of lysozymes andegress of the cell contents. Clinically, this will result in swellingand inflammation of the treatment region. Smaller blebs may causeporation, which can induce programmed cell death.

FIG. 27 shows cultured adipocytes treated with PC/DC in vivo at 4 weeks.Blebbing was a prominent feature. Inflammation was denoted by theformation of a fibrous coating of the cells.

FIG. 28 shows the effect of deoxycholate on a single cultured adipocyteafter four hour incubation. The cell membrane has been disrupted atmultiple sites.

FIG. 29 shows a barren landscape of tissue treated with deoxycholate at4 weeks. There were very few living adipocytes. Fibrous ingrowth wasextensive. These SEM findings correlated with the histology seen indeoxycholate treated tissue. The inflammatory reaction was intense; allcells within millimeters of the treatment region died an acute necroticdeath. This led to extensive scarring such that the “soft” tissue is nolonger soft.

Majno's description of the process of adipocyte cell death is eitherapoptosis or necrosis. (Majno et al., “Apoptosis, oncosis, and necrosis.An overview of cell death,” Am J. Pathol. 1995 January; 146(1): 3-15.)FIGS. 30-31 shows diagrams of a mechanism of action of Majno.

The mechanism of action of injected sodium deoxycholate, is thecausation of immediate cell necrosis in adipoctytes localized to anarrow radius of the injection. Phosphatidylcholine/deoxycholate (PC/DC)was much slower to act. PC/DC induced early apoptosis followed by agradual, more diffuse induction of cell lysis over a period of 4 to 6weeks.

However, the compounds of embodiments can be shown to follow a differentmechanism of action. The mechanism of action includes poration andeffusion. The mechanism of action of lipolytic indole compounds is a newone called chemoporation. SEM micrographs of the mechanism are shown inFIGS. 37-41. A compound of the embodiments was injected into thesubcutaneous fat using either a depot or ray type serially repeatedpattern. No cell necrosis took place. As the compounds of theembodiments are tissue preferential, no other tissues are affected. Thereason no other tissues were affected is because this mechanism ofaction works for fat cells only. An initial response, seen as early asfour hours post-treatment, was poration of the treated cells. Tinyopenings in the adipocyte membrane became more prominent, and the cellwall surface began to appear “holey.” (FIG. 37) Then, for example,hundreds, then thousands of lipid droplets collected immediately underthe cell membrane. As other cells do not have intracellular lipiddroplets, this mechanism does not affect them. (FIG. 38) As the poresbecame larger, lipid droplets diffused through the cell membrane andbecame extracellular. (FIG. 39) With time, thousands of lipid dropletscollected on the surface of the cell wall. (FIG. 40) There was visible“crumpling” or loss of internal cell volume. (FIG. 41) Once a criticalloss of volume occurred, the cell died. The steps in this processfollowing drug injection or other type of application included poration,lipid droplet formation and collection just under the cell wall,diffusion through the cell membrane, exteriorization, and cell implosionwith subsequent death.

FIGS. 32-36 below show examples of a mechanism of action with SEM ofporation and effusion. FIGS. 37-41 below show examples of a mechanism ofaction with SEM of poration and effusion in close-up views.

FIG. 32 shows the effect of Compound A on adipocytes in vivo at 4 weeksposttreatment. The cells underwent a process of lipolysis in whichthousands of lipid droplets coalesce just under the cell membrane.Poration occurred, and the lipid droplets escaped. When cell volumedepletion becomes critical, the cell signals its own death.

FIG. 33 shows poration of a cultured adipocyte caused by Compound B.

FIG. 34 shows the effect of Compound B at 4 weeks. There were plateletson cell at the lower right. Compound B elicited a vascular response,with platelets and white blood cells (WBCs) within the treatment region.There was also a lack of extensive scarring.

FIG. 35 shows severe spongiform poration of an isolated culturedadipocyte after a 4 hour exposure to Compound C. This type of pyroptoticcell death caused less inflammation than deoxycholate's necroticprocess.

FIG. 36 show a negative control with the effect of DMSO excipient at 4weeks. There were cells that appear intact with slight fibrousadhesions.

As discussed above, FIGS. 37-41 show examples of a mechanism of actionwith an SEM of poration and effusion in close-up views. FIG. 37 showsSEM with a close-up view of poration of an adipocyte. FIG. 38 shows acollection of lipid droplets underneath the cell membrane. FIG. 39 showsan SEM with a close-up view of effusion of an adipocyte. This was asingle cell. There were lipid droplets coming out of the pores. FIG. 40shows a close-up view of a cell treated with Compound J at four weeks.There was extrusion of thousands of lipid droplets. FIG. 41 shows aclose-up view of adipocyte death. With the tested compounds of theembodiments, the gradual process over a four week period took longerthan deoxycholate's reaction, which was instantaneous. The testedcompounds of the embodiments worked more quickly than PC/DC. Tissuetreated with PC/DC was just beginning to react at four weeks.

FIGS. 42-45 show comparison of the effect of Compound J with controlcompounds. FIG. 42 shows tissue injected with saline at four weeks. Cellsizes vary. The fibroseptal network is apparent. FIG. 43 shows SEM oftissue treated with PC/DC at four weeks. There is a blebbing mildfibrous reaction. The cells are still intact. FIG. 44 shows tissuetreated with deoxycholate at four weeks. Massive fibrous replacement ofnormal tissue is apparent. FIG. 45 shows tissue treated with Compound Jat four weeks. There are lipid droplets and a single lysed cell. Fibrousresponse with Compound J is modest.

FIGS. 46-50 show the effects of tested compounds. FIG. 46 shows theeffect of Compound D at 4 weeks following injection into human fat. Thiseffect was similar to, but more profound than the effect of PC/DC. Therewas collapse of cell volume with round exteriorized lipid droplets.There were also lumpy shapes just under the cell membrane. These werehundreds of lipid droplets waiting to escape.

FIG. 47 shows the effect of Compound E in vivo after 4 weeks. There areextracellular lipid droplets, and folding of a dying adipocyte. Adisrupted cell is noted in the lower right of the figure. Some fibrousresponse is noted.

FIG. 48 shows tissue treated with Compound I at 4 weeks. There werelipid droplets that have discharged through the cell wall. Thismechanism was characteristic of the compounds of the embodiments.

FIG. 49 shows the effect of Compound H at four weeks. There werecrumpled cells, exteriorized lipid droplets, and more fibrous responsethan other tested compounds.

FIG. 50 shows the effect on cultured cells that were treated withCompound I for four hours. Compound I induced an array of responseincluding some cell lysis.

As shown in the figures, the steps in the adipocyte killing processappeared to be initial poration followed by collection of the lipiddroplets under the cell membrane. The small pores became larger, and thelipid droplets underwent effusion. The cells lost volume and lookedcrumpled. Once a critical mass of volume was lost, cell signalinginduced death.

The invention claimed is:
 1. A method for non-surgical reduction orremoval of one or more localized fat deposits in a subject havinglocalized fat accumulation comprising administering to a target site inthe fat deposit a compound of Formula (I-1), Formula (I-2), or Formula(I-3), wherein Formula (I-1) is represented by:

wherein R¹ is hydrogen or C₁₋₆ alkyl; R² is —(CH₂)_(x)—COOH; R³ ishydrogen or C₁₋₆alkyl; R⁴, R⁶, and R⁷ are independently selected fromhydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, and —OCH₂C₆H₅; R⁵ is halogen;and x is zero; or a pharmaceutically acceptable salt thereof; Formula(I-2) is represented by:

wherein R¹ is hydrogen or C₁₋₆ alkyl; R² is hydrogen or C₁₋₆alkyl; R³ is—CHO; and R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen,C₁₋₆alkyl, C₁₋₆alkoxy, halogen, and —OCH₂C₆H₅; or a pharmaceuticallyacceptable salt thereof; and Formula (I-3) is represented by:

wherein R¹ is hydrogen or C₁₋₆ alkyl; R² is —CHO or —(CH₂)—COOH; R³, R⁴,R⁵, R⁶, and R⁷ are independently selected from hydrogen, C₁₋₆alkyl,C₁₋₆alkoxy, halogen, and —OCH₂C₆H₅; and x is zero; or a pharmaceuticallyacceptable salt thereof.
 2. A method for reducing a subcutaneous fatdeposit in a subject having subcutaneous fat deposit comprisingadministering to a target site in the subcutaneous fat deposit acompound of formula (I-1), formula (I-2), or formula (I-3), whereinformula (I-1) is represented by:

wherein R¹ is hydrogen or C₁₋₆ alkyl; R² is —(CH₂)_(x)—COOH; R³ ishydrogen or C₁₋₆alkyl; R⁴, R⁶, and R⁷ are independently selected fromhydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, and —OCH₂C₆H₅; R⁵ is halogen;and x is zero; or a pharmaceutically acceptable salt thereof; formula(I-2) is represented by:

wherein R¹ is hydrogen or C₁₋₆ alkyl; R² is hydrogen or C₁₋₆alkyl; R³ is—CHO; and R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen,C₁₋₆alkyl, C₁₋₆alkoxy, halogen, and —OCH₂C₆H₅; or a pharmaceuticallyacceptable salt thereof; and formula (I-3) is represented by:

wherein R¹ is hydrogen or C₁₋₆ alkyl; R² is —CHO or —(CH₂)_(x)—COOH; R³,R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen, C₁₋₆alkyl,C₁₋₆alkoxy, halogen, and —OCH₂C₆H₅; and x is zero; or a pharmaceuticallyacceptable salt thereof.
 3. A method selected from: (i) a method fortreating an adipose tissue disorder or an adipose tissue tumor in asubject comprising locally administering to the subject a compound ofFormula (I-1), Formula (I-2), or Formula (I-3), wherein Formula (I-1) isrepresented by:

 wherein R¹ is hydrogen or C₁₋₆ alkyl; R² is —(CH₂)_(x)—COOH; R³ ishydrogen or C₁₋₆alkyl; R⁴, R⁶, and R⁷ are independently selected fromhydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, and —OCH₂C₆H₅; R⁵ is halogen;and x is zero; or a pharmaceutically acceptable salt thereof; Formula(I-2) is represented by:

 wherein R¹ is hydrogen or C₁₋₆ alkyl; R² is hydrogen or C₁₋₆alkyl; R³is —CHO; and R⁴, R⁵, R⁶, and R⁷ are independently selected fromhydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, and —OCH₂C₆H₅; or apharmaceutically acceptable salt thereof; and Formula (I-3) isrepresented by:

 wherein R¹ is hydrogen or C₁₋₆ alkyl; R² is —CHO or —(CH₂)_(x)—COOH;R³, R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen,C₁₋₆alkyl, C₁₋₆alkoxy, halogen, and —OCH₂C₆H₅; and x is zero; or apharmaceutically acceptable salt thereof; and (ii) a method fordecreasing a submental fat deposit under a skin area in a subjectcomprising administering to a target site in the fat deposit a compoundof Formula (I-1), Formula (I-2), or Formula (I-3), wherein Formula (I-1)is represented by:

 wherein R¹ is hydrogen or C₁₋₆ alkyl; R² is —(CH₂)_(x)—COOH; R³ ishydrogen or C₁₋₆alkyl; R⁴, R⁶, and R⁷ are independently selected fromhydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, and —OCH₂C₆H₅; R⁵ is halogen;and x is zero; or a pharmaceutically acceptable salt thereof; Formula(I-2) is represented by:

 wherein R¹ is hydrogen or C₁₋₆ alkyl; R² is hydrogen or C₁₋₆alkyl; R³is —CHO; and R⁴, R⁵, R⁶, and R⁷ are independently selected fromhydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, and —OCH₂C₆H₅; or apharmaceutically acceptable salt thereof; and Formula (I-3) isrepresented by:

 wherein R¹ is hydrogen or C₁₋₆ alkyl; R² is —CHO or —(CH₂)_(x)—COOH;R³, R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen,C₁₋₆alkyl, C₁₋₆alkoxy, halogen, and —OCH₂C₆H₅; and x is zero; or apharmaceutically acceptable salt thereof.
 4. The method of claim 3,wherein the method is for decreasing a submental fat deposit under askin area in a subject comprising administering to a target site in thefat deposit a compound of Formula (I-1) or Formula (I-2), whereinFormula (I-1) is represented by:

wherein R¹ is hydrogen or C₁₋₆ alkyl; R² is —(CH₂)_(x)—COOH; R³ ishydrogen or C₁₋₆alkyl; R⁴, R⁶, and R⁷ are independently selected fromhydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, and —OCH₂C₆H₅; R⁵ is halogen;and x is zero; or a pharmaceutically acceptable salt thereof; andFormula (I-2) is represented by:

wherein R¹ is hydrogen or C₁₋₆ alkyl; R² is hydrogen or C₁₋₆alkyl; R³ is—CHO; and R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen,C₁₋₆alkyl, C₁₋₆alkoxy, halogen, and —OCH₂C₆H₅; or a pharmaceuticallyacceptable salt thereof.
 5. The method of claim 1, wherein the compoundis of Formula (II):

wherein R¹ is hydrogen or C₁₋₆ alkyl; R² is hydrogen or C₁₋₆alkyl; R³ is—CHO; R⁴ is —OCH₂C₆H₅; and R⁵, R⁶, and R⁷ are independently selectedfrom hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, and halogen; or a pharmaceuticallyacceptable salt thereof.
 6. The method of claim 1, wherein the compoundis of Formula (III):

wherein R¹ is hydrogen or C₁₋₆ alkyl; R² is —(CH₂)_(x)—COOH; R³ ishydrogen or C₁₋₆alkyl; R⁴, R⁶, and R⁷ are independently selected fromhydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, halogen, and —OCH₂C₆H₅; R⁵ is bromo;and x is zero; or a pharmaceutically acceptable salt thereof.
 7. Themethod of claim 1, wherein the compound is of Formula (IV):

wherein R¹ is hydrogen or C₁₋₆ alkyl; R² is —CHO or —(CH₂)_(x)—COOH; R³is hydrogen, C₁₋₆alkyl, or C₁₋₆alkoxy; R⁴, R⁵, R⁶, and R⁷ areindependently selected from hydrogen, C₁₋₆alkyl, C₁₋₆alkoxy, andhalogen; and x is zero; or a pharmaceutically acceptable salt thereof.8. The method of claim 1, wherein the compound is of Formula (V):

wherein R¹ is hydrogen or C₁₋₆ alkyl; R² is hydrogen or C₁₋₆alkyl; R³ is—CHO; and R⁴, R⁵, R⁶, and R⁷ are independently selected from hydrogen,C₁₋₆alkyl, C₁₋₆alkoxy, —OCH₂C₆H₅, and halogen; or a pharmaceuticallyacceptable salt thereof.
 9. A method for non-surgical reduction orremoval of one or more localized fat deposits in a subject havinglocalized fat accumulation comprising administering to a target site inthe fat deposit a compound in Table 1A below, or a pharmaceuticallyacceptable salt thereof: TABLE 1A Compound Structure Chemical Name  2

1H-indole-2-carbaldehyde 29

1H-indole-2-carboxylic acid 38

5-bromo-1H-indole 40

5-bromo-1H-indole-2-carboxylic acid 41

2-(5-bromo-1H-indol-3-yl)acetic acid 43

4-(benzyloxy)-1H-indole-3-carbaldehyde 44

6-(benzyloxy)-1H-indole-3-carbaldehyde.


10. The method of claim 1, wherein the compound is of Formula:


11. The method of claim 1, wherein the compound is of Formula:


12. The method of claim 1, wherein the administering step is byinjection, transdermal pump, transdermal patch, or a subdermal depot.13. The method of claim 1, wherein the administering step is bysubcutaneous injection or intradermal injection.
 14. The method of claim1, wherein the subject is a mammal.
 15. The method of claim 1, whereinthe subject is a human.
 16. The method of claim 1, further comprisingadministering to the subject a second therapeutic agent.